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Benzo|7?lquinoline Ligands and Complexes Thereof
The present invention relates to substituted tridentate benzo[/?]quinoline ligands and complexes
thereof. The invention also relates to the preparation of the ligands and the respective complexes, as
well as to processes for using the complexes in catalytic reactions.
WO2009/007443 (to the Universita degli Studi di Udine) describes a class of compounds derived from
benzo[/?]quinoline comprising a - CH N group in position 2 . WO2009/007443 describes the
synthesis of HCNN-H, HCNN-Me and HCNN-'Bu but does not describe the compounds, ligands or
complexes of the present invention.
The present inventors have developed substituted tridentate benzo[/?]quinoline ligands and
complexes thereof. The processes for the preparation of the ligands overcome problems associated
with the prior art. The processes are more suited to large-scale manufacture of the ruthenium
complexes.
Summary of the invention
In one aspect, the present invention provides a benzo[/?]quinoline compound of formula ( 1a) or ( 1 b),
or salts thereof:
wherein R R2, R3, R4, R5, R6, R7, b and c are as defined herein.
In another aspect, the invention provides a process for preparing a compound of formula ( 1 a) or ( 1 b),
the process comprising the step of reacting a compound (4a) or (4b) with a base and a compound of
formula (5):
wherein R R2, R3, R4, R5, R6, R7, b, c and Y are as defined herein.
In another aspect, the invention provides a compound which is selected from the compounds of
formulae (4a), (4b), (6a), (6b), (7a), (7b), (9a), (9b), ( 12a), ( 12b), ( 13a), ( 1 3b), (20a) or (20b).
wherein R R3, R4, R5, R , R7, b and c are as defined herein.
In another aspect, the invention provides a transition metal complex of formula (3):
[M X (L1)m (L2)]
(3)
wherein:
M is ruthenium, osmium or iron;
X is an anionic ligand;
L is a monodentate phosphorus ligand, or a bidentate phosphorus ligand;
m is 1 or 2 , wherein,
when m is 1, L is a bidentate phosphorus ligand;
when m is 2 , each L is a monodentate phosphorus ligand ; and
L2 is a tridentate ligand of formula (2a) or (2b):
In another aspect, the invention provides a process for preparing a transition metal complex of
formula (3) as defined herein, the process comprising the step of reacting a transition metal complex,
a ligand L , a compound of formula ( 1a) or ( 1 b) or salts thereof, and a base in an alcohol solvent,
wherein:
the transition metal complex is selected from the group consisting of [ruthenium (arene) (halogen)2]2,
[ruthenium (halogen) (P(unsubstituted or substituted aryl)3)], [osmium (arene) (halogen)2] , [osmium
(halogen)2 (P(unsubstituted or substituted aryl)3)] and [osmium (N(unsubstituted or substituted
alkyl)3)4 (halogen)2] ;
wherein R R2, R3, R4, R5, R6, R7, b and c are as defined herein; and
C-8 of the compound of formula ( 1a) or ( 1 b) is -H.
In another aspect, the invention provides a method of catalysing a reaction, the method comprising
the step of reacting a substrate comprising a carbon-oxygen double bond in the presence of a
complex of formula (3) as defined herein.
In another aspect, the invention provides a method of catalysing a reaction, the method comprising
the step of performing the reaction in the presence of a complex of formula (3) as defined herein ,
wherein the reaction is selected from the group consisting the isomerization of allylic alcohols,
dehydrogenation reactions, the reduction of the alkenyl bond in α,β-unsaturated carbonyls and in
"hydrogen borrowing" reactions.
Definitions
The point of attachment of a moiety or substituent is represented by For example, -OH is attached
through the oxygen atom.
"Alkyl" refers to a straight-chain or branched saturated hydrocarbon group. In certain embodiments,
the alkyl group may have from 1-20 carbon atoms, in certain embodiments from 1- 15 carbon atoms,
in certain embodiments, 1-8 carbon atoms. The alkyl group may be unsubstituted . Alternatively, the
alkyl group may be substituted. Unless otherwise specified, the alkyl group may be attached at any
suitable carbon atom and, if substituted, may be substituted at any suitable atom. Typical alkyl
groups include but are not limited to methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl,
tert-butyl, n-pentyl, n-hexyl and the like.
The term "cycloalkyl" is used to denote a saturated carbocyclic hydrocarbon radical. In certain
embodiments, the cycloalkyl group may have from 3-1 5 carbon atoms, in certain embodiments, from
3-1 0 carbon atoms, in certain embodiments, from 3-8 carbon atoms. The cycloalkyl group may
unsubstituted. Alternatively, the cycloalkyl group may be substituted. Unless other specified, the
cycloalkyl group may be attached at any suitable carbon atom and, if substituted, may be substituted
at any suitable atom. Typical cycloalkyl groups include but are not limited to cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl and the like.
"Alkoxy" refers to an optionally substituted group of the formula alkyl-O- or cycloalkyl-O-, wherein alkyl
and cycloalkyl are as defined above.
"Aryl" refers to an aromatic carbocyclic group. The aryl group may have a single ring or multiple
condensed rings. In certain embodiments, the aryl group can have from 6-20 carbon atoms, in certain
embodiments from 6-1 5 carbon atoms, in certain embodiments, 6-1 2 carbon atoms. The aryl group
may be unsubstituted. Alternatively, the aryl group may be substituted. Unless otherwise specified,
the aryl group may be attached at any suitable carbon atom and , if substituted , may be substituted at
any suitable atom. Examples of aryl groups include, but are not limited to, phenyl, naphthyl,
anthracenyl and the like.
"Arylalkyl" refers to an optionally substituted group of the formula aryl-alkyl-, where aryl and alkyl are
as defined above.
"Halo", "hal" or "halide" refers to -F, -CI, -Br and -I.
"Heteroalkyl" refers to a straight-chain or branched saturated hydrocarbon group wherein one or more
carbon atoms are independently replaced with one or more heteroatoms (e.g. nitrogen, oxygen,
phosphorus and/or sulfur atoms). In certain embodiments, the heteroalkyl group may have from 1-20
carbon atoms, in certain embodiments from 1- 15 carbon atoms, in certain embodiments, 1-8 carbon
atoms. The heteroalkyl group may be unsubstituted . Alternatively, the heteroalkyl group may
substituted. Unless otherwise specified, the heteroalkyl group may be attached at any suitable atom
and , if substituted, may be substituted at any suitable atom. Examples of heteralkyl groups include
but are not limited to ethers, thioethers, primary amines, secondary amines, tertiary amines and the
like.
"Heterocycloalkyl" refers to a saturated cyclic hydrocarbon group wherein one or more carbon atoms
are independently replaced with one or more heteroatoms (e.g. nitrogen, oxygen, phosphorus and/or
sulfur atoms). In certain embodiments, the heterocycloalkyl group may have from 2-20 carbon atoms,
in certain embodiments from 2-1 0 carbon atoms, in certain embodiments, 2-8 carbon atoms. The
heterocycloalkyl group may be unsubstituted. Alternatively, the heterocycloalkyl group may be
substituted. Unless otherwise specified, the heterocycloalkyl group may be attached at any suitable
atom and , if substituted, may be substituted at any suitable atom. Examples of heterocycloalkyl
groups include but are not limited to epoxide, morpholinyl, piperadinyl, piperazinyl, thirranyl,
pyrrolidinyl, pyrazolidinyl, imidazolidinyl, thiazolidinyl, thiomorpholinyl and the like.
"Heteroaryl" refers to an aromatic carbocyclic group wherein one or more carbon atoms are
independently replaced with one or more heteroatoms (e.g . nitrogen, oxygen, phosphorus and/or
sulfur atoms). In certain embodiments, the heteroaryl group may have from 3-20 carbon atoms, in
certain embodiments from 3-1 5 carbon atoms, in certain embodiments, 3-8 carbon atoms. The
heteroaryl group may be unsubstituted. Alternatively, the heteroaryl group may substituted. Unless
otherwise specified, the heteroaryl group may be attached at any suitable atom and , if substituted ,
may be substituted at any suitable atom. Examples of heteroaryl groups include but are not limited to
thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl,
thiadiazolyl, thiophenyl, oxadiazolyl, pyridinyl, pyrimidyl, benzoxazolyl, benzthiazolyl, benzimidazolyl,
indolyl, quinolinyl and the like.
"Substituted" refers to a group in which one or more hydrogen atoms are each independently replaced
with substituents (e.g. 1, 2 , 3 , 4 , 5 or more) which may be the same or different. Examples of
substituents include but are not limited to -halo ,-CF 3, -Ra, -O-R , -S-Ra, -NRaR , -CN, -C(0)-R a, -
COORa, -C(S)-Ra, -C(S)ORa, -S(0) 2OH, -S(0) 2-Ra, -S(0) 2NRaR and -CONRaR , preferably -halo -
CF3, -Ra, -O-R , -NRaR , -COOR a, -S(0) 2OH, -S(0) 2-Ra, -S(0) 2NRaR and -CONRaR . Ra and R are
independently selected from the groups consisting of H , alkyl, aryl, arylalkyi, heteroalkyi, heteroaryl, or
Ra and R together with the atom to which they are attached form a heterocycloalkyi group, and
wherein Ra and R may be unsubstituted or further substituted as defined herein.
Detailed description
Compounds of formula ( 1a) and ( 1 b)
The present invention provides a benzo[/?]quinoline compound of formula ( 1a) or ( 1 b), or salts thereof:
wherein:
R and R2 are independently selected from the group consisting of -H, -OH , unsubstituted C1-2o-alkyl,
substituted C1-2o-alkyl, unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C5.20-
aryl, substituted C5.20-aryl, unsubstituted C^o-heteroalkyl, substituted C^o-heteroalkyl, unsubstituted
C2.20-heterocycloalkyl, substituted C2.20-heterocycloalkyl, unsubstituted C4.20-heteroaryl and
substituted C4.20-heteroaryl;
R3 is selected from the group consisting of -H, unsubstituted C1-2o-alkyl, substituted C1-20-alkyl,
unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C5-20-aryl, substituted C5.20-
aryl, unsubstituted C1-20-heteroalkyl, substituted C1-20-heteroalkyl, unsubstituted C2.20-heterocycloalkyl,
substituted C2.20-heterocycloalkyl, unsubstituted C4.20-heteroaryl and substituted C4.20-heteroaryl;
R4 is selected from the group consisting of unsubstituted C1-20-alkyl, substituted C1-20-alkyl,
unsubstituted C^o-alkoxy, substituted C^o-alkoxy, unsubstituted C5-20-aryl, substituted C5-20-aryl;
R5 is selected from the group consisting of unsubstituted C1-20-alkyl, substituted C1-20-alkyl,
unsubstituted C^o-alkoxy, substituted C^o-alkoxy, unsubstituted C5-20-aryl, substituted C5-20-aryl;
R is selected from the group consisting of -CF3, unsubstituted C1-20-alkyl, substituted C1-20-alkyl,
unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C^o-alkoxy, substituted
20-alkoxy, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C1-20-heteroalkyl, substituted
C1-20-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted C2.20-heterocycloalkyl, unsubstituted
C4 -2o-heteroaryl, substituted C4-2o-heteroaryl, -NR'R" -COOR', -S(0) 2OH, -S(0) 2-R', -S(0) 2NR'R" and
-CONR'R", wherein R' and R" are independently selected from the group consisting of H ,
unsubstituted C o-alkyl, substituted C o-alkyl, unsubstituted C5.20-aryl, substituted C5.20-aryl,
unsubstituted C7.20-arylalkyl, substituted C7.20-arylalkyl, or R' and R" together with the atom to which
they are attached form a substituted or unsubstituted C2.20-heterocycloalkyl group;
R7 is selected from the group consisting of -CF3, unsubstituted C o-alkyl, substituted C o-alkyl,
unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C o-alkoxy, substituted
20-alkoxy, unsubstituted C5.20-aryl, substituted C5.20-aryl, unsubstituted C o-heteroalkyl, substituted
C o-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted C2.20-heterocycloalkyl, unsubstituted
C
-2o-heteroaryl, substituted C4-20-heteroaryl, -NR'R" -COOR', -S(0) 2OH, -S(0) 2-R', -S(0) 2NR'R" and
-CONR'R", wherein R' and R" are independently selected from the group consisting of H ,
unsubstituted C o-alkyl, substituted C o-alkyl, unsubstituted C5.20-aryl, substituted C5.20-aryl,
unsubstituted C7.20-arylalkyl, substituted C7.20-arylalkyl, or R' and R" together with the atom to which
they are attached form a substituted or unsubstituted C2.20-heterocycloalkyl group;
b is an integer selected from 0 , 1 or 2 ; and
c is an integer selected from 0 , 1, 2 , 3 or 4 .
The numbering of the atoms around the benzo[h]quinoline skeleton is illustrated in the formulae
above.
The benzo-fused pyridine ring of the compounds of formulae ( 1) are disubstituted as a group is
present at both C-2 and either at C-3 or C-4. The pyridine ring, therefore, may be substituted by a -
CH(R3)-NR R2 amino group at C-2 and group R4 at C-3 for the compound ( 1a). In this instance, R5 is
-H. Alternatively, the pyridine ring may be substituted by the -CH(R 3)-NR R2 amino group at C-2 and
group R5 at C-4 for the compound ( 1 b). For this compound, R4 is -H.
R and R2 may be independently selected from the group consisting of -H, -OH , unsubstituted C 1-2 o-
alkyl, substituted C 1-2 o-alkyl, unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted
C5.20-aryl, substituted C5.20-aryl, unsubstituted C o-heteroalkyl, substituted C o-heteroalkyl,
unsubstituted C2.20-heterocycloalkyl, substituted C2.20-heterocycloalkyl, unsubstituted C4.20-heteroaryl
and substituted C4.20-heteroaryl. In one embodiment, and R2 are independently selected from the
group consisting of -H, -OH, unsubstituted C 1-2 o-alkyl, substituted C1-20-alkyl, unsubstituted C3.20-
cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C5.20-aryl and substituted C5.20-aryl, such as - H,
methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl,
nonyl, decyl, dodecyl or stearyl, cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl or adamantyl, or aryl groups such as phenyl, naphthyl or anthracyl. In another
embodiment, the alkyl groups may be optionally functionalised with one or more substituents such as
halide (-F, -CI, -Br or -I) or alkoxy groups, e.g. methoxy, ethoxy or propoxy. The aryl group may be
optionally substituted with one or more (e.g . 1, 2 , 3 , 4 , or 5) substituents such as halide (-F, -CI, -Br or
-I), straight- or branched-chain C^C^-alky!, - w alkoxy, straight- or branched-chain - w -
(dialkyl)amino, C3-10 heterocycloalkyl groups (such as morpholinyl and piperadinyl) or tri(halo)methyl
(e.g. F3C-).
In one embodiment, one of and R2 is - H and the other is selected from the group consisting of -H,
-OH, unsubstituted C1-2o-alkyl, substituted C1-2o-alkyl, unsubstituted C3.2o-cycloalkyl, substituted C3_20-
cycloalkyl, unsubstituted C5.20-aryl, substituted C5.20-aryl, unsubstituted C^o-heteroalkyl, substituted
C^o-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted C2.20-heterocycloalkyl, unsubstituted
C4.20-heteroaryl and substituted C4.20-heteroaryl. In one preferred embodiment, one of and R2 is -
H and the other is selected from the group consisting of -H, -OH , unsubstituted C1-2o-alkyl, substituted
C1-20-alkyl, unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C5.20-aryl and
substituted C5-20-aryl, such as -H, -OH, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl,
tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl or stearyl, cycloalkyl groups such as
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or adamantyl, or aryl groups such as phenyl, naphthyl
or anthracyl. In one embodiment, the alkyl groups may be optionally funcationalised with one or more
substituents such as halide (-F, -CI, -Br or -I) or alkoxy groups, e.g . methoxy, ethoxy or propoxy. The
aryl group may be optionally functionalised with one or more (e.g. 1, 2 , 3 , 4 , or 5) substituents such as
halide (-F, -CI, -Br or -I), straight- or branched-chain C^C^-alky!, - w alkoxy, straight- or branched-
chain CrC^-idialkyOamino, C3-10 heterocycloalkyl groups (such as morpholinyl and piperadinyl) or
tri(halo)methyl (e.g. F3C-).
In one preferred embodiment, and R2 are both -H.
R3 is selected from the group consisting of -H, unsubstituted C1-20-alkyl, substituted C1-20-alkyl,
unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C5.20-aryl, substituted C5.20-
aryl, unsubstituted C^o-heteroalkyl, substituted C^o-heteroalkyl, unsubstituted C2.20-heterocycloalkyl,
substituted C2.20-heterocycloalkyl, unsubstituted C4.20-heteroaryl and substituted C4.20-heteroaryl. In
one embodiment, R3 is selected from the group consisting of -H, unsubstituted C1-20-alkyl, substituted
C1-20-alkyl, unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C5.20-aryl and
substituted C5-20-aryl, such as - H, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-
butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl or stearyl, cycloalkyl groups such as
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or adamantyl, or aryl groups such as phenyl, naphthyl
or anthracyl. In another embodiment, the alkyl groups may be optionally substituted with one or more
substituents such as halide (-F, -CI, -Br or -I) or alkoxy groups, e.g. methoxy, ethoxy or propoxy. The
aryl group may be optionally substituted with one or more (e.g. 1, 2 , 3 , 4 , or 5) substituents such as
halide (-F, -CI, -Br or -I), straight- or branched-chain C^C^-alky!, - w alkoxy, straight- or branched-
chain CrC!o-idialkyOamino, C3-10 heterocycloalkyl groups (such as morpholinyl and piperadinyl) or
tri(halo)methyl (e.g. F3C-). More preferably, R3 is selected from -H, methyl, ethyl, n-propyl, iso-propyl,
n-butyl, iso-butyl, sec-butyl, tert-butyl and phenyl. In one embodiment, R3 is -H.
When R3 is -H, the carbon atom to which R3 is attached is not chiral. However, when R3 is not - H,
the compounds ( 1) will contain a chiral centre in the -CH(R 3)-NR R2 group. The compounds ( 1) can
be used as a racemic mixture, as either single enantiomer or as a mixture of enantiomers, preferably
as a single enantiomer. The enantiomers of compounds ( 1) may be obtained in enantiomerically pure
form by the resolution of e.g. a racemic mixture of compound ( 1a) or ( 1 b).
For the compound ( 1a), R4 is selected from the group consisting of unsubstituted C1-2o-alkyl,
substituted C1-2o-alkyl, unsubstituted C^o-alkoxy, substituted C^o-alkoxy, unsubstituted C5_2o-aryl,
substituted C5_2o-aryl. In one embodiment, R4 is selected from the group consisting of unsubstituted
C1-2o-alkyl, substituted C1-20-alkyl, unsubstituted C5-20-aryl, substituted C5-20-aryl. In another
embodiment, R4 may be selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-
butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl, stearyl, phenyl, -
phenyl-CF3 (e.g . 2-, 3- or 4-CF3-phenyl, such as 4-CF3-phenyl), -pentahalophenyl (e.g.
pentafluorophenyl), naphthyl and anthracyl, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-
butyl, sec-butyl, tert-butyl, phenyl, -phenyl-CF 3 (e.g. 2-, 3- or 4-CF3-phenyl, such as 4-CF3-phenyl) or -
pentahalophenyl (e.g. pentafluorophenyl). In another embodiment, R4 is selected from the group
consisting of unsubstituted C1-20-alkyl and unsubstituted C5-20-aryl. In another embodiment, R4 may
be selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-
butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl, stearyl, phenyl, naphthyl and
anthracyl, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, phenyl,
naphthyl and anthracyl. In one embodiment, R4 is methyl. In another embodiment, R4 is phenyl. In
another embodiment, R4 is -phenyl-CF 3. In another embodiment, R4 is pentafluorophenyl.
For the compound ( 1 b), R5 is selected from the group consisting of unsubstituted C1-20-alkyl,
substituted C1-20-alkyl, unsubstituted C^o-alkoxy, substituted C^o-alkoxy, unsubstituted C5-20-aryl,
substituted C5-20-aryl. In one embodiment, R5 is selected from the group consisting of unsubstituted
C1-20-alkyl, substituted C1-20-alkyl, unsubstituted C5-20-aryl, substituted C5-20-aryl. In another
embodiment, R5 may be selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-
butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl, stearyl, phenyl, -
phenyl-CF3 (e.g . 2-, 3- or 4-CF3-phenyl, such as 4-CF3-phenyl), -pentahalophenyl (e.g.
pentafluorophenyl), naphthyl and anthracyl, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-
butyl, sec-butyl, tert-butyl, phenyl, -phenyl-CF 3 (e.g. 2-, 3- or 4-CF3-phenyl, such as 4-CF3-phenyl) or -
pentahalophenyl (e.g. pentafluorophenyl). In another embodiment, R5 is selected from the group
consisting of unsubstituted C1-20-alkyl and unsubstituted C5-20-aryl. In another embodiment, R5 may
be selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-
butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl, stearyl, phenyl, naphthyl and
anthracyl, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, phenyl,
naphthyl and anthracyl. In one preferred embodiment, R5 is methyl. In another embodiment, R5 is
phenyl. In another embodiment, R5 is -phenyl-CF 3. In another embodiment, R5 is pentafluorophenyl.
R may be present or absent. When absent, b is 0 i.e. the aryl ring is unsubstituted. When R is
present, b may be 1 or 2 . When b is 2 , each R may be the same or different to each other. The or
each R may be selected from the group consisting of -CF 3, unsubstituted C1-2o-alkyl, substituted
2o-alkyl, unsubstituted C3_2o-cycloalkyl, substituted C3_2o-cycloalkyl, unsubstituted C^o-alkoxy,
substituted C^o-alkoxy, unsubstituted C5_2o-aryl, substituted C5_2o-aryl, unsubstituted C^o-heteroalkyl,
substituted C^o-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted C2.20-heterocycloalkyl,
unsubstituted C4.20-heteroaryl, substituted C4.20-heteroaryl, -NR'R" -COOR', -S(0) 2OH , -S(0) 2-R', -
S(0) 2NR'R" and -CONR'R", wherein R' and R" are independently selected from the group consisting
of H , unsubstituted C1-2o-alkyl, substituted C1-2o-alkyl, unsubstituted C5.20-aryl, substituted C5.20-aryl,
unsubstituted C7.20-arylalkyl, substituted C7.20-arylalkyl, or R' and R" together with the atom to which
they are attached form a substituted or unsubstituted C2.20-heterocycloalkyl group. In one
embodiment, R is selected from the group consisting of -CF 3, unsubstituted C1-20-alkyl, substituted
C1-20-alkyl, unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C^o-alkoxy,
substituted C^o-alkoxy, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C1-20-heteroalkyl,
substituted C1-20-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted C2.20-heterocycloalkyl,
unsubstituted C4.20-heteroaryl and substituted C4.20-heteroaryl. In one embodiment, R is
independently selected from the group consisting of unsubstituted C1-20-alkyl, substituted C1-20-alkyl,
unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C5.20-aryl and substituted C5_
2o- y . sucn as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl,
heptyl, octyl, nonyl, decyl, dodecyl or stearyl, cycloalkyl groups such as cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl or adamantyl, or aryl groups such as phenyl, naphthyl or anthracyl. In another
embodiment, the alkyl groups may be optionally substituted with one or more substituents such as
halide (-F, -CI, -Br or -I) or alkoxy groups, e.g. methoxy, ethoxy or propoxy. The aryl group may be
optionally substituted with one or more (e.g . 1, 2 , 3 , 4 , or 5) substituents such as halide (-F, -CI, -Br or
-I), straight- or branched-chain C^C^-alky!, - w alkoxy, straight- or branched-chain - w -
(dialkyl)amino, C3-10 heterocycloalkyl groups (such as morpholinyl and piperadinyl) or tri(halo)methyl
(e.g. F3C-). In one preferred embodiment, b is 0 i.e. R is absent.
R7 may be present or absent. When absent, c is 0 i.e. the aryl ring is unsubstituted. When R7 is
present, c may be 1, 2 , 3 or 4 , such as 1, 2 or 3 . When c is 2 , 3 or 4 , each R7 may be the same or
different to each other. The or each R7 may be selected from the group consisting of -CF 3,
unsubstituted C1-20-alkyl, substituted C1-20-alkyl, unsubstituted C3.20-cycloalkyl, substituted C3.20-
cycloalkyl, unsubstituted C^o-alkoxy, substituted C^o-alkoxy, unsubstituted C5.20-aryl, substituted C5_
2o-aryl, unsubstituted C^o-heteroalkyl, substituted C^o-heteroalkyl, unsubstituted C2.20-
heterocycloalkyl, substituted C2.20-heterocycloalkyl, unsubstituted C4.20-heteroaryl, substituted C4.20-
heteroaryl, -NR'R" -COOR', -S(0) 2OH , -S(0) 2-R', -S(0) 2NR'R" and -CONR'R", wherein R' and R"
are independently selected from the group consisting of H, unsubstituted C1-20-alkyl, substituted C1-20-
alkyl, unsubstituted C5.20-aryl, substituted C5.20-aryl, unsubstituted C7.20-arylalkyl, substituted C7.20-
arylalkyl, or R' and R" together with the atom to which they are attached form a substituted or
unsubstituted C2.20-heterocycloalkyl group. In one embodiment, R7 is selected from the group
consisting of -CF 3, unsubstituted C1-2o-alkyl, substituted C1-2o-alkyl, unsubstituted C3.2o-cycloalkyl,
substituted C3.2o-cycloalkyl, unsubstituted C^o-alkoxy, substituted C^o-alkoxy, unsubstituted C5_20-
aryl, substituted C5.20-aryl, unsubstituted C^o-heteroalkyl, substituted C^o-heteroalkyl, unsubstituted
C2.20-heterocycloalkyl, substituted C2.20-heterocycloalkyl, unsubstituted C4.20-heteroaryl and
substituted C4.20-heteroaryl.. In one embodiment, R7 is independently selected from the group
consisting of unsubstituted C1-2o-alkyl, substituted C1-20-alkyl, unsubstituted C3.20-cycloalkyl,
substituted C3.20-cycloalkyl, unsubstituted C5.20-aryl and substituted C5-20-aryl, such as methyl, ethyl,
n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl,
dodecyl or stearyl, cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or
adamantyl, or aryl groups such as phenyl, naphthyl or anthracyl. In another embodiment, the alkyl
groups may be optionally substituted with one or more substituents such as halide (-F, -CI, -Br or -I) or
alkoxy groups, e.g. methoxy, ethoxy or propoxy. The aryl group may be optionally substituted with
one or more (e.g. 1, 2 , 3 , 4 , or 5) substituents such as halide (-F, -CI, -Br or -I), straight- or branched-
chain C^C^-alky!, - w alkoxy, straight- or branched-chain CrC^-idialkyOamino, C3-10
heterocycloalkyi groups (such as morpholinyl and piperadinyl) or tri(halo)methyl (e.g . F3C-). In one
preferred embodiment, the aromatic ring is unsubstituted at C-8 i.e. R7 is absent at C-8.
In one preferred embodiment, c is 0 i.e. R7 is absent.
In another preferred embodiment, c is 1 and is present at C-5. R may be present or absent as
described above, preferably, absent i.e. b is 0 . The compounds of formula ( 1a) and ( 1 b) therefore
have the following structures:
( 1a) ( 1 b)
In one preferred embodiment, the compound of formula ( 1a) may be selected from the group
consisting of:
In one particularly preferred embodiment, the compound of formula ( 1a) may be selected from the
group consisting of:
In one preferred embodiment, the compound of formula ( 1 b) may be selected from the group
consisting of:
In one particularly preferred embodiment, the compound of formula ( 1 b) may be selected from the
group consisting of:
The compounds of formula ( 1 a) and ( 1 b) may form a salt with a suitable acid e.g. a suitable organic or
inorganic acid. The compound ( 1a) or ( 1 b) may be reacted as the free base with a suitable acid to
form the salt. Alternatively, the acid may be present in situ during the preparation of the compounds
( 1a) and ( 1 b). In this instance, the salts of ( 1a) and ( 1 b) may be isolated directly from the reaction
mixture. In one embodiment, the acid may be a hydrohalide acid, such as hydrochloric acid,
hydrobromic acid or hydroiodic acid. The salts of compounds ( 1a) or ( 1 b) may accordingly be
hydrochloride salts, hydrobromide salts or hydroiodide salts. In one embodiment, the salt is a
hydrochloride salt. In another embodiment, the acid may be selected from the group consisting of
acetic acid, trifluoroacetic acid, methylsulfonic acid, trifluoromethylsulfonic acid , p-toluenesulfonic acid
phosphoric acid, benzoic acid , salicylic acid, and citric acid. The salts of compounds ( 1a) or ( 1 b) may
accordingly be acetate salts, trifluoroacetate salts, methylsulfonate salts, trifluoromethylsulfonate
salts, p-toluenesulfonate salts, phosphate salts, benzoate salts, salicylate salts, or citrate salts.
When R3 of the compound ( 1 a) or ( 1 b) is not -H, optical resolution of the enantiomers of compounds
( 1a) and ( 1 b) may be performed by methods known in the art. For example, a racemic mixture of
compound ( 1a) may be optically resolved using an acid chiral resolving agent. A racemic mixture of
compound ( 1 b) may be optically resolved likewise. Chiral resolving agents include but are not limited
to L-(+)- tartaric acid, D-(-)-tartaric acid, L-(+)- mandelic acid or D-(-)-mandelic acid. It is envisaged
that a racemic chiral acid may be used to form a diastereomeric mixture of salts of compounds ( 1a)
and ( 1 b). If desired, resolution of the diastereomers may occur by fractional crystallisation . It is also
envisaged that enzymatic resolution of the enantiomers of compounds ( 1 a) and ( 1 b) may be possible
with an enzyme such as a lipase.
The isolation of the compounds ( 1a) and ( 1 b) as salts (in particular, hydrochloride salts) provide
stable ligand precursors, which can be stored in air at room temperature in the absence of moisture
for a long time without degradation (for example, for more than two years) and can be used directly in
the preparation of transition metal complexes.
Preparation of the compounds of formula ( 1a) and ( 1 b)
The compounds of formula ( 1a) and ( 1 b), and salts thereof, may be prepared from a compound of
formula (4a) or (4b), and salts thereof, by methods known in the art. In this respect, a compound (4a)
reacts to form a compound ( 1a) and a compound (4b) reacts to form a compound ( 1 b). For example,
the compound (4a) or (4b) may be reacted with a base and a compound of formula (5):
(4a) (4b)
wherein:
Y is a leaving group.
R R3 , R4, R5 , R , R7, b and c are as generally described above.
In this instance, R2 may be selected from the group consisting of unsubstituted C1-2o-alkyl, substituted
C1-2o-alkyl, unsubstituted C3.2o-cycloalkyl, substituted C3_2o-cycloalkyl, unsubstituted C^o-heteroalkyl,
substituted C^o-heteroalkyl, unsubstituted C2.20-heterocycloalkyl and substituted C2.20-
heterocycloalkyl. In one embodiment, R2 may be selected from the group consisting of unsubstituted
C1-2o-alkyl, substituted C1-20-alkyl, unsubstituted C3.20-cycloalkyl and substituted C3.20-cycloalkyl.
The base may be any suitable base which is capable of deprotonating the -NHRT group of the
compound (4a) or (4b). Suitable bases include but are not limited to organic or inorganic bases.
Inorganic bases may be selected from the group consisting of hydroxides, alkoxides, carbonates,
acetates. Suitable hydroxides include alkali metal hydroxides (e.g. lithium hydroxide, sodium
hydroxide or potassium hydroxide) or tetraalkylammonium hydroxides (e.g. tetrabutylammonium
hydroxide). Suitable alkoxides include alkali metal alkoxides (e.g. lithium alkoxide, sodium alkoxide
(such as sodium methoxide) or potassium alkoxide) or tetraalkylammonium alkoxides (e.g
tetrabutylammonium hydroxide). Suitable carbonates include but are not limited to potassium
carbonate or sodium carbonate. Suitable acetates include but are not limited to potassium acetate or
sodium acetate. Organic bases include but are not limited to organolithium reagents, such as
butyllithium (e.g. n-, sec- or tert-butyllithium) or lithium diisopropylamide (LDA).
The reaction may be carried out under an inert atmosphere (such as nitrogen or argon). Suitably, a
solvent may be used, for example, any suitable protic or aprotic polar solvent or combinations thereof
) . Suitable protic solvent include but are not limited to alcohols (such as methanol, ethanol, 1-
propanol, 2-propanol, 1-butanol, 2-butanol, t-butanol or benzylic alcohol). Suitable aprotic solvents
include but are not limited to ethers (e.g . tetrahydrofuran (THF), 2-methyltetrahydrofuran (2-Me-THF),
dioxane, methyltertbutylether (MTBE) or diethylether), amides (e.g. dimethylformamide (DMF), N-
methylpyrrolidine (NMP) or dimethylacetamide (DMAc)) or chlorinated alkanes (such as
chloromethane or dichloromethane (DCM)). The solvent may be anhydrous.
The compound (4a) or (4b), the base, the solvent and the compound (5) may be added in any suitable
order. In one embodiment of the invention, however, the compound (4a) or (4b) and the base is
placed in a reaction vessel, together with the solvent, and then the compound (5) is added.
Y is a leaving group and may be a halide. In one embodiment, the halide may be selected from the
group consisting of chloride, bromide or iodide.
The reaction may be continued for a suitable period of time until it is determined (e.g . by GC) that the
reaction substantially complete. The period of time may vary from about 30 minutes to about 72
hours, preferably 30 minutes to about 24 hours. During this time, the reaction temperature may be
varied one or more times between about - 10°C and about 25°C. If desired , on completion of the
reaction, the compound of formula ( 1a) or ( 1 b) may be separated from the reaction mixture by any
appropriate method.
As described above, the compounds of formula ( 1a) and ( 1 b) may form a salt with a suitable acid.
The compounds ( 1a) and ( 1 b) may be reacted as the free base with a suitable acid to form the salt.
Alternatively, the acid may be present in situ during the preparation of compounds ( 1 a) and ( 1 b) . For
example, the compounds (4a) and (4b) may be reacted as acid addition salts of compounds (4a) and
(4b) forming the acid addition salts of compounds ( 1a) and ( 1 b). The extra addition of acid to the
reaction mixture comprising compounds (4a) and (4b), therefore, may not be necessary in order to
prepare salts of compounds ( 1a) and ( 1 b). The acid used is as generally described above.
Preparation of the compounds of formulae (4a) and (4b)
The compound of formula (4a) or (4b) may be prepared by reducing a compound (6a) or (6b). In this
respect, a compound (6a) is reduced to a compound (4a) and a compound (6b) is reduced to a
compound (4b).
(6a) (6b)
R , R3, R4, R5, R6, R7, b and c are as generally described above.
It will be understood that, in the depictions herein, where P is connected by a wavy line (·~«~ ) , both
or either enantiomer may be present.
In one embodiment, the reduction may be a hydrogenation reaction . The hydrogenation reaction may
comprise reacting the compound (6a) or (6b) with gaseous hydrogen in the presence of a
hydrogenation catalyst and an acid in a suitable solvent. The hydrogenation catalyst may be a
heterogeneous or homogeneous catalyst, preferably a heterogeneous catalyst. The catalyst (whether
heterogeneous or homogeneous) should be selected such that the catalyst preferentially reduces the
-(R3)C=N(R )- double bond rather than reducing another group present in the compound (6a) or (6b).
In one embodiment, the heterogeneous catalyst is a heterogeneous platinum group metal (PGM)
catalyst, for example, a heterogeneous palladium or platinum catalyst. In one embodiment, the
heterogeneous catalyst is a heterogeneous palladium catalyst. Examples of palladium catalysts
include but are not limited to colloidal palladium, palladium sponge, palladium plate or palladium wire.
Examples of platinum catalysts include but are not limited to colloidal platinum, platinum sponge,
platinum plate or platinum wire.
The heterogeneous PGM metal catalyst may be a PGM on a solid support. The support may be
selected from the group consisting of carbon , alumina, calcium carbonate, barium carbonate, barium
sulfate, titania, silica, zirconia, ceria and a combination thereof. When the support is alumina, the
alumina may be in the form of alpha-AI20 3, beta-AI20 3, gamma-AI20 3, delta-AI20 3, theta-AI20 3 or a
combination thereof. When the support is carbon, the carbon may be in the form of activated carbon
(e.g. neutral, basic or acidic activated carbon), carbon black or graphite (e.g . natural or synthetic
graphite). An example of a heterogeneous PGM catalyst is palladium on carbon. An example of
another heterogeneous PGM catalyst is platinum on carbon.
The catalyst loading may be up to about 20 mole%. A greater catalyst loading may perform the
desired reduction, however, increasing the quantity of the PGM may make the process uneconomical.
In one embodiment, the catalyst loading may be up to 10 mole% and, in another embodiment, may be
in the range of about 0 .1- 10.0 mole % .
The acid may be any suitable acid, such as a hydrohalide acid e.g. hydrochloric acid, hydrobromic
acid or hydroiodic acid. The acid may be added as a reagent to the hydrogenation reaction or the
compounds (6a) and (6b) may be reacted as acid addition salts. The salts are as generally described
above. Without wishing to be bound by theory, it is believed that the benzo-fused pyridinyl N atom
needs to be protonated in order for the hydrogenation to proceed.
Any suitable solvent may be utilised e.g. polar solvents, such as an alcohol. The alcohol may be
selected from the group consisting of methanol, ethanol, isopropanol and mixtures thereof. In one
embodiment, the solvent is methanol.
The compound (6a) or (6b) may be placed in a pressure vessel together with the hydrogenation
catalyst. The pressure vessel may then be assembled and purged with one or more nitrogen/vacuum
cycles (e.g. one, two, three or four cycles). The alcohol solvent may then added via the injection port
to form a solution of the compound (6a) or (6b), which may have concentration in the range of about
0.01 to about 1 molar, such as about 0.3 molar. If the hydrogenation catalyst is heterogeneous, the
catalyst will not dissolve in the alcohol solvent. However, if the hydrogenation catalyst is
homogeneous, it may dissolve in the alcohol solvent and form a solution with the compound (5a) or
(5b).
Once the alcohol solvent has been added, the pressure vessel may be purged once again with one or
more nitrogen/vacuum cycles (e.g. one, two, three, four or five cycles), followed by one or more
hydrogen/vacuum cycles (e.g. one, two, three, four or five cycles). During purging the reaction
mixture may be agitated (by either stirring or shaking) to encourage removal of dissolved oxygen.
The pressure vessel may then be pressurised with hydrogen (e.g. to about 5 bar), stirred and heated
to temperature (e.g. about 30 °C). Hydrogen gas uptake may begin after a period of time has elapsed
(e.g. after about 45 minutes on a 6 g scale reaction). Once hydrogen uptake begins, the pressure
vessel may optionally be depressurised with hydrogen
While it is typically sufficient for a single charge of hydrogenation catalyst to be added to the reaction
mixture, a second or further charge may be added and the hydrogenation continued if it has been
determined (e.g. via in-process analysis) that the reaction has not gone substantially to completion
and starting material remains.
There is no particular limitation on the pressure at which the hydrogenation is carried out. In this
regard, the hydrogenation may conveniently be carried out with an initial hydrogen pressure in the
range of up to about 7 bar (about 100 psi) e.g. about 5 ± 1 bar.
The reaction temperature may be suitably in the range from about 15 to about 75 °C, such as in the
range from about 20 to about 60 °C, for example, about 25 to about 50 °C. In one embodiment, the
reaction temperature may be about 30 °C.
The reaction mixture may then be stirred in the presence of hydrogen gas until hydrogen uptake is no
longer apparent. The hydrogenation reaction is carried out for a period of time until it is determined
that the reaction is substantially complete. Completion of the reaction may be determined by in-
process analysis or by identifying that there is no longer an uptake of hydrogen gas. Typically the
hydrogenation is complete within about 24 hours, and in some embodiments, within about 90 minutes.
On completion of the reaction, the reaction vessel may be cooled to ambient temperature and purged
with one or more nitrogen/vacuum cycles (e.g. one, two, three, four or five cycles) to remove excess
hydrogen gas. The hydrogenation catalyst may be removed by any appropriate method, such as
filtration (e.g . using a pad of Celite), washed one or more times with alcohol solvent (e.g. one, two,
three or more times) and the filtrate further treated as desired. A proportion of the solvent may be
evaporated if desired prior to recovery of the compound of formula (4a) or (4b).
Howsoever the compound (4a) or (4b) is recovered, the separated compounds may be washed and
then dried. Drying may be performed using known methods, for example at temperatures in the
range 10-60°C and preferably 20-40°C under 1-30 mbar vacuum for 1 hour to 5 days. If desired the
compound (4a) or (4b) may be recrystallised, although in certain embodiments this is generally not
required and the compounds (4a) and (4b), or salts thereof, may be used to form compounds ( 1a) and
( 1 b), or salts thereof, without further purification.
In this embodiment, in the compounds (6a) and (6b), R may be as generally described above or may
be -OH. In one embodiment, R is -OH i.e. the -(R3)C=N(OH) group is an oxime. In this instance,
the compounds (6a) and (6b) have the following structure:
In this embodiment, when the -(R3)C=N(OH)- group is hydrogenated, the -OH is replaced by a - H
during the reaction. The compound ( 1a) or ( 1 b), therefore, may be prepared directly from a
compound (6a) or (6b) as the compound ( 1a) or ( 1 b) comprises a primary amine i.e. an -NH 2 group.
Alternatively, when R is OH for the compounds (6a) and (6b), the oxime group -(R3)C=N(OH) may be
reduced to the primary amine using a reducing agent selected from the group consisting of lithium
aluminium hydride (LiAIH4) , LiAIH(OMe)3, LiAIH(OEt)3, AIH3, BH3 THF (borane tetrahydrofuran
complex) solution , BH3 DMS (borane dimethyl sulfide complex) solution, sodium borohydride (NaBH4)
and B2H . In one embodiment, the reducing agent may be LiAIH4. In another embodiment, the
reducing agent may be NaBH4.
In another embodiment, when R is OH for the compounds (6a) and (6b), the oxime group -
(R3)C=N(OH) may be reduced to the primary amine using a reducing agent which is zinc and acetic
acid.
In another embodiment, the reduction may be a transfer hydrogenation reaction. The transfer
hydrogenation reaction may comprise reacting a compound (6a) or (6b) with a hydrogen donor in the
presence of a transfer hydrogenation catalyst. The hydrogen donor may be selected from formic acid,
a formic acid alkali salt (for example, sodium formate) and an alcohol, such as an alcohol having a
hydrogen atom at a carbon that is a to the carbon atom to which the alcohol group is attached. An
example of a suitable alcohol includes but is not limited to iso-propanol. In this embodiment,
hydrogen is formally added across the -(R3)C=N(R )- double bond , however, gaseous hydrogen (H2)
is not the source.
The transfer hydrogenation catalyst may be catalysts of the type [(sulphonylated diamine) RuCI
(arene)] or heterogeneous PGM catalysts as described above.
In this embodiment, is not -OH and is as generally described above.
When R is not - H or -OH, the compound (6a) or (6b) may be reduced with an achiral catalyst to form
a racemate. Compounds (4a) and (4b) can then be obtained in enantiomerically pure form by
resolution of the racemic mixture as generally described above. Suitable acid resolving agents are
also as generally described above.
Alternatively, when is not - H or -OH , the compound (6a) or (6b) may be asymmetrically reduced
with a chiral catalyst to produce an enantiomerically enriched compound (4a) or (4b). Each
enantiomer is within the scope of the present invention.
The compounds of formula (6a) or (6b) may form a salt with a suitable acid . The compounds (6a) and
(6b) may be reacted as the free base with a suitable acid to form the salt. Alternatively, the acid may
be present in situ during the preparation of compounds (6a) and (6b). For example, the compounds
(7a) and (7b), described below, may be reacted as acid addition salts of compounds (7a) and (7b)
forming the acid addition salts of compounds (6a) and (6b). The extra addition of acid to the reaction
mixture comprising compounds (7a) and (7b), therefore, may not be necessary in order to prepare
salts of compounds (6a) and (6b). Suitable acids are as generally described above.
In one embodiment, the acid may be a hydrohalide acid, such as hydrochloric acid, hydrobromic acid
or hydroiodic acid. The salts of compounds (6a) and (6b) may accordingly be hydrochloride salts,
hydrobromide salts or hydroiodide salts. In one embodiment, the salt is a hydrochloride salt.
Preparation of compounds of formulae (6a) and (6b)
The compound (6a) or (6b), or salts thereof, may be prepared by the reaction of a compound of
formula (7a) or (7b). In this respect, a compound (7a) reacts to form a compound (6a), or salt thereof,
and a compound (7b) reacts to form a compound (6b), or salt thereof.
(7a) (7b)
R 3 , R 4 , R 5 , R , R7, b and c are as generally described above.
Compounds (7a) and (7b) may be reacted with a compound of formula (8), or salt thereof, in an
alcohol solvent to form compound (6a) or (6b).
/
R3-
\
H
(8)
wherein,
R 3 is as defined above; and
R 3 0 is selected from the group consisting of - H and -OH.
The compound (8) reacts with the carbonyl group of compounds (7a) and (7b) to form the iminyl
group of compounds (6a) and (6b). In one embodiment, R 3 0 is - H i.e. the compound (8) is a primary
amine. In another embodiment, R 3 0 is -OH i.e. the compound (8) is a hydroxylamine.
Salts of compounds (8) may be used in this reaction. The salts of compounds ( 1a) or ( 1 b) may be
hydrochloride salts, hydrobromide salts or hydroiodide salts. In one embodiment, the salt is a
hydrochloride salt. Salts of compounds (6a) and (6b) may be precipitated from the reaction mixture
when salts of compounds (8) are utilised as a reactant, thus facilitating the isolation of the compounds
(6a) and (6b) and, if desired, subsequent purification.
When compound (8) is a hydroxylamine (i.e. when R 3 0 is -OH) and the hydroxylamine is reacted as
the hydrochloride salt, the inventors have noted that the oxime hydrochlorides (6a) and (6b) may
precipitate from the reaction mixture as stable solids.
The compound (8), or salt thereof, may be present in stoichiometric or greater quantities to the
compound (7a) or (7b). The molar ratio of the compound (7a) or (7b) to compound (8), or salt thereof,
may be in the range of about 1 to about 5 , such as about 1 to about 3 , for example, about 1 to about
2 . In one embodiment, the molar ratio of the compound (7a) or (7b) to compound (8), or salt thereof,
is about 1 to about 1. In another embodiment, the molar ratio of the compound (7a) or (7b) to
compound (8), or salt thereof, is about 1 to about 1.8.
When the free base of compound (7a) or (7b) is reacted, stoichiometric or slight excess of base may
be suitable, for example, about 1 : about 1.1 to about 1 : about 1.5 molar ratio of compound ( 1a) or
( 1 b) to base.
The reaction comprises an alcohol solvent. The alcohol may be selected from the group consisting of
methanol, ethanol, isopropanol and mixtures thereof. In one embodiment, the solvent is ethanol. The
concentration of compound (7a) or (7b) in the alcohol solvent may be about 0.001 mol/L to about 1.0
mol/L, such as about 0.01 to about 0.75 mol/L, for example, about 0 .1 mol/L to about 0.5 mol/L. In
one embodiment, the concentration of compound (7a) or (7b) in the alcohol solvent is about 0.2 to
about 0.4 mol/L, for example, about 0.28 mol/L or about 0.37 mol/L.
The compound (7a) or (7b), the solvent and the compound (8) may be added in any suitable order. In
one embodiment, however, the compound (7a) or (7b) is suspended in the alcohol solvent in a
reaction vessel, optionally heated to temperature, and then the compound (8) is added . The
compound (8) may be added in one portion or portionwise. In one embodiment, the compound (8) is
added in one portion. When compound (8) is a hydroxylamine hydrochloride (i.e. when R30 is -OH),
the reaction mixture may form a solution on addition of the hydroxylamine.
The reaction temperature may be suitably in the range from about 15 to about 75 °C, such as in the
range from about 20 to about 60 °C, for example, about 25 to about 50 °C. In one embodiment, the
reaction temperature may be about 40 °C.
The reaction is carried out for a period of time until it is determined that the reaction is substantially
complete. Completion of the reaction may be determined by in-process analysis. Typically the
reaction is complete within about 24 hours, and in some embodiments, within about 90 minutes.
On completion of the reaction, the reaction mixture may be cooled (e.g. to 0 °C using an ice-bath).
When a free base of compound (8) has been used, the free base of the compounds (6a) and (6b)
may be isolated as the product by evaporating a proportion of the solvent. Alternatively, salts of
compounds (6a) and (6b) may be isolated by treating the reaction mixture comprising the free bases
of the compounds (6a) and (6b) with a suitable acid. Suitable acids are as generally described above.
In one embodiment, the acid may be a hydrohalide acid, such as hydrochloric acid, hydrobromic acid
or hydroiodic acid. The salts of compounds (6a) and (6b) may accordingly be hydrochloride salts,
hydrobromide salts or hydroiodide salts. In one embodiment, the salt is a hydrochloride salt. In yet
another embodiment, salts of compounds (6a) and (6b) may be obtained on utilising a salt of
compound (8). In this instance, on completion of the reaction and on cooling the reaction vessel
additional product may precipitate from the reaction mixture. The solid may be filtered and washed
one or more times with alcohol solvent (e.g. one, two, three or more times).
Howsoever the compound (6a) or (6b), or salt thereof, is recovered, the compounds may be dried.
Drying may be performed using known methods, for example at temperatures in the range 10-60°C
and preferably 20-40°C under 1-30 mbar vacuum for 1 hour to 5 days. Typically, the compounds (6a)
and (6b), or salts thereof, may be used to form the compounds (4a) and (4b) without further
purification.
Preparation of the compounds of formulae (7a) and (7b)
The compounds of formula (7a) or (7b) may be prepared in a process comprising the steps of:
(a) reacting a compound of formula (9a) or (9b) with a lithiating agent in an ethereal solvent
to form the lithiated compound ( 1 0a) or ( 10b); and
reacting the lithiated compound ( 10a) or ( 10b) with a compound of formula ( 1 1) to form
the compound of formula (7a) or (7b).
wherein:
R3, R4, R5, R , R7, b and c are as generally described above; and
Z is -N(alkyl) 2 or -Hal.
A compound (9a) reacts via compound ( 10a) to form a compound (7a) and a compound (9b) reacts
via a compound ( 10b) to form a compound (7b).
The lithiating agent may be an alkyl lithium reagent, such as n-BuLi or sec-BuLi. The alkyl lithium
reagent may be conveniently purchased as a solution in a solvent, such as hexane. Stoichiometric or
slight excess of lithiating agent may be used. For example, the molar ratio of compound (9a) or (9b)
to lithiating agent may be about 1 to about 1 or about 1.1 to about 1 to about 1.5, such as about 1 to
about 1.25.
The ethereal solvent may be an alkyl ether. Preferably, the alkyl ether is anhydrous. In one
embodiment, the alkyl ether is a cyclic alkyl ether and more preferably tetrahydrofuran (THF). In
another embodiment, the alkyl ether is diethyl ether or methyl tert-butyl ether (MTBE). With regard to
THF and MTBE, the use of alkyl ethers such as these have higher flashpoint temperatures and , as
such, may provide improved safety in handling. The concentration of compound (9a) or (9b) in the
ethereal solvent may be about 0.001 mol/L to about 1.0 mol/L, such as about 0.01 to about 0.9 mol/L,
for example, about 0 .1 mol/L to about 0.85 mol/L. In one embodiment, the concentration of
compound (9a) or (9b) in the ethereal solvent is about 0.25 to about 0.8 mol/L, for example, about
0.72 mol/L or about 0.33 mol/L.
The solution of the compound (9a) or (9b) may be cooled to e.g. about -78 °C before the lithiating
agent is added. In this respect, the reaction temperature at which the lithiating reaction may occur
can be suitably in the range from about -78 to about -20 °C, such as in the range from about -78 to
about -50 °C. In one embodiment, the reaction temperature may be about -78 °C. An isopropanol/dry
ice bath may be used to cool the reaction mixture to about -78 °C.
The compound (9a) or (9b), the ethereal solvent and the lithiating agent may be added in any suitable
order. In one embodiment, the compound (9a) or (9b) is dissolved in the ethereal solvent in a
reaction vessel, cooled, before adding the lithiating agent. The lithiating agent may be added in one
portion or portionwise (e.g . dropwise) over a period of time. In one embodiment, the lithiating agent is
added portionwise. The lithiating agent may be added using a syringe or a dropping funnel. If
desired , the syringe or dropping funnel may be washed with a portion of ethereal solvent and the
wash added to the reaction mixture.
The reaction mixture of step (a) is stirred for a period of time of up to about 3 hours when reacting
compounds (9a) and (9b) with the lithiating agent on a scale of about 22 g or less. For larger
reactions, however, the lithiating step may require a longer reaction time.
The compound of formula ( 1 1) is added to the reaction mixture comprising the compound ( 10a) or
( 10b) to form the compound (7a) or (7b). Stoichiometric or excess of compound ( 1 1) may be used.
For example, the molar ratio of compound (9a) or (9b) to compound ( 1 1) may be about 1 to about 1 or
about 1 to about 1.1 to about 1 to about 1.5, such as about 1 to about 1.25.
The compound ( 1 1) may be selected from the group consisting of Ν ,Ν-dimethylformamide (DMF),
Ν ,Ν-dimethylacetamide (DMA), N,N-dimethylpropionamide, Ν ,Ν-dimethylbutionamide and N,N-
dimethylbenzamide. DMF provides a compound (7a) or (7b) where R3 is -H, DMA provides a
compound (7a) or (7b) where R3 is -Me, Ν ,Ν-dimethylpropionamide provides a compound (7a) or (7b)
where R3 is -Et, Ν ,Ν-dimethylbutionamide provides a compound (7a) or (7b) where R3 is -Bu and
Ν ,Ν-dimethylbenzamide provides a compound (7a) or (7b) where R3 is -Ph.
Step (b) may be carried out at one or more temperatures in the range of about -78 to about 30 °C. In
one embodiment, the compound ( 1 1) is reacted with the compound ( 10a) or ( 10b) at a temperature
lower than -65 °C and the reaction mixture allowed to warm slowly to room temperature.
Step (b) is carried out for a period of time until it is determined that the reaction is substantially
complete. Completion of the reaction may be determined by in-process analysis. Typically the
reaction is complete within about 24 hours, and in some embodiments, within about 16 hours.
Steps (a) and (b) are typically conducted under an inert atmosphere, such as nitrogen or argon.
On completion of the reaction , an alcohol (e.g . methanol) and an organic acid (e.g . acetic acid) may
be added to quench the reaction mixture, followed by the addition of water and an aprotic solvent
(such as dichloromethane). The organic phase may be separated from the aqueous phase and the
organic phase washed one or more times with water (e.g. one, two, three or more times), one or more
times with brine (e.g . one, two, three or more times), dried (e.g . using magnesium sulfate) and
concentrated in vacuo to give the compound (7a) or (7b) as an oil or solid. Typically, the compounds
(7a) and (7b) may be used to form the compounds (6a) and (6b) without further purification.
Preparation of the compounds of formulae (9a) and (9b)
The compound of formula (9a) or (9b) may be prepared in a process comprising the reaction of a
compound of formula ( 12a) or ( 12b) with a halogenating agent in a solvent.
( 12a) ( 12b)
wherein:
R 4 , R 5 , R , R7, b and c are as generally described above.
The compound ( 12a) reacts to form the compound (9a) and the compound ( 12b) reacts to form the
compound (9b).
The halogenating agent may be a brominating agent or a chlorinating agent. The halogenating agent
may be selected from the group consisting of phosphoryl bromide (POBr3) and phosphoryl chloride
(POCI3) . In one embodiment, the halogenating agent is POBr3. In another embodiment, the
halogenating agent is POCI3.
Any suitable solvent may be used, for example, an aromatic hydrocarbon, such as benzene, toluene
or xylene or amide solvent, such as dimethylformamide or dimethacetamide. In one embodiment, the
aromatic solvent is toluene. In another embodiment, the amide solvent is dimethylformamide. In one
embodiment, the solvent is anhydrous. The concentration of compound ( 12a) or ( 12b) in the solvent
may be about 0.001 mol/L to about 2.0 mol/L, such as about 0.01 to about 1.75 mol/L, for example,
about 0.05 mol/L to about 1.5 mol/L. In one embodiment, the concentration of compound ( 12a) or
( 12b) in the solvent is about 0.5 to about 2.0 mol/L, for example, about 0.7 to about 1.0, such as about
0.74 mol/L or about 0.75 mol/L or about 0.969 mol/L. In one embodiment, the concentration of
compound ( 12a) or ( 12b) in the solvent is about 0.01 to about 0.5 mol/L, for example, about 0.05 to
about 0 .1 mol/L, such as about 0.06 mol/L.
If desired, the compound ( 12a) or ( 12b) may be azeotropically dried before it is reacted with the
halogenating agent.
The compound ( 12a) or ( 12b), the solvent and the halogenating agent may be added in any suitable
order. In one embodiment, however, the compound ( 12a) or ( 12b) and halogenating agent are
combined with the solvent in a reaction vessel. In another embodiment, the compound ( 12) or ( 12b)
is charged to a reaction vessel with the solvent, followed by the addition of the halogenating agent.
The reaction mixture may be heated to a temperature in the range from about 50 to about 200 °C,
such as in the range from about 60 to about 175 °C, for example, about 75 to about 160 °C. In one
embodiment, the reaction may be heated to the reflux temperature of the solvent. Accordingly, when
the solvent is benzene, the reaction temperature may be the boiling point of benzene i.e about 80 °C.
When the solvent is toluene, the reaction temperature may be the boiling point of toluene i.e. about
111 °C. When the solvent is xylene, the reaction temperature may be in the boiling point of xylene i.e.
in the range of about 138 to about 144 °C. When the solvent is dimethylformamide, the reaction
temperature may be the boiling point of DMF i.e. about 153 °C.
The reaction may be conducted under an inert atmosphere, such as argon or nitrogen.
The reaction is carried out for a period of time until it is determined that the reaction is substantially
complete. Completion of the reaction may be determined by in-process analysis. Typically the
reaction is complete within about 24 hours, and in some embodiments, within about 16 hours.
Hydrogen halide (e.g. HBr or HCI) may be formed during the course of the reaction which may be
released through the use of a bubbler.
On completion of the reaction, the reaction mixture may be suspended in ice/water, stirred for a
period of time (e.g . about 2 hours), filtered and dried in vacuum. Drying may be performed using
known methods, for example at temperatures in the range 10-60°C and preferably 20-40°C under 1-
30 mbar vacuum for 1 hour to 5 days.
Alternatively, the reaction mixture may be cooled (e.g. to room temperature). Water may be added to
the reaction mixture and optionally an inorganic base. Examples of suitable inorganic bases include
but are not limited to hydroxides and alkoxides. Suitable hydroxides include alkali metal hydroxides
(e.g . lithium hydroxide, sodium hydroxide or potassium hydroxide) or tetraalkylammonium hydroxides
(e.g. tetrabutylammonium hydroxide). In one embodiment, the inorganic base is a hydroxide which is
sodium hydroxide. Sodium hydroxide may be added to the reaction mixture until the pH is about 10-
14 . Suitable alkoxides include alkali metal alkoxides (e.g. lithium alkoxide, sodium alkoxide or
potassium alkoxide, such as lithium methoxide, sodium methoxide or potassium methoixde) or
tetraalkylammonium alkoxides (e.g. tetrabutylammonium hydroxide).
The aqueous and organic phases may be separated and the aqueous phase washed one or more
times with solvent (for example, one, two or three times with an aromatic solvent as described above).
The organic phases may be combined and washed one or more times with brine (e.g . one, two, three
or more times), dried (e.g. using magnesium sulfate) and concentrated in vacuo to give the compound
(9a) or (9b). The compound (9a) or (9b) may be dissolved in a polar aprotic solvent (such as
dichloromethane), optionally passed through a pad of silica gel, and the solvent removed in vacuo to
provide a pure product.
Alternatively, the combined organic phases may be dried and concentrated in vacuo. The product
may be taken up in a ketone solvent (e.g . acetone) and the solution heated to reflux, before being
filtered hot. The ketone solvent may then be partially evaporated to produce a slurry, which may be
filtered and dried.
Typically, the compounds (9a) and (9b) may be used to form the compounds (7a) and (7b) without
further purification.
Preparation of the compounds of formula ( 12a) and ( 12b)
The compound of formula ( 12a) or ( 12b) may be prepared in a process comprising the step of
reacting a compound of formula ( 13a) or ( 13b) with an acid.
( 13a) ( 13b)
wherein:
R4, R5, R , R7, b and c are as generally described above.
The compound ( 13a) reacts to form the compound ( 12a) and the compound ( 13b) reacts to form the
compound ( 12b).
Any suitable acid may be used which is capable of cyclising the compound ( 1 3a) or ( 1 3b) to form the
compound ( 12a) or ( 12b). The acid may be mineral acid , such as sulphuric acid or hydrochloric acid .
In one embodiment, the acid may be concentrated acid (e.g. 98% sulphuric acid). In another
embodiment, the acid may be an aqueous solution of acid. Any suitable w/w ratio of water : acid may
be used. For example, the w/w/ ratio of water : acid may be from about 10 : about 0.01 to about 0.01
: about 10 , such as about 5 : about 1 to about 1 : about 5 , e.g. about 1 : about 3 . The quantities of
water and/or acid are not particularly limiting provided there is enough water and/or acid to cyclise the
compound ( 1 3a) or ( 13b) into the compound ( 12a) or ( 12b).
The w/w ratio of compound of formula ( 1 3a) or ( 1 3b) : acid may be in the range from about 10 : about
0.01 to about 0.01 : about 10 , such as about 5 : about 1 to about 1 : about 5 , e.g. about 1 : about 3 .
The acid may be heated to a temperature in the range of about 50 to about 95 °C, such as about 50 to
about 85 °C, for example about 60 to about 80 °C e.g. about 75 °C before it is reacted with the
compound ( 13a) or ( 13b). The compound ( 13a) or ( 13b) and the acid may be added in any suitable
order. In one embodiment, however, the acid is charged to a reaction vessel and the compound ( 13a)
or ( 13b) is added to the acid. The compound ( 13a) or ( 13b) may be added in one portion or
portionwise over a period of time (e.g. 30 minutes). In another embodiment, the compound ( 13a) or
( 13b) is charged to a reaction vessel and the acid is added to the compound ( 13a) or ( 1 3b). The acid
may be added in one portion or portionwise over a period of time.
The reaction mixture may be heated to a temperature in the range from about 50 to about 100 °C,
such as in the range from about 60 to about 100 °C, for example, about 75 to about 100 °C. The
reaction mixture is typically stirred during the course of the reaction and if any lumps of solid are
produced, these may be broken up as appropriate (e.g. using a Teflon rod).
The reaction is carried out for a period of time until it is determined that the reaction is substantially
complete. Completion of the reaction may be determined by in-process analysis. Typically the
reaction is complete within about 24 hours, and in some embodiments, within about 5 hours.
On completion of the reaction, the reaction mixture may be cooled (e.g. to room temperature). The
reaction mixture may be diluted with water e.g. by adding the reaction mixture to water or adding
water to the reaction mixture to afford a precipitate. The precipitate may be filtered and optionally
washed one or more times with water (e.g. one, two, three or more times) and dried. In one
embodiment, the precipitate may then crystallised from ethanol and the solid obtained stripped with
an aromatic hydrocarbon solvent, such as toluene, one or more times (e.g . one, two, three or more
times) to remove residual water. In another embodiment, the precipitate may be washed with a
ketone solvent, such as acetone, one or more times (e.g. one, two, three or more times) and the solid
dried.
Howsoever the compound ( 12a) or ( 12b) is recovered , the compounds may be dried . Drying may be
performed using known methods, for example at temperatures in the range 10-60°C and preferably
20-40°C under 1-30 mbar vacuum for 1 hour to 5 days. Typically, the compounds ( 12a) and ( 12b)
may be used to form the compounds (9a) and (9b) without further purification.
Preparation of the compound of formula ( 1 3a)
The compound of formula ( 13a) may be prepared in a process comprising the step of reacting a
naphthylamine of formula ( 14), or salt thereof, with a compound of formula ( 15):
( 14) ( 15)
wherein:
R4, R , R7, b and c are as generally described above; and
LG is a leaving group.
The naphthylamine of formula ( 14) may be a free base or salt thereof. In one embodiment, the salt of
compounds ( 14) may be a hydrochloride salt, hydrobromide salt or hydroiodide salt.
LG is a leaving group which may be selected from the group consisting of a halide, -O-alkyl and a
sulfonate ester. In one embodiment, the leaving group is a halide, such as -CI, -Br or - I. In another
embodiment, the leaving group is an -O-alkyl, such as -O-Et or -O-Me.
In one embodiment, the compound of formula ( 15) is propionyl chloride.
The reaction may further comprise a base. Any suitable base may be used which is capable of
deprotonating the -NH 2 group of the compound ( 14) but does not otherwise adversely affect the
reaction. Suitable bases include but are not limited to inorganic bases, such as sodium acetate, and
organic bases, such as lutidine or triethylamine.
The compound ( 15) may be present in stoichiometric or greater quantities to the compound ( 14), or
salt thereof. When the free base of compound ( 15) is reacted, stoichiometric or slight excess of base
may be suitable, for example, about 1 : 1.1 to 1 : 1.5 molar ratio of compound ( 15) to base. When
salts of compound ( 15) are utilised, however, excess base is generally required in order to form the
free base of the compound ( 15) from the salt of compound ( 15), and deprotonate the amino group. In
this respect, the molar ratio of the salts of compound ( 1 5) to base may be about 1 : 5 to about 1 : 20,
such as about 1 : 7.5 to about 1: 15 , such as about 1 : 10 .
The reaction may further comprise a solvent. Any suitable solvent may be used, for example,
chlorinated solvents, such as dichloromethane (DCM), aromatic hydrocarbons, such as benzene,
toluene or xylene, or ethereal solvents, for example alkyl ethers, such as THF or MTBE. In one
embodiment, the solvent is xylene. The concentration of compound ( 14) in the solvent may be about
0.001 mol/L to about 10.0 mol/L, such as about 0.01 to about 7.5 mol/L, for example, about 0.05
mol/L to about 5.0 mol/L. In one embodiment, the concentration of compound ( 14) in the solvent is
about 0.78 mol/L.
The reaction may be conducted under an inert atmosphere, such as argon or nitrogen.
The compound ( 14), the compound ( 15), the base (if any) and the solvent (if any) may be added in
any suitable order. In one embodiment of the invention, however, the compound ( 14) and the solvent
(if any) are charged to a reaction vessel, the base (if any) and compound ( 15) are added.
While the compound ( 15) is added to the reaction mixture, the temperature range of the reaction may
generally be maintained at one or more temperatures between about - 10°C to about 35°C. In one
embodiment, the reaction mixture is maintained at a temperature of less than about 5°C, such as
about 0 °C. In order to keep the temperature of the reaction mixture within these ranges, the
compound of formula ( 15) may be added slowly over a period of time.
The reaction may be continued for a period of from about 30 minutes to about 72 hours, such as
about 30 minutes to about 24 hours. During this time, the reaction temperature may be varied one or
more times between about - 10°C and about 25°C. On completion of the reaction, the precipitate may
be filtered off and the filtrate extracted with one or more times (e.g. one, two, three or more times)
with e.g. DCM/1 0% HCI. The organic layer may be separated from the aqueous layer and the organic
layers combined, dried (e.g . using magnesium sulfate) and concentrated in vacuo. Drying may be
performed using known methods, for example at temperatures in the range 10-60°C and preferably
20-40°C under 1-30 mbar vacuum for 1 hour to 5 days. Typically, the compound ( 13a) may be used
to form the compound ( 12a) without further purification.
Preparation of the compound of formula ( 1 3b)
The compound of formula ( 13b) may be prepared by reacting a compound of formula ( 14) with a
compound of formula ( 16) or a compound of formula ( 17).
( 14) ( 16) ( 17)
wherein:
R5, R , R7, b and c are as generally defined above;
R40 and R4 are independently selected from the group consisting of unsubstituted alkyl and
substituted alkyl, or R40 and R4 are interconnected to form a ring with the carbon to which they are
attached; and
LG is a leaving group.
In one embodiment, R40 and R4 are methyl groups.
When R40 and R4 are interconnected to form a ring with the carbon atom to which they are attached,
the groups may form substituted or unsubstituted chiral or achiral bridges which are derived, for
example, from the skeletons -(CH2)n- (n=2, 3 or 4), -CH(CH 3)CH(CH 3)-, -CH(CH 3)CH2CH(CH3)-, -
CMe2- , -CHMe-, no limitation being implied by this listing.
LG is a leaving group which may be selected from the group consisting of a halide, -O-alkyl and a
sulfonate ester. In one embodiment, the leaving group is a halide, such as -CI, -Br or - I. In another
embodiment, the leaving group is an -O-alkyl, such as -O-Et or -O-Me.
The reaction may further comprise a base. Any suitable base may be used which is capable of
deprotonating the -NH 2 group of the compound ( 14) but does not otherwise adversely affect the
reaction. Suitable bases include but are not limited to inorganic bases, such as sodium acetate, and
organic bases, such as lutidine or triethylamine.
The compound ( 14) may be present in stoichiometric or greater quantities to the compound ( 14), or
salt thereof. When the free base of compound ( 14) is reacted, stoichiometric or slight excess of base
may be suitable, for example, about 1 : 1.1 to 1 : 1.5 molar ratio of compound ( 14) to base. When
salts of compound ( 14) are utilised, however, excess base is generally required in order to form the
free base of the compound ( 14) from the salt of compound ( 14), and deprotonate the amino group. In
this respect, the molar ratio of the salts of compound ( 14) to base may be about 1 : 5 to about 1 : 20,
such as about 1 : 7.5 to about 1: 15 , such as about 1 : 10 .
The reaction may further comprise a solvent. Any suitable solvent may be used, for example,
chlorinated solvents, such as dichloromethane (DCM), aromatic hydrocarbons, such as benzene,
toluene or xylene, or ethereal solvents, for example alkyl ethers, such as THF or MTBE. In one
embodiment, the solvent is xylene. The concentration of compound ( 14) in the solvent may be about
0.001 mol/L to about 10.0 mol/L, such as about 0.01 to about 7.5 mol/L, for example, about 0.05
mol/L to about 5.0 mol/L. In one embodiment, the concentration of compound ( 14) in the solvent is
about 0.78 mol/L. In another embodiment, the concentration of compound ( 14) in the solvent is about
4 .11 mol/L.
The napthylamine of formula ( 14), LG, the base (if any), the solvent (if any) are as generally described
above.
The compound ( 16) or ( 17) may be present in stoichiometric or greater quantities to the compound
( 14), or salt thereof. When the free base of compound ( 14) is reacted, stoichiometric or slight excess
of compound ( 16) or ( 17) may be suitable, for example, about 1 : 1.1 to 1 : 1.5 molar ratio of
compound ( 14) to compound ( 16) or ( 17). When salts of compound ( 14) are utilised, however, excess
base is generally required in order to form the free base of the compound ( 14) from the salt of
compound ( 14), and deprotonate the amino group. In this respect, the molar ratio of the salts of
compound ( 14) to base may be about 1 : 5 to about 1 : 20, such as about 1 : 7.5 to about 1: 15 , such
as about 1 : 10 .
The reaction may be conducted under an inert atmosphere, such as argon or nitrogen.
The compound ( 14), the compound ( 16) or ( 17), the base (if any) and the solvent (if any) may be
added in any suitable order. In one embodiment of the invention, however, the compound ( 14) and
the solvent (if any) are charged to a reaction vessel, the base (if any) and compound ( 16) or ( 17) are
added.
While the compound ( 16) or ( 17) is added to the reaction mixture, the temperature range of the
reaction may generally be maintained at one or more temperatures between about 50 °C to about
200°C. The temperature selected is such that the desired amide is formed instead of an imine.
Without wishing to be bound by theory, it is believed that higher temperatures (e.g. by refluxing the
reaction mixture in xylene) favour the formation of the desired amide, whereas lower temperatures
favour the formation of an imine. In one embodiment, the reaction mixture is maintained at a
temperature of less than about 175°C, such as about 160-1 65 °C. In another embodiment, the
reaction is maintained at the reflux temperature of THF i.e. at about 66 °C.
The reaction may be continued for a period of from about 30 minutes to about 72 hours, such as
about 30 minutes to about 24 hours. On completion of the reaction, the reaction mixture may be
concentrated in vacuo until the product solidifies in the reaction flask. The precipitate may be
collected using an alkane solvent (such as hexane or heptane) to do so and optionally washed one or
more times with further alkane solvent (such as hexane or heptane). Alternatively, aqueous acid (e.g.
aqueous HCI acid) may be added to the reaction mixture with vigorous stirring for a period of time
before filtering the precipitate. The precipitate may then be washed one or more times with water and
dried in a desiccator.
The precipitate may be dried using known methods, for example at temperatures in the range 10-
60°C and preferably 20-40°C under 1-30 mbar vacuum for 1 hour to 5 days.
Alternatively, on completion of the reaction, the reaction mixture may be diluted with an ester solvent
(such as ethyl acetate), washed one or more times (e.g. one, two, three or more times) with water,
washed one or more times (e.g . one, two, three or more times) with brine and dried (e.g. over sodium
sulfate). The product may be obtained by removal of the organic solvents, such as by increasing the
temperature or reducing the pressure using distillation or stripping methods well known in the art.
The compound of formula ( 13b) may be used to form the compound ( 12b) without further purification .
Preparation of compounds of formulae ( 1a) and ( 1 b)
In addition to the process described above, the compounds of formulae ( 1a) and ( 1 b), or salts thereof,
(illustrated below) may be prepared by reducing a compound of formula (20a) or (20b), or salts
thereof. A compound (20a) is reduced to the compound ( 1a) and the compound (20b) is reduced to
the compound ( 1 b).
As the process comprises the reduction of a cyano (-CN) group, R R2 and R3 in the compounds of
formulae ( 1a) and ( 1 b) are all -H.
R4, R5, R , R7, b and c are as generally described above.
In one embodiment, the reduction may be a hydrogenation reaction . The hydrogenation reaction may
comprise reacting the compound (20a) or (20b) with gaseous hydrogen in the presence of a
hydrogenation catalyst in a suitable solvent. The hydrogenation catalyst may be a heterogeneous or
homogeneous catalyst, preferably a heterogeneous catalyst. The catalyst (whether heterogeneous or
homogeneous) should be selected such that the catalyst preferentially reduces the cyano (-CN) group
rather than reducing another group present in the compound (20a) or (20b). In one embodiment, the
heterogeneous catalyst is a heterogeneous platinum group metal (PGM) catalyst, for example, a
heterogeneous palladium or platinum catalyst. In one embodiment, the heterogeneous catalyst is a
heterogeneous palladium catalyst. Examples of palladium catalysts include but are not limited to
colloidal palladium, palladium sponge, palladium plate or palladium wire. Examples of platinum
catalysts include but are not limited to colloidal platinum, platinum sponge, platinum plate or platinum
wire.
The heterogeneous PGM metal catalyst may be a PGM on a solid support. The support may be
selected from the group consisting of carbon , alumina, calcium carbonate, barium carbonate, barium
sulfate, titania, silica, zirconia, ceria and a combination thereof. When the support is alumina, the
alumina may be in the form of alpha-AI20 3, beta-AI20 3, gamma-AI20 3, delta-AI20 3, theta-AI20 3 or a
combination thereof. When the support is carbon, the carbon may be in the form of activated carbon
(e.g. neutral, basic or acidic activated carbon), carbon black or graphite (e.g . natural or synthetic
graphite). An example of a heterogeneous PGM catalyst is palladium on carbon. An example of
another heterogeneous PGM catalyst is platinum on carbon.
The catalyst loading may be up to about 20 mole%. A greater catalyst loading may perform the
desired reduction, however, increasing the quantity of the PGM may make the process uneconomical.
In one embodiment, the catalyst loading may be up to 10 mole% and, in another embodiment, may be
in the range of about 0 .1- 10.0 mole % .
The reaction mixture may further comprise an acid. Without wishing to be bound by theory, it is
believed the acid helps the formation of the amine by avoiding dimerization side reactions. The acid
may be any suitable acid, such as a hydrohalide acid e.g. hydrochloric acid, hydrobromic acid or
hydroiodic acid. The acid may be added as a reagent to the hydrogenation reaction or the
compounds (20a) and (20b) may be reacted as acid addition salts. The salts are as generally
described above. Without wishing to be bound by theory, it is believed that the benzo-fused pyridinyl
N atom needs to be protonated in order for the hydrogenation to proceed.
Any suitable solvent may be utilised e.g. polar solvents, such as an alcohol. The alcohol may be
selected from the group consisting of methanol, ethanol, isopropanol and mixtures thereof. In one
embodiment, the solvent is methanol.
The compound (20a) or (20b) may be placed in a pressure vessel together with the hydrogenation
catalyst. The pressure vessel may then be assembled and purged with one or more nitrogen/vacuum
cycles (e.g . one, two, three or four cycles). The alcohol solvent may then added via the injection port
to form a solution of the compound (20a) or (20b), which may have concentration in the range of
about 0.01 to about 1 molar, such as about 0.3 molar. If the hydrogenation catalyst is heterogeneous,
the catalyst will not dissolve in the alcohol solvent. However, if the hydrogenation catalyst is
homogeneous, it may dissolve in the alcohol solvent and form a solution with the compound (20a) or
(20b).
Once the alcohol solvent has been added, the pressure vessel may be purged once again with one or
more nitrogen/vacuum cycles (e.g. one, two, three, four or five cycles), followed by one or more
hydrogen/vacuum cycles (e.g. one, two, three, four or five cycles). During purging the reaction
mixture may be agitated (by either stirring or shaking) to encourage removal of dissolved oxygen.
The pressure vessel may then be pressurised with hydrogen (e.g. to about 5 bar) , stirred and heated
to temperature (e.g. about 30 °C). Hydrogen gas uptake may begin after a period of time has
elapsed . Once hydrogen uptake begins, the pressure vessel may optionally be depressurised with
hydrogen
While it is typically sufficient for a single charge of hydrogenation catalyst to be added to the reaction
mixture, a second or further charge may be added and the hydrogenation continued if it has been
determined (e.g. via in-process analysis) that the reaction has not gone substantially to completion
and starting material remains.
There is no particular limitation on the pressure at which the hydrogenation is carried out. In this
regard, the hydrogenation may conveniently be carried out with an initial hydrogen pressure in the
range of up to about 7 bar (about 100 psi) e.g. about 5 ± 1 bar.
The reaction temperature may be suitably in the range from about 15 to about 75 °C, such as in the
range from about 20 to about 60 °C, for example, about 25 to about 50 °C. In one embodiment, the
reaction temperature may be about 30 °C.
The reaction mixture may then be stirred in the presence of hydrogen gas until hydrogen uptake is no
longer apparent. The hydrogenation reaction is carried out for a period of time until it is determined
that the reaction is substantially complete. Completion of the reaction may be determined by in-
process analysis or by identifying that there is no longer an uptake of hydrogen gas. Typically the
hydrogenation is complete within about 24 hours, and in some embodiments, within about 90 minutes.
On completion of the reaction, the reaction vessel may be cooled to ambient temperature and purged
with one or more nitrogen/vacuum cycles (e.g. one, two, three, four or five cycles) to remove excess
hydrogen gas. The hydrogenation catalyst may be removed by any appropriate method, such as
filtration (e.g . using a pad of Celite), washed one or more times with alcohol solvent (e.g. one, two,
three or more times) and the filtrate further treated as desired. A proportion of the solvent may be
evaporated if desired prior to recovery of the compound of formula ( 1a) or ( 1 b).
Howsoever the compound ( 1a) or ( 1 b) is recovered, the separated compounds may be washed and
then dried. Drying may be performed using known methods, for example at temperatures in the
range 10-60°C and preferably 20-40°C under 1-30 mbar vacuum for 1 hour to 5 days. If desired the
compound ( 1a) or ( 1 b) may be recrystallised, although in certain embodiments this is generally not
required.
Preparation of compounds of formulae (20a) and (20b)
The compounds of formulae (20a) and (20b) may be prepared by cyanating the compounds of
formulae (9a) and (9b) (discussed above).
In this respect, the compound (9a) is cyanated to the compound (20a) and the compound (9b) is
cyanated to the compound (20b).
R4, R5, R , R7, b and c are as generally described above.
The process may comprise treating the compound of formula (20a) or (20b) with a cyanating reagent
in solvent.
The cyanation reagent may be any suitable cyanation reagent, such as copper(l) cyanide, Zn(CN) 2 or
K4Fe(CN) (potassium ferrocyanide).
The solvent may be any suitable solvent, such as polar aprotic solvents. Polar aprotic solvents may
be selected from the group consisting of amides (such as Ν ,Ν-dimethylformamide (DMF) or N,N-
dimethylacetamide (DMA)) and N-(alkyl)-pyrrolidinones (such as N-methyl-2-pyrrolidinone). In one
embodiment, the solvent is N-methyl-2-pyrrolidinone (NMP). In one embodiment, the solvent is
anhydrous. The concentration of compound (9a) or (9b) in the solvent may be about 0.001 mol/L to
about 2.0 mol/L, such as about 0.01 to about 1.75 mol/L, for example, about 0.05 mol/L to about 1.5
mol/L. In one embodiment, the concentration of compound (9a) or (9b) in the solvent is about 0 .1 to
about 1.0 mol/L, for example, about 0 .1 to about 0.9, such as about 0.2 mol/L or about 0.6 mol/L or
about 0.7 mol/L. In one embodiment, the concentration of compound (9a) or (9b) in the solvent is
about 0.01 to about 0.9 mol/L, for example, about 0.3 to about 0.7 mol/L, such as about 0.47 or 0.6
mol/L.
The compound (9a) or (9b), the cyanation reagent and the solvent may be added in any suitable
order. In one embodiment, however, the compound (9a) or (9b) and cyanation reagent are combined
with the solvent in a reaction vessel. In another embodiment, the compound (9a) or (9b) is charged to
a reaction vessel with the solvent, followed by the addition of the cyanation reagent.
The reaction mixture may be heated to a temperature in the range from about 50 to about 200 °C,
such as in the range from about 60 to about 175 °C, for example, about 100 to about 160 °C e.g. 150
°C.
The reaction may be conducted under an inert atmosphere, such as argon or nitrogen.
The reaction is carried out for a period of time until it is determined that the reaction is substantially
complete. Completion of the reaction may be determined by in-process analysis. Typically the
reaction is complete within about 24 hours, and in some embodiments, within about 4 hours.
On completion of the reaction , the reaction mixture may be quenched (e.g. by adding it to a mixture of
iron(l ll) chloride hexahydrate, water and hydrochloric acid), stirred for a period of time (e.g . about 2
hours) and extracted with a chlorinated solvent such as dichloromethane. The crude product may be
recovered simply by evaporating the chlorinated solvent, whereupon it may be slurried in water and
filtered. The compound of formula (20a) or (20b) may obtained in pure form by fractionally
crystallising the crude material from toluene.
Howsoever the complex is recovered, the separated compound is preferably dried . Drying may be
performed using known methods, for example, at temperatures in the range of about 10-60 °C and
such as about 20-40 °C under O.1-30 mbar for 1 hour to 5 days.
Transition metal complexes of formula (3)
In another aspect, the invention provides transition metal complexes of formula (3):
[M X (L1)m (L2)]
(3)
wherein:
M is ruthenium, osmium or iron;
X is an anionic ligand;
L is a monodentate phosphorus ligand, or a bidentate phosphorus ligand;
m is 1 or 2 , wherein,
when m is 1, L is a bidentate phosphorus ligand;
when m is 2 , each L is a monodentate phosphorus ligand ; and
L2 is a tridentate ligand of formula (2a) or (2b):
(2a) (2b)
wherein:
and R2 are independently selected from the group consisting of -H, -OH , unsubstituted C1-2o-alkyl,
substituted C1-2o-alkyl, unsubstituted C3_2o-cycloalkyl, substituted C3.2o-cycloalkyl, unsubstituted C5.20-
aryl, substituted C5.20-aryl, unsubstituted C^o-heteroalkyl, substituted C^o-heteroalkyl, unsubstituted
C2.20-heterocycloalkyl, substituted C2.20-heterocycloalkyl, unsubstituted C4.20-heteroaryl and
substituted C4.20-heteroaryl;
R3 is selected from the group consisting of -H, unsubstituted C1-2o-alkyl, substituted C1-20-alkyl,
unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C5-20-aryl, substituted C5.20-
aryl, unsubstituted C1-20-heteroalkyl, substituted C1-20-heteroalkyl, unsubstituted C2.20-heterocycloalkyl,
substituted C2.20-heterocycloalkyl, unsubstituted C4.20-heteroaryl and substituted C4.20-heteroaryl;
R4 is selected from the group consisting of unsubstituted C1-20-alkyl, substituted C1-20-alkyl,
unsubstituted C^o-alkoxy, substituted C^o-alkoxy, unsubstituted C5-20-aryl, substituted C5-20-aryl;
R5 is selected from the group consisting of unsubstituted C1-20-alkyl, substituted C1-20-alkyl,
unsubstituted C^o-alkoxy, substituted C^o-alkoxy, unsubstituted C5-20-aryl, substituted C5-20-aryl;
R is selected from the group consisting of unsubstituted C1-20-alkyl, substituted C1-20-alkyl,
unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C^o-alkoxy, substituted
20-alkoxy, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C1-20-heteroalkyl, substituted
C1-20-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted C2.20-heterocycloalkyl, unsubstituted
C4.20-heteroaryl, substituted C4.20-heteroaryl, -NR'R" -COOR', -S(0) 2OH, -S(0) 2-R', -S(0) 2NR'R" and
-CONR'R", wherein R' and R" are independently selected from the group consisting of H ,
unsubstituted C1-20-alkyl, substituted C1-20-alkyl, unsubstituted C5-20-aryl, substituted C5-20-aryl,
unsubstituted C7.20-arylalkyl, substituted C7.20-arylalkyl, or R' and R" together with the atom to which
they are attached form a substituted or unsubstituted C2.20-heterocycloalkyl group;
R7 is selected from the group consisting of -H, unsubstituted C1-20-alkyl, substituted C1-20-alkyl,
unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C^o-alkoxy, substituted
20-alkoxy, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C1-20-heteroalkyl, substituted
C1-20-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted C2.20-heterocycloalkyl, unsubstituted
C4.20-heteroaryl, substituted C4.20-heteroaryl, -NR'R" -COOR', -S(0) 2OH, -S(0) 2-R', -S(0) 2NR'R" and
-CONR'R", wherein R' and R" are independently selected from the group consisting of H ,
unsubstituted C1-20-alkyl, substituted C1-20-alkyl, unsubstituted C5-20-aryl, substituted C5-20-aryl,
unsubstituted C7.20-arylalkyl, substituted C7.20-arylalkyl, or R' and R" together with the atom to which
they are attached form a substituted or unsubstituted C2.20-heterocycloalkyl group;
b is an integer selected from 0 , 1 or 2 ; and
c is an integer selected from 0 , 1, 2 or 3 .
M is a transition metal selected from the group consisting of ruthenium, osmium or iron. In one
embodiment, M is ruthenium. When M is ruthenium, M may be Ru(ll). In another embodiment, M is
osmium. When M is osmium, M may be Os(l l). In another embodiment, M is iron.
X is an anionic ligand and may be a coordinating or non-coordinating. In one embodiment, X is a
coordinating anionic ligand. In another embodiment, X is a non-coordinating anionic ligand. The
anionic ligand may be selected from the group consisting of halide, hydride (-H) or C^o-alkoxide (-0-
CMo-alkyl). When the anionic ligand is a halide, the halide may be selected from the group consisting
of -CI, -Br and - I, for example, X is -CI. In another embodiment, the anionic ligand may be a hydride
(-H). In yet another embodiment, the anionic ligand may be an alkoxide selected from the group
consisting of -OMe, -OEt, -OPr (n- or i-), -OBu (n-, i- or t-).
L is a phosphorus ligand. Any suitable phosphorus compound capable of forming a ligand-metal
interaction with the M atom may be used. In the ligand , each phosphorus atom is covalently bonded
to either 3 carbon atoms (tertiary phosphines) or to n heteroatoms and 3-n carbon atoms, where n =
1, 2 or 3 . Preferably, the heteroatom is selected from the group consisting of N and O.
The ligand L may be chiral or achiral, although in many instances it is preferred that the phosphorus
ligand is chiral. A variety of chiral phosphorus ligands has been described and reviews are available,
for example see W . Tang and X . Zhang, Chem Rev. 2003, 103, 3029 - 3070 and J.C. Carretero,
Angew. Chem. Int. Ed . , 2006, 45, 7674-771 5 .
When L is a monodentate phosphorus ligand, m is 2 . Each L may be the same or different.
Preferably, L is a tertiary phosphine ligand PR R 2R 3. R , R 2 and R 3 may be independently
selected from the group consisting of unsubstituted C^o-alkyl, substituted C^o-alkyl, unsubstituted
C3-2o-cycloalkyl, substituted C3_2o-cycloalkyl, unsubstituted C^o-alkoxy, substituted C^o-alkoxy,
unsubstituted C5_2o-aryl, substituted C5_2o-aryl, unsubstituted C^o-heteroalkyl, substituted C^o-
heteroalkyl, unsubstituted C2-2o-heterocycloalkyl, substituted C2.20-heterocycloalkyl, unsubstituted C4_
20-heteroaryl and substituted C4.20-heteroaryl. R , R 2 and R 3 may be independently substituted or
unsubstituted branched- or straight-chain alkyl groups such as methyl, ethyl, n-propyl, iso-propyl, n-
butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl or stearyl,
cycloalkyi groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or adamantyl, or aryl groups
such as phenyl, naphthyl or anthracyl. In one embodiment, the alkyl groups may be optionally
substituted with one or more substituents such as halide (F, CI, Br or I) or alkoxy groups, e.g.
methoxy, ethoxy or propoxy. The aryl group may be optionally substituted with one or more (e.g . 1, 2 ,
3 , 4 , or 5) substituents such as halide (-F, -CI, -Br or -I), straight- or branched-chain C^C^-alky! (e.g.
methyl), C C alkoxy, straight- or branched-chain CrC^-idialkyOamino, C3. 0 heterocycloalkyl
groups (such as morpholinyl and piperadinyl) or tri(halo)methyl (e.g. F3C-). Substituted or
unsubstituted heteroaryl groups such as pyridyl may also be used . In an alternative embodiment, any
two of R , R 2 and R 3 may be linked to form a ring structure with the phosphorus atom, preferably 4-
to 7-membered rings. Preferably, R , R 2 and R 3 are the same and are phenyl i.e. PR R 2R 3 is
triphenylphosphine. Alternatively, R , R 2 and R 3 may be the same and are tolyl i.e. PR R 2R 3 is
tritolylphosphine (e.g. ortho-, meta- or para- tritolylphosphine).
Alternatively, L is a bidentate phosphorus ligand and, in this instance, m is 1. Phosphorus ligands
that may be used in the present invention include but are not restricted to the following structural
types:
BINAP, R = aryl and alkyl P-PHOS R= aryl, alkyl
R = aryl, alkyl = O, S, N
, -. „ , BITIANAP
-BINAP, R = aryl and alkyl R= ary , ai yi R = aryl, alkylX = O BIBFUPX = O, S, N X = NH o S
JOSIPHOS TANIAPHOS WALPHOS
R = alkyl, aryl R = alkyl, aryl R = alkyl, aryl
R2 = alkyl, aryl R2 = alkyl, aryl R2 = alkyl, aryl
R3 = alkyl, aryl R3 = alkyl
Pr
BOPH Cy
R = alkyl, aryl
R2 = alkyl, aryl, OalkyI, Oaryl
R3 = alkyl, aryl
R4 = alkyl, aryl
Me - FERROTANE FERROPHOS
R = alkyl, aryl
R3 = 3-pentyl
3 , R = Ph, dppp
4 , R = Ph, dppb R = alkyl, aryl
= Ph, dppf
R , R2 and R3 = Me: HEXAPHEMP
BPPM BPPM amide DIOP
R = alkyl, aryl R = alkyl, aryl R = alkyl, aryl
R2 = alkyl, aryl R2 = alkyl, aryl
R3 _= substituted alkyl R3 -= alkyl, aryl, OR4, NR 2
R4 = alkyl, aryl
BPE -type DUPHOS -type MALPHOS type
R = alkyl, aryl, CH2OR2 R = alkyl, CH2OR2 X = O, NR
R3 = H or OR2 R3 = H or OR2
R2 = alkyl R2 = alkyl
R2-
2P O
DPPE DAPE DIPA P CHIRAPHOS DEGPHOS
R ,R2 = phenyl ,R2 = alkyl R = phenyl R = R2 alkyl R = aryl
R = 4-MeO-phenyl PROPHOS R = alkyl, aryl, OR2 , NR22
R2 = alkyl R = H R2 = alkyl, aryl
SKEWPHOS
R' = R" = alkyl
A r = aryl, substituted
aryl
In the above structures -PR 2 may be -P(alkyl) 2 in which alkyl is preferably alkyl, -P(aryl) 2 where
aryl includes phenyl and naphthyl which may be substituted or unsubstituted or -P(0-alkyl) 2 and -P(0-
aryl) 2 with alkyl and aryl as defined above. -PR 2 may also be substituted or unsubstituted -
P(heteroaryl) 2, where heteroaryl includes furanyl (e.g . 2-furanyl or 3-furanyl). -PR 2 is preferably
either -P(aryl) 2 where aryl includes phenyl, tolyl, xylyl or anisyl or -P(0-aryl) 2. If -PR 2 is -P(0-aryl) 2, the
most preferred O-aryl groups are those based on chiral or achiral substituted 1,1'-biphenol and 1,1'-
binaphtol. Alternatively, the R groups on the P-atom may be linked as part of a cyclic structure.
Substituting groups may be present on the alkyl or aryl substituents in the phosphorus ligands. Such
substituting groups are typically branched or linear C1-6 alkyl groups such as methyl, ethyl, propyl,
isopropyl, tert butyl and cyclohexyl.
The phosphorus ligands are preferably used in their single enantiomer form. These phosphorus
ligands are generally available commercially and their preparation is known. For example, the
preparation of PARAPHOS ligands is given in WO 04/1 11065, the preparation of Bophoz ligands in
WO02/26750 and US690621 2 and the preparation of Josiphos ligands in EP564406B and
EP61 2758B.
The phosphorus ligand L preferably includes Binap ligands, PPhos ligands, PhanePhos ligands,
QPhos ligands, Josiphos ligands and Bophoz ligands.
When L is a Binap ligand, the ligand may be of formula (la) or (lb):
(la) (lb)
wherein,
R20 and R2 are each independently selected from the group consisting of unsubstituted C3_20-
cycloalkyl, substituted C3_2o-cycloalkyl, unsubstituted C5.20-aryl and substituted C5.20-aryl. In one
embodiment, R20 and R2 are each independently selected from the group consisting of cycloalkyl
groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or adamantyl, or aryl groups such as
phenyl, naphthyl or anthracyl. In one embodiment, the cycloalkyl groups may be optionally
substituted with one or more substituents such as halide (F, CI, Br or I) or alkoxy groups, e.g.
methoxy, ethoxy or propoxy. The aryl group may be optionally substituted with one or more (e.g . 1, 2 ,
3 , 4 , or 5) substituents such as halide (-F, -CI, -Br or -I), straight- or branched-chain C^C^-alky! (e.g.
methyl), - w alkoxy, straight- or branched-chain C C^-idialkyOamino, C3. 0 heterocycloalkyl
groups (such as morpholinyl and piperadinyl) or tri(halo)methyl (e.g . F3C-). Preferably, R20 and R2
are the same and are selected from the group consisting of phenyl, tolyl (o-, m- or p-, preferably p-
tolyl) and xylyl (e.g. 3,5-xylyl).
When L is a Josiphos ligand, the ligand may be of formula (lla) or (lib):
(Ma) (lib)
wherein,
R22 and R23 are independently selected from the group consisting of unsubstituted C1-2o-alkyl,
substituted C1-2o-alkyl, unsubstituted C3.2o-cycloalkyl, substituted C3.2o-cycloalkyl, unsubstituted C1-20-
alkoxy, substituted C^o-alkoxy, unsubstituted C5.20-aryl, substituted C5.20-aryl, unsubstituted C1-20-
heteroalkyl, substituted C1-20-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted C2.20-
heterocycloalkyl, unsubstituted C4.20-heteroaryl and substituted C4.20-heteroaryl;
R24 and R25 are independently selected from the group consisting of unsubstituted C1-20-alkyl,
substituted C1-20-alkyl, unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C1-20-
alkoxy, substituted C^o-alkoxy, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C1-20-
heteroalkyl, substituted C1-20-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted C2.20-
heterocycloalkyl, unsubstituted C4.20-heteroaryl and substituted C4.20-heteroaryl; and
R2 is selected from the group consisting of unsubstituted C1-20-alkyl and substituted C1-20-alkyl.
In one embodiment, R22 and R23 are independently selected from the group consisting of substituted
or unsubstituted branched- or straight-chain alkyl groups such as methyl, ethyl, n-propyl, iso-propyl, n-
butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl or stearyl,
cycloalkyi groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or adamantyl, aryl groups
such as phenyl, naphthyl or anthracyl and heteroaryl groups such as furyl. In one embodiment, the
alkyl groups may be optionally substituted with one or more substituents such as halide (F, CI, Br or I)
or alkoxy groups, e.g. methoxy, ethoxy or propoxy. The aryl group may be optionally substituted with
one or more (e.g. 1, 2 , 3 , 4 , or 5) substituents such as halide (-F, -CI, -Br or -I), straight- or branched-
chain C^C^-alky! (e.g. methyl), - w alkoxy, straight- or branched-chain CrC^-idialkyOamino, C3-10
heterocycloalkyl groups (such as morpholinyl and piperadinyl) or tri(halo)methyl (e.g . F3C-). The
heteroaryl group may be optionally substituted with one or more (e.g. 1, 2 , 3 , 4 , or 5) substituents
such as halide (-F, -CI, -Br or -I), straight- or branched-chain C^C^-alky! (e.g . methyl), - w alkoxy,
straight- or branched-chain CrC^-idialkyOamino or tri(halo)methyl (e.g. F3C-). Preferably, R22 and
R23 are the same and are selected from the group consisting of tert-butyl, cyclohexyl, phenyl, 3,5-
bis(trifluoromethyl)phenyl, 4-methoxy-3,5-dimethylphenyl, 4-trifluoromethylphenyl, 1-naphthyl, 3,5-
xylyl, 2-methylphenyl and 2-furyl, most preferably tert-butyl, cyclohexyl, phenyl, 3,5-
bis(trifluoromethyl)phenyl, 4-methoxy-3,5-dimethylphenyl, 4-trifluoromethylphenyl, 1-naphthyl and 2-
furyl.
In one embodiment, R24 and R25 are independently selected from the group consisting of substituted
or unsubstituted branched- or straight-chain alkyl groups such as methyl, ethyl, n-propyl, iso-propyl, n-
butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl or stearyl,
cycloalkyi groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or adamantyl, aryl groups
such as phenyl, naphthyl or anthracyl and heteroaryl groups such as furyl. In one embodiment, the
alkyl groups may be optionally substituted with one or more substituents such as halide (F, CI, Br or I)
or alkoxy groups, e.g. methoxy, ethoxy or propoxy. The aryl group may be optionally substituted with
one or more (e.g. 1, 2 , 3 , 4 , or 5) substituents such as halide (-F, -CI, -Br or -I), straight- or branched-
chain C^C^-alky! (e.g. methyl), C C alkoxy, straight- or branched-chain CrC^-idialkyOamino, C3. 0
heterocycloalkyl groups (such as morpholinyl and piperadinyl) or tri(halo)methyl (e.g . F3C-). The
heteroaryl group may be optionally substituted with one or more (e.g. 1, 2 , 3 , 4 , or 5) substituents
such as halide (-F, -CI, -Br or -I), straight- or branched-chain C^C^-alky! (e.g . methyl), C C alkoxy,
straight- or branched-chain CrC^-idialkyOamino or tri(halo)methyl (e.g. F3C-). Preferably, R24 and
R25 are the same and are selected from the group consisting of tert-butyl, cyclohexyl, phenyl, 3,5-
bis(trifluoromethyl)phenyl, 4-methoxy-3,5-dimethylphenyl, 4-trifluoromethylphenyl, 1-naphthyl, 3,5-
xylyl, 2-methylphenyl and 2-furyl, most preferably tert-butyl, cyclohexyl, phenyl, 3,5-xylyl and 2-
methylphenyl.
In one embodiment, R26 is an unsubstituted branched- or straight-chain alkyl groups such as methyl,
ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl,
decyl, dodecyl or stearyl. Preferably, R26 is methyl.
In one embodiment, the ligand of formula (Ma) is selected from the group consisting of:
(R)-1 -[(S)-2-(diphenylphosphino)ferrocenyl]ethyldicyclohexylphosphine,
(R)-1 -[(S)-2-(diphenylphosphino)ferrocenyl]ethyldi-tert-butylphosphine,
(R)-1 -[(S)-2-(dicyclohexylphosphino)ferrocenyl]ethyldicyclohexylphosphine,
(R)-1 -[(S)-2-(dicyclohexylphosphino)ferrocenyl]ethyldiphenylphosphine,
(R)-1 -[(S)-2-(diphenylphosphino)ferrocenyl]ethyldi-3,5-xylylphosphine,
(R)-1 -[(S)-2-(di-3,5-bis(trifluoromethyl)phenylphosphino)ferrocenyl]ethyldicyclohexylphosphine,
(R)-1 -[(S)-2-(di-4-methoxy-3,5-dimethylphenylphosphino)ferrocenyl]ethyldicyclohexylphosphine,
(R)-1 -[(S)-2-(di-3,5-bis(trifluoromethyl)phenylphosphino)ferrocenyl]ethyldi-3,5-xylylphosphine,
(R)-1 -[(S)-2-(dicyclohexylphosphino)ferrocenyl]ethyldi-tert-butylphosphine,
(R)-1 -[(S)-2-(di-(4-trifluoromethyl)phenylphosphino)ferrocenyl]ethyldi-tert-butylphosphine,
(R)-1 -[(S)-2-(di-4-methoxy-3,5-dimethylphenylphosphino)ferrocenyl]ethyldi-tert-butylphosphine,
(R)-1 -[(S)-2-(di-2-furylphosphino)ferrocenyl]ethyldi-3,5-xylylphosphine,
(R)-1 -[(S)-2-(di-2-furylphosphino)ferrocenyl]ethyldi-tert-butylphosphine,
(R)-1 -[(S)-2-(di-1 -naphthylphosphino)ferrocenyl]ethyldi-tert-butylphosphine,
(R)-1 -[(S)-2-(di-1 -naphthylphosphino)ferrocenyl]ethyldi-3,5-xylylphosphine,
(R)-1 -[(S)-2-(di-4-methoxy-3,5-dimethylphenylphosphino)ferrocenyl]ethyldi-3,5-xylylphosphine,
(R)-1 -[(S)-2-(di-4-methoxy-3,5-dimethylphenylphosphino)ferrocenyl]ethyldi-(2-
methylphenyl)phosphine,
(R)-1 -[(S)-2-(di-2-furylphosphino)ferrocenyl]ethyldi-(2-methylphenyl)phosphine,
(R)-1 -[(S)-2-(di-tert-butylphosphino)ferrocenyl]ethyldiphenylphosphine,
(R)-1 -[(S)-2-(di-tert-butylphosphino)ferrocenyl]ethyldi-(2-methylphenyl)phosphine,
(R)-1 -[(S)-2-(diphenylphosphino)ferrocenyl]ethyldiphenylphosphine,
(R)-1 -[(S)-2-(diphenylphosphino)ferrocenyl]ethyldi(adamantyl)phosphine, and
(R)-1 -[(S)-2-(di(adamantyl)phosphino)ferrocenyl]ethyldiphenylphosphine.
In one embodiment, the ligand of formula (lib) is selected from the group consisting of:
(S)-1 -[(R)-2-di(phenylphosphino)ferrocenyl]ethyldicyclohexylphosphine,
(S)-1 -[(R)-2-di(phenylphosphino)ferrocenyl]ethyldi-tert-butylphosphine,
(S)-1 -[(R)-2-di(cyclohexylphosphino)ferrocenyl]ethyldicyclohexylphosphine,
(S)-1 -[(R)-2-di(cyclohexylphosphino)ferrocenyl]ethyldiphenylphosphine,
(S)-1 -[(R)-2-di(phenylphosphino)ferrocenyl]ethyldi-3,5-xylylphosphine,
(S)-1 -[(R)-2-di-(3,5-bis(trifluoromethyl)phenylphosphino)ferrocenyl]ethyldicyclohexylphosphine,
(S)-1 -[(R)-2-di-(4-methoxy-3,5-dimethyl)phenylphosphino)ferrocenyl]ethyldicyclohexylphosphine,
(S)-1 -[(R)-2-di-(3,5-bis(trifluoromethyl)phenylphosphino)ferrocenyl]ethyldi-3,5-xylylphosphine,
(S)-1 -[(R)-2-di(cyclohexylphosphino)ferrocenyl]ethyldi-tert-butylphosphine,
(S)-1 -[(R)-2-di-((4-trifluoromethyl)phenylphosphino)ferrocenyl]ethyldi-tert-butylphosphine,
(S)-1 -[(R)-2-di-(4-methoxy-3,5-dimethyl)phenylphosphino)ferrocenyl]ethyldi-tert-butylphosphine,
(S)-1 -[(R)-2-di-(2-furyl)phosphino)ferrocenyl]ethyldi-3,5-xylylphosphine,
(S)-1 -[(R)-2-di-(2-furyl)phosphino)ferrocenyl]ethyldi-tert-butylphosphine,
(S)-1 -[(R)-2-di(1 -naphthyl)phosphino)ferrocenyl]ethyldi-tert-butylphosphine,
(S)-1 -[(R)-2-di(1 -naphthyl)phosphino)ferrocenyl]ethyldi-3,5-xylylphosphine,
(S)-1 -[(R)-2-di-(4-methoxy-3,5-dimethyl)phenylphosphino)ferrocenyl]ethyldi-3,5-xylylphosphine,
(S)-1 -[(R)-2-di-(4-methoxy-3,5-dimethyl)phenylphosphino)ferrocenyl]ethyldi-(2-
methylphenyl)phosphine,
(S)-1 -[(R)-2-di-(2-furyl)phosphinoferrocenyl]ethyldi-(2-methylphenyl)phosphine,
(S)-1 -[(R)-2-di(tert-butylphosphino)ferrocenyl]ethyldiphenylphosphine,
(S)-1 -[(R)-2-di(tert-butylphosphino)ferrocenyl]ethyldi-(2-methylphenyl)phosphine,
(S)-1 -[(R)-2-diphenylphosphinoferrocenyl]ethyldiphenylphosphine,
(S)-1 -[(R)-2-(diphenylphosphino)ferrocenyl]ethyldi(adamantyl)phosphine, and
(S)-1 -[(R)-2-(di(adamantyl)phosphino)ferrocenyl]ethyldiphenylphosphine.
In one preferred embodiment, the ligand of formula (Ma) is (R)-1 -[(S)-2-
diphenylphosphinoferrocenyl]ethyldiphenylphosphine. In another preferred embodiment, the ligand of
formula (lib) is (S)-1 -[(R)-2-diphenylphosphinoferrocenyl]ethyldiphenylphosphine.
The phosphorus ligand L also preferably includes PPh3, PCy3 (tricyclohexylphosphine), dppf ( 1 ,1'-
bis(diphenylphosphino)ferrocene), dppp ( 1 ,3-bis(diphenylphosphino)propane), dppb ( 1 ,4-
bis(diphenylphosphino)butane), Dipfc ( 1 ,1 '-bis(di-isopropylphosphino)ferrocene), dCyPfc ( 1 ,1'-bis(di-
cyclohexylphosphino)ferrocene and DB'PF ( 1 ,1 '-bis(di-tert-butylphosphino)ferrocene). In one
embodiment, the phosphorus ligand L is unsubstituted. In another embodiment, the ligand L is
substituted.
Particularly preferred phosphorus ligands L may be selected from the group consisting of dppf, dppp
and dppb.
L2 is a CNN tridentate ligand of formula (2a) or (2b), each comprising a carbon-M bond , a pyridinyl
group and an amino group. The ligands are tridentate as they each coordinate to the M atom via:
a) a carbon-M bond (at C-8). The carbon-M bond is a carbon-metal bond created by
orthometallation during the synthesis of the [M X (L )m (L2)] complex of formula (3);
b) the nitrogen atom of the pyridinyl ring ; and
c) the nitrogen atom of the amino group.
In one embodiment, L2 is a tridentate ligand of formula (2a). In another embodiment, L2 is a tridentate
ligand of formula (2b).
, R2, R3, R4, R5, R6, R and b are as generally described above.
R7 may be present or absent. When absent, c is 0 i.e. the aryl ring is unsubstituted . When R7 is
present, c may be 1, 2 or 3 . When c is 2 or 3 , each R7 may be the same or different to each other.
The or each R7 are as generally described above. In one preferred embodiment, c is 0 i.e. R7 is
absent.
Preparation of the complex of formula (3)
The complex of formula (3) may be prepared by reacting a suitable transition metal complex, a ligand
L , a compound of formula ( 1a) or ( 1 b) or salts thereof, and a base in an alcohol solvent, provided C-8
of the compound of formula ( 1a) or ( 1 b) is -H.
The compound of formula ( 1a) or salts thereof, the compound of formula ( 1 b) or salts thereof and the
ligand L are as generally described above.
The ligand L may be present in stoichiometric or greater quantities to the compound ( 1a) or ( 1 b), or
salt thereof. When the free base of compound ( 1a) or ( 1 b) is reacted , stoichiometric or slight excess
of L may be suitable, for example, about 1 : 1.1 to 1 : 1.5 molar ratio of compound ( 1a) or ( 1 b) to L .
The transition metal complex may be selected from the group consisting of [ruthenium (arene)
(halogen)2]2, [ruthenium (halogen) (P(unsubstituted or substituted aryl)3)], [osmium (arene)
(halogen)2] , [osmium (halogen) 2 (P(unsubstituted or substituted aryl)3)] and [osmium (N(unsubstituted
or substituted alkyl)3)4 (halogen)2] .
The arene may be an unsubstituted or substituted benzene wherein the substituents are selected
from chain C1-6 alkyl, C1-6 alkoxy, C1-6 carboalkoxy, -OH or N0 2. In one embodiment, the arene may
be selected from the group consisting of benzene, cymene, toluene, xylene, trimethylbenzene,
hexamethylbenzene, ethylbenzene, t-butylbenzene, cumene (isopropylbenzene), anisole
(methoxybenzene), methylanisole, chlorobenzene, dichlorobenzene, trichlorobenzene,
bromobenzene, fluorobenzene, methylbenzoate and methyl methyl benzoate (e.g. methyl 2-
methylbenzoate). In another embodiment, the arene is benzene, p-cymene or mesitylene ( 1 ,3,5-
trimethylbenzene).
The halogen may be selected from the group consisting of chlorine, bromine and iodine, e.g. chlorine.
The P(unsubstituted or substituted aryl)3 may be a P(substituted aryl)3 or a P(unsubstituted aryl)3.
Examples of P(substituted aryl)3 and P(unsubstituted aryl)3 include but are not limited to PPh3 or
P(Tol)3, where the tolyl group may be ortho-, para- or meta-substituted.
The N(unsubstituted or substituted alkyl)3 may be a N(substituted alkyl)3 or a N(unsubstituted alkyl)3
(such as NEt3) .
In one embodiment, the [ruthenium (halogen) (P(unsubstituted or substituted aryl)3)] may be
RuCI2PPh3 or RuCI2(P(o-Tol) 3) . In one embodiment, the [osmium (halogen)2 (P(unsubstituted or
substituted aryl)3)] may be OsCI2PPh3 or OsCI2(P(o-Tol)3) .
In one embodiment, the [ruthenium (arene) (halogen)2]2 may be [RuCI2(p-cymene)] 2,
[RuCI2(benzene)] 2 or [RuCI2(mesitylene)] 2. In one embodiment, the [osmium (arene) (halogen)2] may
be [OsCI2(p-cymene)], [OsCI2(benzene)] or [OsCI2(mesitylene)]
In one embodiment, the [osmium (N(unsubstituted or substituted alkyl)3)4 (halogen)2] may be [(Et3N)4
Os Cl2] .
In the presence of a suitable base and when a hydrogen atom is present at C-8 of the compounds
( 1a) and ( 1 b), the compounds ( 1a) and ( 1 b) orthometallate with the transition metal atom (e.g . Ru or
Os) to form a transition metal complex comprising the CNN-tridentate ligands (2a) and (2b). R R2,
R3, R4, R5, R , R 7 and b are as generally described above and c may be 0 , 1, 2 or 3 (but not 4).
(2a) (2b)
The base may be any suitable base which is capable of removing the hydrogen at C-8 in the
compounds ( 1a) or ( 1 b). Examples of bases include trialkylamines (such as triethylamine), pyridine,
dimethylpyridine (e.g. 2,6-, 2,3-, 3,5-, 2,5- or 3,4-dimethylpyridine), alkali metal hydroxides (such as
sodium hydroxide or potassium hydroxide) or alkali metal alkoxides (such as sodium methoxide or
potassium methoxide).
The base may be present in stoichiometric or greater quantities to the compound ( 1a) or ( 1 b), or salt
thereof. When the free base of compound ( 1a) or ( 1 b) is reacted, stoichiometric or slight excess of
base may be suitable, for example, about 1 : 1.1 to 1 : 1.5 molar ratio of compound ( 1a) or ( 1 b) to
base. When salts of compound ( 1a) or ( 1 b) are utilised, however, excess base is generally required
in order to form the free base of the compound ( 1a) or ( 1 b) from the salt of compound ( 1a) and ( 1 b),
and deprotonate the compound ( 1 a) or ( 1 b) at C-1 4 to form the ligand (2a) or (2b). In this respect, the
molar ratio of the salts of compound ( 1a) or ( 1 b) to base may be about 1 : 5 to about 1 : 20, such as
about 1 : 7.5 to about 1: 15 , such as about 1 : 10 .
Any suitable alcohol solvent may be utilised. Suitable alcohols have boiling points at atmospheric
pressure (i.e. 1.01 35 x 105 Pa) below 120 °C, more preferably below 110 °C and even more
preferably below 100 °C. Preferably the alcohol is dry. The alcohol solvent may be selected from the
group consisting of methanol, ethanol, isopropanol and mixtures thereof. In one embodiment, the
alcohol solvent is iso-propanol (i.e. 2-propanol).
The concentration of the transition metal complex in the solvent may be about 0.001 mol/L to about
10.0 mol/L, such as about 0.01 to about 1.0 mol/L, for example, about 0.02 mol/L to about 0.5 mol/L.
In combining the transition metal complex, the ligand L , the ligand L2 and base in the alcohol, the
components may be mixed in any suitable order, although, in one embodiment, the transition metal
complex and ligand L are slurried or suspended in the alcohol solvent, followed by the addition of the
ligand L2 and the base. After the transition metal complex and the ligand L are combined with the
alcohol, the reaction mixture may be stirred and heated (e.g. at reflux) for a period of time (e.g. for up
to 2-3 hours). The mixture may be stirred for a period e.g. preferably 1 minute to 3 hours, more
preferably 2 minutes to 2 hours and most preferably 2.5 minutes to 1.5 hours. The ligand L2 and the
base may then be added to the reaction mixture and the reaction mixture stirred and heated (e.g . at
reflux) for a further period of time (e.g. for up to 5-6 hours).
The reaction may be conducted under an inert atmosphere, such as nitrogen or argon.
The reaction mixture may be treated with an alkane (such as pentane, hexane or heptane) which
causes the complex (3) to precipitate or crystallise. The solid complex (3) may be recovered directly
by filtering, decanting or centrifuging. If desired a proportion of the alcohol/alkane solvent mixture
may be evaporated prior to the recovery of the complex.
Alternatively, the solid complex (3) may be recovered simply by evaporating the alcohol/alkane
solvent mixture.
Howsoever the complex is recovered, the separated complex is preferably dried . Drying may be
performed using known methods, for example, at temperatures in the range of about 10-60 °C and
such as about 20-40 °C under 0 .1-30 mbar for 1 hour to 5 days. It may be desirable to store the
complex under conditions which substantially excludes light.
The complexes prepared by the processes of the present invention are pure and may be used in
catalytic applications as obtained or further dried. The methods are suited to large-scale manufacture
and large-scale catalytic applications.
Methods of Catalysis
In one aspect of the invention there is provided the use of a complex of formula (3) as a catalyst, for
example in a hydrogenation reaction or a transfer hydrogenation reaction. Such reactions may be
broadly referred to as hydrogen reduction reactions. It is envisaged that the complexes may also be
used in deuteration reactions, tritiation reactions, the isomerization of allylic alcohols,
dehydrogenation reactions which may be carried out with or without a hydrogen acceptor (e.g. the
dehydrogenation of alcohols to aldehydes or ketones, or the dehydrogenation of alcohols to esters),
the reduction of the alkenyl bond in α ,β-unsaturated carbonyls and in "hydrogen borrowing" reactions
(which include dehydrogenation and hydrogenation steps, e.g. the alkylation of amines with alcohols).
The complex of formula (3) is as described above.
In one embodiment, the method comprises the step of reacting a substrate comprising a carbon-
oxygen double bond in the presence of a complex of formula (3).
In one embodiment, the reaction is a hydrogenation reaction, and the method includes reacting the
substrate with hydrogen gas in the presence of a complex of formula (3). The reaction may further
comprise an alkali metal alkoxide (such as i-PrONa).
In one embodiment, the reaction is a deuteration reaction, and the method includes reacting the
substrate with deuterium gas in the presence of a complex of formula (3). The reaction may further
comprise an alkali metal alkoxide (such as i-PrONa).
In one embodiment, the reaction is a tritiation reaction , and the method includes reacting the
substrate with tritium gas in the presence of a complex of formula (3). The reaction may further
comprise an alkali metal alkoxide (such as i-PrONa).
In one embodiment, the reaction is a transfer hydrogenation , and the method includes reacting the
substrate with a hydrogen donor in the in the presence of a complex of formula (3). The hydrogen
donor may be selected from formic acid, a formic acid alkali metal salt, and an alcohol, such as an
alcohol having a hydrogen atom at a carbon atom that is a to the carbon atom to which the alcohol
group is attached, such as /'so-propanol. The reaction may further comprise an alkali metal alkoxide
(such as i-PrONa). In one embodiment, the substrate may be an aldehyde and the hydrogen donor
may be ammonium formate. In this instance, the aldehyde is reduced to a primary alcohol. As used
herein , a hydrogen donor is not gaseous hydrogen.
Examples of compounds containing a carbon-oxygen double bond include ketones, aldehydes, esters
and lactones, amongst others.
The method may include the step of reducing a substrate, for example the hydrogenation of a
carbonyl-containing substrate to yield the corresponding alcohol.
A suitable substrate to be hydrogenated includes, but is not limited to, a carbonyl of formula (I):
wherein,
R500 and R 5 0 are each independently selected from the group consisting of hydrogen , unsubstituted
C1-2 o-alkyl, substituted C1-2 o-alkyl, unsubstituted C3 _2 o-cycloalkyl, substituted C3 _2 o-cycloalkyl,
unsubstituted C^o-alkoxy, substituted C^o-alkoxy, unsubstituted C3 _2 o-cycloalkoxy, substituted C3_20-
cycloalkoxy, unsubstituted C2.20-alkenyl, substituted C2.20-alkenyl, unsubstituted C4.20-cycloalkenyl,
substituted C4.20-cycloalkenyl, unsubstituted C2.20-alkynyl, substituted C2.20-alkynyl, unsubstituted C _
20-aryl, substituted C .20-aryl, unsubstituted C^o-heteroalkyl, substituted C^o-heteroalkyl,
unsubstituted C2.20-cycloheteroalkyl, substituted C2.20-cycloheteroalkyl, unsubstituted C3.20-heteroaryl,
substituted C3.20-heteroaryl, -NR 600 R6io, -COR 600 , -COOR 600 , -CONR 600 R6io, unsubstituted -C^o-alkyl-
COOR 0 o, substituted -C^o -alkyl-COOReoo, unsubstituted -C^o -alkyl-COReoo, substituted -C^o-alkyl-
COR oo, unsubstituted substituted
unsubstituted -C2.20-alkynyl-C .20-aryl, substituted -C2.20-alkynyl-C .20-aryl, unsubstituted - C2.20-alkynyl-
C1-2 o-alkyl, substituted - C2-2 o-alkynyl-C 1-20-alkyl; or
R5oo and R5 0 are bound by an unsubstituted C1-2o alkyl, substituted C1-2o alkyl, unsubstituted C1-2o
alkoxy, substituted C1-20 alkoxy, unsubstituted C2.20 alkenyl or substituted C2.20 alkenyl; or
R500 and R5 0 are bound to form a 5 , 6 or 7 membered ring by an unsubstituted -(CH2)t-(ortho-C5. -
aryl)-(CH 2)u- chain, substituted -(CH2)t-(ortho-C5. -aryl)-(CH 2)u- chain, unsubstituted -(CH 2)t-(ortho-
C5. -aryl)-L Q-(CH2) - chain, substituted -(CH 2)t-(ortho-C 5. -aryl)-LQ-(CH2) - chain,
unsubstituted -(CH2)t-(ortho-C 5. -heteroaryl)-(CH 2)u- chain or substituted -(CH2)t-(ortho-C5. -
heteroaryl)-(CH 2)u- chain;
wherein t is an integer selected from 0 or 1,
u is an integer selected from 2 , 3 or 4 ,
-LQ- is selected from the group consisting of -0-, -N- and -S0 2- ,
wherein the substituents are selected from the group consisting of unsubstituted C1-20-alkyl,
unsubstituted C3.20-cycloalkyl, unsubstituted C^o-alkoxy, unsubstituted C3.20-cycloalkoxy,
unsubstituted C .20-aryl, unsubstituted C .20 aryloxy, unsubstituted C^o-heteroalkyl, unsubstituted C2_
20-cycloheteroalkyl, unsubstituted C3.20-heteroaryl, straight or branched tri-C _o-alkylsilyl-, -Hal, -OH, -
CN, -NR 0oR6io, -COR600 , -COOR 600, -CONR 0oR6 o and -CF3,
wherein R600 and R 0 are independently selected from the group consisting of hydrogen,
unsubstituted C1-20-alkyl, unsubstituted C3.20-cycloalkyl, unsubstituted C^o-alkoxy, unsubstituted C3.20-
cycloalkoxy, unsubstituted C .20-aryl, unsubstituted C .20 aryloxy and -OH.
In one embodiment, R500 and R5 0 are not both hydrogen.
In one embodiment, one of R500 and R5 0 is hydrogen and the other of R500 and R5 0 is selected from
the groups described above i.e. the carbonyl of formula (I) is an aldehyde.
In one embodiment, R500 and R5 0 are independently selected from the groups described above
provided that neither R500 or R5 0 are hydrogen i.e. the carbonyl of formula (I) is a ketone.
The reaction may be a non-asymmetric or asymmetric reduction reaction.
When R500 and/or R5 0 are different, the compounds of formula (I) are prochiral when the compound of
formula (I) is an aldehyde or ketone. In this instance, the hydrogenation catalysed by the complex of
formula (3) may be enantioselective when the phosphorus ligand L or the ligand L2 is chiral.
The enantiomeric excess may be greater than 80% ee. In certain embodiments, the enantiomeric
excess may be greater than 85% ee, in certain embodiments greater than 90% ee, in certain
embodiments greater than 93% ee.
The reaction conditions for the reduction reactions are not particularly limited, and may be performed
at the temperatures, pressures, concentrations that are appropriate to maximise the yield and
stereoselectivity of the reaction, whilst minimising reaction time and reaction impurities.
Example reaction conditions for transfer hydrogenation reactions are described in WO2009/007443,
the contents of which are hereby incorporated by reference.
After the reduction reaction is deemed complete, the reaction mixture may be at least partially
separated , for example to isolate the product, and/or to isolate the complex. In a stereoselective
reaction the product may be isolated from undesired stereoisomers.
The complexes of the invention may be separated from the reaction mixture by precipitation, for
example following the addition of an anti-solvent to the reaction mixture or following the concentration
of the reaction mixture.
The methods described above may be performed under an inert atmosphere, such as an argon or
nitrogen atmosphere.
Other Preferences
Each and every compatible combination of the embodiments described above is explicitly disclosed
herein, as if each and every combination was individually and explicitly recited.
Various further aspects and embodiments of the present invention will be apparent to those skilled in
the art in view of the present disclosure.
"and/or" where used herein is to be taken as specific disclosure of each of the two specified features
or components with or without the other. For example "A and/or B" is to be taken as specific
disclosure of each of (i) A , (ii) B and (iii) A and B, just as if each is set out individually herein.
Unless context dictates otherwise, the descriptions and definitions of the features set out above are
not limited to any particular aspect or embodiment of the invention and apply equally to all aspects
and embodiments which are described.
Certain aspects and embodiments of the invention will now be described by the way of the following
non-limiting Examples.
Examples
All reactions were carried out under argon or nitrogen atmosphere. Anhydrous THF, toluene, MeOH,
2-propanol were purchased from Aldrich and absolute EtOH was purchased from VWR. The
bisphosphines dppp, dppb, dppf and rac-BINAP were purchased from Alfa Aesar (Johnson Matthey),
whereas (S,f?)-JOSIPHOS was purchased from STREM. RuCI2(PPh3)3 and [RuCI2(p-cymene)] 2 used
were commercial grade products from Johnson Matthey. NMR measurements were recorded on
Bruker AC 200 and Bruker Advance 400 spectrometers and the chemical shifts, in ppm, are relative to
TMS for H and C{ H}, and 85% H3P0 4 for P{ H}. High-resolution mass spectra (HRMS) were
acquired on a Bruker BioApex II 4.7e FTICR mass spectrometer, whereas the GC analysis was
performed with a Varian GP-3380 gas chromatograph equipped with a MEGADEX-ETTBDMS- β chiral
column.
Abbreviations
AMPY 2-(aminomethyl)pyridine
DCM dichloromethane
DMF dimethylformamide
dppp 1,3-bis(diphenylphosphino)propane
dppb 1,4-bis(diphenylphospino)butane
dppf 1,1'-bis(diphenylphosphino)ferrocene
(S,f?)-JOSIPHOS (S)-1 -{(f?)-2-[diphenylphosphine]ferrocenyl}ethyldicyclohexylphosphine
eq. equivalent
h hour
HY hydrogenation
L Litre
mL millilitre
RT Room Temperature
TH transfer hydrogenation
Example 1
Synthesis of N-(naphthalen-1 -yl)-3-oxo-3-phenylpropanamide (1 ).
The 1-naphthylamine reagent used might have contained a few ppm quantity of the highly
carcinogenic 2-naphtylamine. While the 1-naphthylamine reagent had a quality allowing its use, 2-
naphtylamine is banned from use in Europe and many other countries. An occupational health
assessment required that in order to minimise exposure the N-(naphthalen-1 -yl)-3-oxo-3-
phenylpropanamide 1 should be assayed and characterised as a crude product and then converted
on as described in Example 2 .
1-Naphthylamine ( 1 183g , 8.26mol) and xylene (isomer mixture, 10L) was charged to a 20L round
bottom flask, equipped with a distillation setup that allowed distillation of the reaction side product
ethanol as azeotrope with xylene. The reaction was heated at an oil bath temperature of 160°C. Ethyl
benzoylacetate ( 1775g , 9.23mol) was added over 1.5 hours, resulting in a steady distillation of
ethanol/xylene. After completion of the addition, the reaction temperature was kept at 160°C (oil bath)
for two hours and then allowed to cool to 120°C. At this temperature the reaction solvent was distilled
by vacuum distillation. The resulting brown solid was cooled to room temperature and slurried in n-
heptane (9L).
The slurry was filtered, the solid product further washed with 1L of heptane and dried under vacuum
in a desiccator (over KOH) at 40°C to afford the pale brown solid 1, 1929g, 8 1 % yield . The product
may be used in the next step without further purification. H NMR (400 MHz, CDCI3) : δ 10.03 (br s ,
1H , NH), 8.05 (d, 1H , J = 7.6), 8.00 (d, 2H, J = 7.8), 7.79 (d, 1H , J = 7.8), 7.77 (d, 1H , J = 8.3),
7.68 - 7.58 (m, 1H), 7.55-7.35 (m, 6H), 4 .18 (s, 2H) (complex spectrum, only major resonances
given). C{ H} NMR ( 100.61 MHz, CDC3 , ) : δ 197.31 (C C=0), 164.3 (C C=0 amide), 136. 11,
134.51 , 134.1 0 , 132.39, 129.05, 128.71 , 128.63, 128.36, 128.71 , 127.93, 126.51 , 125.78, 125.47,
120.8, 119.72, 44.9 (complex spectrum, only major resonances given).
Example 2
Synthesis of 4-phenylbenzo[/7]quinolin-2(1 H)-one (2).
To crushed ice ( 1608 g) in a 20L round bottom flask with efficient overhead stirring was added
cautiously 4828g of 98% sulphuric acid. At the end of the addition, the mixture had a temperature
(internal) of 80°C. N-(naphthalen-1 -yl)-3-oxo-3-phenylpropanamide (1 , 1929g, as produced in
example 1) was added as solid in portions over 30 minutes. After the addition had completed, the
mixture had a temperature (internal) of 49°C. The reaction was then carefully heated in an oil bath,
set to 100°C. A very thick slurry of purple solid had formed after 5 hours at this temperature and the
mixture was allowed to cool to room temperature. 3 L of cold water was added with external cooling
by crushed ice and the mixture was stirred for three hours. The slurry was filtered and the solid
purple product washed with 3L of water and sucked dry as much as possible. The product was then
transferred to a 10L flask and stirred with 6L of acetone for 30 minutes. The slurry was again filtered
and the solid washed with 4x 1L of acetone. The pale -brown purple solid was dried in a desiccator
over KOH at 40°C to afford the solid product 2 ( 1571 g , 87% yield, 70 % in two steps from 1-
naphtylamine used in Example 1) . The product may be used in the next step without further
purification. HRMS found: [M+H]+ 272. 1058; calcd for C19H14NO: 272. 1070. H NMR (400 MHz,
DMSO-cf): δ 12.26 (s, br, NH) 8.94 ( 1 H, d , J = 7.9 Hz) , 7.97 ( 1 H, d , J = 6.9 Hz), 7.72- 7.62 (2 H, m),
7.60- 7.46 (6 H , m), 7.40 ( 1 H , d , J = 8.8 Hz), 6.54 ( 1 H , s). C{ H} NMR ( 100.61 MHz, DMSO-d 6) : δ
162.34, 152.95, 137.66, 134.06, 129.26, 129.20, 128.80, 128.66, 127. 13 , 123.46, 123.1 0 , 122.65 (the
solubility of the compound is so low that only the 12 non quaternary carbons are visible
Example 3
Synthesis of 2-bromo-4-phenylbenzo[/7]quinoline (3).
The product obtained in example 2 , 1571 g of 4-phenylbenzo[/?]quinolin-2(1 H)-one (2, 5.79 mol) was
dissolved in 7.8L of toluene and azeotropically dried using Dean-Stark distillation. At room
temperature 1660 g of POBr3 was carefully added in portions. After the reaction mixture was heated
overnight at 120°C it was cooled to room temperature. This mixture was added to 10L of water and
aqueous concentrated NaOH was added until a pH = 14 was measured in the water phase. At this
stage the reaction mixture had to be filtered over Celite to remove a very fine, very insoluble impurity.
The Celite pad was washed with several 1L quantities of toluene. The organic filtrate was stripped to
dryness and the residue recrystallized from isopropyl alcohol to afford the product 3 as a brown
powder ( 1392 g , 72 % yield). This batch was assayed for water content and 0.06 % wt wt residual
water content was determined. HRMS found: [M+H]+ 334.0221 , calcd for C19H13BrN: 334.0226. H
NMR (400 MHz, CDCI3) : δ 9 .19 ( 1 H, d , J = 7.7 Hz), 7.79 ( 1 H , d , J = 7.5 Hz), 7.70- 7.57 (4H , m), 7.51
( 1 H , s), 7.48-7.37 (5H, m) . C{ H} NMR ( 100.61 MHz, CDCI3) : δ 150.91 , 147.61 , 140.50, 137.05,
133.60, 130.70, 129.60, 129.55, 128.86, 128.81 , 128.73, 128.03, 127.58, 127.32, 126.20, 125.24,
123.52, 122.64.
Example 4
Synthesis of 4-phenyl-benzo[/7]quinoline-2-carbaldehyde (4).
33. 1 g of 2-bromo-4-phenylbenzo[/?]quinoline (3, 0 .1 mol) was dissolved in dry THF (300 mL) in a 1L
three neck round bottom flask and the mixture was cooled to -75°C (IPA/dry ice bath). 45 mL of 2.5M
n-butyl lithium in hexanes (0. 1125mol, 1.125 eq) was added slowly so that the internal temperature
never went above -70°C. After stirring the reaction for another one hour at -75°C, 11 g of anhydrous
dimethylformamide (0. 15 mol, 1.5 eq) was added in small drops so that the internal temperature
never went above -65°C. The reaction was then allowed to reach room temperature overnight. The
next day, 100 ml_ of water was added to quench the reaction, followed by 15 mL of glacial acetic acid.
The organic layer was separated and washed with 50ml of saturated sodium chloride solution. It was
then dried over sodium sulphate. The filtrate after removal of the sodium sulphate was concentrated
to dryness. The residue was treated with 75ml_ of ethanol and the resulting slurry filtered to obtain the
product 4 , which is dried under vacuum. Yield 20.0 g (70.6%). HRMS found: [M+H]+ 284. 1073, calcd
for C20H14NO: 284. 1070. H NMR (400 MHz, CDCI3) : δ 10.41 ( 1 H , s), 9.50 ( 1 H , d , J = 7.7 Hz) , 8 .12
( 1 H , s), 7.93 ( 1 H, d , J = 7.7 Hz), 7.89 (2H , s), 7.85 - 7.75 (7H , m). C{ H} NMR ( 1 00 MHz, CDCI3) : δ
194.3, 150.5, 149.5, 147.0, 137.8, 133.5, 13 1 .7, 130.5, 129.7, 129.0, 128.7, 128.2, 127.8, 127.0,
125.0, 124.0, 122.8, 118.9.
In a second reaction, 2-bromo-4-phenylbenzo[/?]quinoline (21 .56 g , 64.51 mmol) in less solvent (90
mL of dry THF) was reacted as above at -78 °C with 32.3 mL n-BuLi ( 2.5 M in hexane, 80.63 mmol,
1.25 eq.), then with dry DMF (6.29 mL, 80.63 mmol, 1.25 eq). After a workup similar to above, 19.35 g
of impure product was obtained and used without further purification for the synthesis of 5 .
Example 5
Synthesis of 2-carbaldehyde-4-phenylbenzo[/7]quinoline oxime hydrochloride (5).
The crude aldehyde 4 from the second reaction above ( 19.35 g , 68.3 mmol) was slurried in absolute
ethanol (240 mL) and heated at 40 °C. Hydroxylamine hydrochloride (8.54 g , 122.3 mmol, 1.8 eq.)
was added at once, affording a red solution which was stirred at 40 °C for 1.5 h . During this time the
formed oxime started to precipitate as a bright yellow solid . The reaction mixture was cooled down to
0 °C for 1h , affording an additional yellow precipitate. The solid was filtered, washed with EtOH ( 10
mL) and dried under reduced pressure to give the hydrochloride salt of the oxime as a bright yellow
solid (5, 14 g , 4 1 .82 mmol, 6 1 %). HRMS found: [M+H]+ 299.1 166, calcd for C2oH 15N20: 299. 1179. H
NMR (400 MHz, methanol-d 4) : δ 9 .12 ( 1 H , t , J = 4.7 Hz), 8.63 ( 1 H , s), 8 .17 ( 1 H , s), 7.99 ( H , t , J =
4.6 Hz), 7.95 ( 1 H , d , J = 9.2 Hz) , 7.82 (2H , t , J = 4.6 Hz) , 7.77 ( 1 H, d , J = 9.2 Hz), 7.57 - 7.50 (5H,
m). C{ H} NMR ( 100 MHz, methanol-d 4) : δ 155.3, 147.5, 144.1 , 140.25, 136.38, 134.5, 130.5,
130.2, 129.7, 129.5, 129.3, 128.8, 128.7, 128.3, 125.6, 125.45, 123.4, 122.2, 119.1 7 .
When the 20g (0.07 mol) of pure solid 4-phenylbenzoquinoline-2-carboxaldehyde (4) obtained in
example 4 were slurried in 250 mL of ethanol followed by addition of 6.9g (0. 1mol) of
hydroxylamine hydrochloride in one lot, a quantitative yield of 20.93 g of 2-carbaldehyde-4-
phenylbenzo[/?]quinoline oxime hydrochloride 5 was obtained. The ethanol slurry of the 4-
phenylbenzoquinoline-2-carboxaldehyde and the hydroxylamine hydrochloride was heated to 50°C for
2 hours. The slurry was filtered and the solid product washed with ethanol.
Example 5a
Synthesis of 4-phenyl-2-cyanobenzo[/7]quinol
10g (0.03 mol) of 4-phenyl-2-bromo-benzo[/?]quinoline was combined with 3.2g (0.036mol) of
copper(l) cyanide and 50 ml_ of commercial grade N-methylpyrrolidone. The reaction mixture was
heated to 150°C for 4 hours, at which point no starting material remained. The cooled reaction mixture
was quenched by its addition to a mixture of 10g iron ( 111) chloride hexahydrate, 1L of water and a few
drops of concentrated hydrochloric acid . The mixture was extracted with dichloromethane. The
dichloromethane phase was stripped and the crude product slurried in water to give a solid which was
isolated by filtration. The crude product was taken up in toluene. Fractional crystallisation gives
initially a compound fraction that was identified and characterised as 4-phenyl-benzo[/?] quinoline-2-
carboxamide (5b). As second pure fraction 3.3g (39%) of the title compound 4-phenyl-2-
cyanobenzo[/?]quinoline 5a was isolated.
4-Phenyl-2-cyanobenzo [ 7] quinoline 5a: MS(ESI) m/z: 281 (MH+) H-NMR (DMSO-D6, 400MHz) δ :
9 .18 ( 1 H , m), 8 .18 ( 1 H , s), 8.09 (2H, m , J=9. 1) , 7.86 (2H, m), 7.78 ( 1 H , d , J=9.2), 7.64 (5H, m).
C{ H} NMR (DMSO-D6, 100MHz) δ : 149.5, 146.7, 136.2, 133.3, 13 1 .2, 13 1 .1 , 130. 1,129.9, 129.4,
129.0, 128.4, 128.3, 125.8, 125.7, 124.5, 122.2, 118.1 (shift overlap of two C resonances)
4-Phenylbenzo [ 7]quinoline-2-carboxamide 5b: MS(ESI) m/z: 299 (MH+). H-NMR (DMSO-D6,
400MHz) δ : 9.68 ( 1 H , m), 8.80 ( 1 H , s), 8.1 9 ( 1 H , s), 8.08 ( 1 H , m), 8.03 ( 1 H , d , J=9.2Hz), 7.91 ( 1 H, s),
7.84 (2H, m), 7.81 ( 1 H , d , J=9.2Hz), 7.63 (5H , m). C{ H} NMR (DMSO-D6, 100MHz) δ : 166.3, 149.2,
148.5, 145.2, 137.6, 133.3, 13 1 .1 , 129.7, 129.5, 129.2, 129.0, 128.9, 128.0, 127.7, 125.7, 125.1 ,
122.5, 120.0.
Example 6
Synthesis of 4-phenyl-2-aminomethyl-benzo[A)]quinoline hydrochloride (HCNN h-HCI) (6).
2-carbaldehyde-4-phenylbenzo[/?]quinoline oxime hydrochloride (5, 6.0 g , 17.9 mmol) was placed in a
100 mL Parr autoclave followed by 10 % Pd/C Type 338 ( 1 .94 g of paste catalyst, Manufacturer
Johnson Matthey). The autoclave was assembled, purged with nitrogen and depressurized . MeOH
(60 mL) was added via the injection port. Stirring was started and autoclave was purged again with N2
(5x2 bar) and H2 (5x5 bar). The autoclave was pressurized with hydrogen to 5 bar and heated at 30
°C. The gas uptake starts occurring after ca 45 min. Hydrogen was refilled to keep 5 bar and the
reaction mixture was stirred until gas uptake was no longer apparent (ca. 90 min .). The autoclave was
carefully depressurized and purged with N2 (5x2 bar). Reaction mixture was filtered over a pad of
celite and the pad was washed with MeOH (50 mL). The solvent was evaporated under reduced
pressure to give the title compound as off-white solid (6, 5.5 g , 96 % yield). HRMS found: [M+H]+
285. 1387, calcd for C2oH 1 N2: 285. 1386. H NMR (400 MHz, methanol-d 4) : δ 9.52 ( 1 H , d , J = 8.0),
7.94 ( 1 H , d , J = 7.6), 7.86 - 7.70 (4H, m) , 7.61 - 7.51 (6H, m), 4.5 (2H, s). C{ H} NMR ( 100 MHz,
methanol-d 4) : δ 150.7, 149.9, 145.9, 137.8, 133.7, 13 1 .0, 129.3, 128.5, 127.8, 127.5, 126.9, 124.8,
123.6, 122.2, 120.2, 43.1 .
Example 7
Synthesis of N-(naphthalen-1 -yl)-3-oxobutanamide (7).
The 1-naphthylamine reagent used might have contained a few ppm quantity of the highly
carcinogenic 2-naphtylamine. While the 1-naphthylamine reagent had a quality allowing its use, 2-
naphtylamine is banned from use in Europe and many other countries. An occupational health
assessment required that in order to minimise exposure the N-(naphthalen-1 -yl)-3-oxobutanamide 7
should be assayed and characterised as a crude product and then converted on as described in
Example 8 .
1-Naphthylamine (500 g , 3.49 mol) was placed in a 10L round bottom flask and dissolved in THF (850
ml_). Solid anhydrous sodium acetate (286.7 g , 3.6 mol) was charged next, followed by 2,2,6-
trimethyl-4H-1 ,3-dioxin-4-one (700 g , 4.92 mol). The slurry was heated at reflux temperature for 26
hours. Then the reaction mixture was cooled to room temperature and 3L dilute 2M aqueous HCI was
added with vigorous stirring. The resulting slurry was stirred for 1 hour and then filtered. The pale
purple solid was washed with water (2 x 150 ml_) and dried in a desiccator over KOH at 40°C. 720 g
of N-(naphthalen-1 -yl)-3-oxobutanamide (7, 9 1 % yield) were obtained. H NMR (400 MHz, CDCI3) : δ
9.97 (br s , 1H , NH), 7.98 (d, 1H , J = 7.5), 7.94 (d , 1H , J = 8.3), 7.78 (d, 1H , J = 8.0), 7.59 (d , 1H , J =
8.3), 7.48 (t, 1H , J = 7.5), 7.42 (t, 1H, J = 7.6), 7.37 (t, 1H, J = 8.0), 3.64 (s, 2H), 2.28 (s, 3H). C{ H}
NMR ( 100.61 MHz, CDC3) : δ 206.22 (C C=0), 163.9 (C C=0 amide), 134.07, 132.28, 128.70,
126.60, 126.47, 125.74, 125.51 , 120.76, 119.79, 49. 19 , 3 1 .43.
In a repeat synthesis 1-Naphthylamine (900 g , 6.29 mol) was dissolved in 1.5L of THF in a 10L round
bottom flask with overhead stirrer. Solid anhydrous sodium acetate (51 6g , 6.29 mol) was charged
next, followed by 2,2,6-trimethyl-4H-1 ,3-dioxin-4-one ( 1260 g , 8.86 mol). In this repeat 952 g of N-
(naphthalen-1 -yl)-3-oxobutanamide (7, 67 % yield) were obtained.
Example 8
Synthesis of 4-methylbenzo[A)]quinolin-2(1 H)-one (8).
3000 g of 98% sulphuric acid were heated in a 10L round bottom flask with efficient overhead stirring
to an internal temperature of 65°C. 952 g of N-(naphthalen-1 -yl)-3-oxobutanamide 7 was added in
portions so that despite the very exothermic reaction the internal temperature did not exceed 90°C.
The mixture was heated to 95°C for 1 hour and then cooled to 50°C. This mixture was slowly added
to 15 kg of crushed ice in another 20L round bottom flask with efficient overhead stirring. The slurry
was stirred for 1 hour and then filtered. The purple solid was washed with 3 x 1L of water and sucked
dry as much as possible. The product is then transferred to a 10L flask and stirred with 4L of ethanol
for 30 minutes. The slurry is again filtered and the pale purple solid is dried in a desiccator over KOH
at 40°C to afford the solid product (8, 8 14 g , 93% yield). HRMS found: [M+H]+ 2 10.0906, calcd for
C14H10NO: 2 10.091 3 . H NMR (400 MHz, CDCI3) : δ 8.51 ( 1 H , d , J = 8.3 Hz), 7.85 ( 1 H, d , J = 8.0 Hz),
7.77- 7.56 (4 H , m), 6.68 ( 1 H, s), 2.56 (3H, s). C{ H} NMR ( 100.61 MHz, CDCI3) : δ 162.84, 150.70,
134.71 , 134.05, 128.73, 128.1 8 , 127.28, 123.4, 12 1 .29, 12 1 .89, 12 1 .03, 119.90, 116.96, 19.94.
Example 9
Synthesis of 2-bromo-4-methylbenzo[/7]quinoline (9).
8 14 g of 4-methylbenzo[/?]quinolin-2(1 H)-one (8, 3.876 mol), obtained in Example 8 was dissolved in
4L of toluene and azeotropically dried using Dean-Stark distillation. At room temperature 1115 g of
POBr3 was carefully added in portions. After the reaction mixture was heated overnight at 120 °C and
6.5L of water were added, NaOH was added until a pH = 14 was measured in the water phase. At this
stage the reaction mixture had to be filtered over Celite to remove a very fine, very insoluble impurity.
The Celite pad was washed with five 1L quantities of toluene. The combined organic filtrate was dried
and all toluene was removed by reduced pressure distillation. The residue was taken up in acetone
(8.5L), heated to reflux and the hot solution filtered through Celite. The acetone was partially distilled
under reduced pressure until a very thick slurry was obtained. The slurry at room temperature was
filtered to give the product 9 as a grey solid (584 g , 55 % yield).
By repeating this reaction, another 621 g were obtained in higher yield of 75 % . The 584 g and the
621 g were combined and dissolved in hot toluene, treated with activated charcoal and the charcoal
was removed by filtration and the charcoal pad washed with further toluene. The combined toluene
fractions were partially stripped giving a crop of 887 g of a pure cream solid 2-bromo-4-
methylbenzo[/?]quinoline 9 . The water assay by Karl Fischer method gave 0.06 % wt wt residual
water.
As further fractions 155 g , then 80 g of less pure material were obtained. Analysis on the pure
product: HRMS found : [M+H]+ 272.0059, calcd. for C H BrN: 272.0069. H NMR (400 MHz, CDCI3) :
δ 9.0964 ( 1 H, dd, J = 2.0, 7.0 Hz), 7.75 ( 1 H, dd, J = 2.0, 7.0 Hz), 7.67 (s,1 H), 7.65 (s, 1H), 7.59 ( 1 H,
d , J = 6.0 Hz), 7.65 - 7.56 (m, 1H), 7.31 (s,1 H), 2.51 (s,3H). C{ H} NMR ( 100 MHz, CDCI3) : δ 146.9,
146.5, 140.7, 133.5, 130.7, 128.5, 127.7, 127.6, 127.2, 126.6, 125. 1, 124.6, 120.8, 18.7
Example 10
Synthesis of 4-methylbenzo[/7]quinoline-2-carbaldehyde (10).
54.4 g of 2-Bromo-4-methylbenzo[/?]quinoline 9 (0.2 mol) was dissolved in 400 mL of THF in a 1L
three neck round bottom flask and the mixture was cooled to -75°C (IPA/dry ice bath). 100 mL of
2.5m n-butyl lithium in hexanes (0.25 mol, 1.25 eq) was added slowly so that the internal temperature
never went above -70°C. The mixture was left to stir for 45 minutes at -75°C. Then 22 g of anhydrous
dimethylformamide (0.30 mol, 1.5 eq) was added in small drops so that the internal temperature
never went above -65°C. The reaction was then allowed to reach room temperature overnight.
The next day, 350 mL of water was added to quench the reaction , followed by 40 mL of glacial acetic
acid. A solid precipitated and was filtered off and washed with water and n-heptane to give a first
crop. The organic layer of the filtrate was separated from the aqueous phase and the solvents were
removed by distillation at reduced pressure. The residue was triturated with 150mL of methanol to
give a second crop that was filtered off and washed with methanol. The two crops were combined
and dried under vacuum affording compound 10 . Yield 29.4g (68%). H NMR (400 MHz, CDCI3) : δ
10.35 ( 1 H , s), 9.47 ( 1 H , d , J = 8 .1 Hz), 8.04-7.93 (4H, m), 7.86 - 7.75 (3H, m), 2.89 (3H, s). C{ H}
NMR ( 100 MHz, CDCI3) : δ 194.5, 150.5, 146.1 , 145.4, 133.4, 13 1 .9, 130.3, 128.7, 128.4, 127.9,
127.7, 12 1 .1, 119.3, 19.3.
Example 11
Synthesis of 4-methylbenzo[A)]quinoline-2-carbaldehyde oxime hydrochloride (1 1).
29 g of 4-methylbenzo[/?]quinoline-2-carbaldehyde 10 (0. 13 mol) from example 10 were slurried in
300 mL of ethanol followed by addition of 9.6 g (0. 143 mol) of hydroxylamine hydrochloride in one lot.
The ethanol slurry of the 4-phenylbenzoquinoline-2-carboxaldehyde and the hydroxylamine
hydrochloride was heated to 50°C for 90 minutes and the slurry then filtered and the solid product
washed with cold ethanol. A 76 % yield of 26.0 g of 2-carbaldehyde-4-methylbenzo[/?]quinoline
oxime hydrochloride 11 was obtained. HRMS found: [M+H]+ 237. 10 18 , calcd for C15H13N20 :
237. 1022. H NMR (400 MHz, methanol-d 4) : δ 9 .16 - 9 .10 ( 1 H , m), 8.75 ( 1 H , s), 8.32 ( 1 H , s), 8.20 -
8 .10 (3H, m), 7.95 - 7.91 (2H, m), 3.05 (3H , s). C{ H} NMR ( 100 MHz, methanol-d 4) : δ 155.6, 146.6,
142.7, 137.4, 134.7, 130.79, 130.4, 129.0, 128.5, 127.2, 124.1 , 123.03, 120.7, 119.7, 19.3.
Example 11a
Synthesis of 4-methyl-2-cyanobenzo[/7]quinoline (1 1a)
13.6g (0.035 mol) of 4-methyl-2-bromo-benzo[/?]quinoline (9) were combined with 5.6g (0.062mol) of
copper(l) cyanide and 75 mL of commercial grade N-methylpyrrolidone. The reaction mixture was
heated to 150°C for 4 hours, at which point no starting material remained. The cooled reaction mixture
was quenched by its addition to a mixture of 20g iron(ll l) chloride hexahydrate, 150 mL of water and 2
mL of concentrated hydrochloric acid . A solid precipitated and was isolated by filtration. After
washing with water and drying the solid was recrystallized from toluene to give 7.5 g of 4-methyl-2-
cyanobenzo[/?]quinoline (1 1a) contaminated with less than 20 % w/w 4-methyl-benzo[/?]quinoline-2-
carboxamide (1 1b).
4-methyl-2-cyanobenzo [ 7]quinoline 11a : MS(ESI) m/z: 2 19 (MH+) . H-NMR (DMSO-D6, 400MHz) δ :
9.08 ( 1 H , m) , 8.1 3-7.96 (4H, m), 7.82 (2H, m), 2.75 (3H, s). C{ H} NMR (DMSO-D6, 100MHz) δ :
147.3, 133.4, 130.6, 129.5, 128.3, 128.2, 126.9, 126.3, 124.4, 12 1 .5, 118.2, 18.6 (shift overlap of four
C resonances).
4-Methylbenzo[/?]quinoline-2-carboxamide 11b has been identified as a separate peak in LCMS with
MS(ESI) m/z: 237 (MH+). Mass difference + 18 (water) as expected.
Example 12
Synthesis of 4-methyl-2-aminomethyl-benzo[/7]quinoline hydrochloride (HCNN HCI) (12).
Compound 11 ( 100 mg , 0.36 mmol) was placed in an glass insert of an Biotage Endeavor pressure
screening unit followed by 10 % Pd/C Type 338 ( 15 mg of paste catalyst, Johnson Matthey product).
The Biotage Endeavor was assembled, the vial purged with nitrogen and depressurized. MeOH (3
mL) was added via the injection port. The stirring was started and the autoclave was purged with N2
(5x to 2 bar) and H2 (5x to 5 bar) . The system was pressurized with hydrogen to 5 bar and heated at
30 °C. Gas uptake started after 45 minutes. The hydrogen pressure was kept at 5 bar and the
reaction mixture was stirred until gas uptake was no longer apparent (ca. 90 min). The system was
carefully depressurized and purged with N2 (5x to 2 bar). The reaction mixture was filtered over a pad
of celite and the pad was washed with MeOH ( 10 mL). The solvent was evaporated under reduced
pressure to give 4-methyl-2-aminomethyl-benzo[/?]quinoline hydrochloride 12 as an off-white solid (93
mg). HRMS found: [M+H] + 223. 1230, calcd for C15H15N2: 223. 1230. H NMR (400 MHz, methanol-d 4) :
δ 7.89 ( 1 H , d , J = 8.0 Hz), 6.41 (2H, d , J = 8.7 Hz), 6.35 ( 1 H , d , J = 9 .1 Hz), 6.25 - 6 .14 (2H, m), 5.92
( 1 H , s), 2.97 (2H, s), 1.21 (3H, s). C{ H} NMR ( 100 MHz, methanol-d 4) : δ 149.0, 144.5, 143.4, 132.2,
129.6, 126.5, 126.0, 125.9, 125.2, 123.6, 123.2, 119.3, 119.0, 4 1.4, 16.2.
Example 13
Synthesis of RuCI(CNN h)(dppp) (13).
R = Ph; PP = dppp
RuCI2(PPh3)3 (222 mg, 0.232 mmol) and dppp ( 10 1 mg, 0.244 mmol) were slurried in 2-propanol (4
mL) and the mixture was refluxed in a 25 mL round bottom flask for 1 h . Compound 6 (82 mg , 0.256
mmol) and NEt3 (0.32 mL, 2.3 mmol) were added and the mixture was refluxed for 1 h . The
suspension was cooled to room temperature and heptane (4 mL) was added. The orange precipitate
was filtered, washed with MeOH ( 1 mL), heptane (3 x 1 mL) and dried under reduced pressure (13 ,
17 1 mg , 89 % yield). HRMS found: [M-CI]+ 797.1 787, calcd for C47H4 N2P2Ru: 797. 1783. H NMR
(200. 1 MHz, CD2C I2) : δ 8.06 (m, 1H), 7.95-7.81 (m, 4H), 7.66-6.90 (m, 2 1H), 6.59 (t, J = 7 .1 Hz, 1H),
6.28 (t, J = 6.8 Hz, 2H), 5.77 (t, J = 8.2 Hz, 2H) , 4.53 (d , J = 14.4 Hz, NCH2, 1H) , 4 .12 (m, NH2, 1H),
3.91 (m, NCH2, 1H), 2.98 (t, J = 12.6 Hz, CH2,1H), 2.65 (t, J = 12.4.1 Hz, CH2, 1H), 2.37 (t, J = 13.8
Hz, CH2, 1H), 2.20 (m, NH2, 1H), 1.72-1 .58 (m, CH2, 2H), 1.29 (m, CH2, 1H). C{ H} NMR (50.3 MHz,
CD2C I2) : δ 170.0 (dd, 2J(CP) = 15.1 , 9.5 Hz; CRu), 155.2, 152.2, 146.4, 146.1 , 143.2, 142.4, 138.9,
138.6, 138.1 , 137.7, 137.1 , 135.9, 135.7, 134.3, 133.8, 133.6, 133.4, 13 1 .6, 13 1 .5, 130.0, 129.8,
129.2, 129.1 , 128.9, 128.8, 128.6, 128.5, 128.2, 128.0, 127.6, 127.4, 127.2, 125.9, 125.7, 123.0,
120.5, 118.4, 117.1 , 52.0 (d, J = 2.0 Hz, CH2N) 29.8, (d, J = 26.4 Hz, CH2P), 24.8, (d, J = 35.6 Hz,
CH2P), 2 1 .0 (s, CH2P) . P{ H} NMR (81 .0 MHz, CD2C I2) : δ 54.7 (d, J = 48.6 Hz), 35.7 (d, J = 48.6
Hz).
Example 14
Synthesis of RuCI(CNN h)(dppb) (14).
R = Ph; PP = dppb
RuCI2(PPh3)3 (2.22 g , 2.32 mmol) and dppb ( 1 .04 g , 2.44 mmol) were suspended in anhydrous 2-
propanol (40 mL) and the mixture was refluxed in a 250 mL round bottom flask for 1.5 h . Compound 6
(820 mg , 2.56 mmol) and NEt3 (3.2 mL, 23 mmol) were added and the mixture was refluxed for 1.5 h.
The suspension was cooled to room temperature and the bright orange precipitate was filtered,
washed with MeOH ( 1 0 mL), heptane (3 x 10 mL) and dried under reduced pressure (14,1.68 g , 85 %
yield). HRMS found: [M-CI]+ 8 11.1943, calcd for C48H43N2P2Ru 8 11.1940. H NMR (200. 1 MHz,
CD2C I2) : δ 8.25 (pseudo t , J = 7.6 Hz, 2H, aromatic protons), 8.04 (d, J = 7.0 Hz, 1H , aromatic
proton), 7.85 (pseudo t , J = 8.0 Hz, 2H, aromatic protons), 7.65-7.31 (m, 20H, aromatic protons), 6.95
(s, 1H , aromatic proton), 6.56 (t, J = 7.2 Hz, 1H , aromatic proton), 6.23 (pseudo t , J = 7.4 Hz, 2H,
aromatic protons), 5.54 (t, J = 7.8 Hz, 2H, aromatic protons), 4.37 (dd, J = 16.2, 5.2 Hz, 1H , NCH2) ,
4.02(m, 1H , NCH2) , 3.68 (m, 1H , NH2) , 2.96 (m, 2H, CH2) , 2.38-1 .00 (m, 7H, CH2 and NH2) . C{ H}
NMR (50.3 MHz, CD2C I2) : δ 168.1 , 166.0, 159.3, 159. 1, 157.5, 150.0, 149.8, 144.8, 144.7, 143.3,
142.6, 142.2, 142. 1, 14 1 .8, 14 1 .6, 14 1 .4, 14 1 .3, 140.8, 140.6, 139. 1, 139.0, 133.9, 109.6, 43.9, 43.2,
40. 1, 35.2. P{ H} NMR (81 .0 MHz, CD2CI2) : δ 57.3 (d , J = 38. 1 Hz), 43.3 (d, J = 38. 1) .
Example 15
Synthesis of RuCI(CNN h)(dppf) (15).
R = Ph ; PP = dppf
RuCI2(PPh3)3 (2.22 g , 2.32 mmol) and dppf ( 1 .54 mg , 2.78 mmol) were suspended in 2-propanol (20
mL) and the mixture was refluxed in a 250 mL round bottom flask for 1.5 h . Compound 6 (820 mg,
2.55 mmol) and NEt3 (3.2 mL, 23mmol) were added and the mixture was refluxed for 5 h . The
suspension was cooled to room temperature and heptane (40 mL) was added. The orange precipitate
was filtered , washed with MeOH ( 1 0 mL), heptane (3 x 10 mL) and dried under reduced pressure (15 ,
2.03 g , 90 % yield). HRMS found: [M-CI]+ 939. 1301 , calcd for C54H43FeN2P2Ru: 939. 1289. H NMR
(200. 1 MHz, CD2CI2) : δ 8.65-8.5 (m, 1H), 8 .13 (pseudo t , J = 7.6 Hz, 2H), 7.85-7.0 (m, 22H), 6.64
(pseudo t , J = 7.4 Hz, 1H), 6.31 (pseudo t , J = 7.2 Hz, 2H), 6.08 (pseudo t , J = 8.0 Hz, 2H), 4.85 (m,
1H), 4.5-4. 1 (m, 5H), 3.9-3.68 (m, 3H), 3.2 (m, 1H), 2.24 (m, 1H). C{ H} NMR (50.3 MHz, CD2C I2) : δ
176.3, 173.8, 167.9, 167.6, 167.3, 165.2, 164.6, 160.9, 160.2, 159.4, 159. 1, 158.9, 155.3, 155.1 ,
154.9, 154.1 , 153.3, 153.1 , 15 1 .6, 150.9, 150.7, 150.5, 150.2, 149.7, 149.5, 149.3, 149.1 , 148.9,
147.9, 147.6, 147.4, 146.7, 146.6, 143.5, 14 1 .4, 139.9, 138.4, 109.0, 108.2, 107.7, 106.7, 98.8, 98.5,
98.1 , 96.8, 95.1 , 94.6, 90.5, 90.4, 90. 1, 53.1 , 50.3, 44.0, 35. 1. P{ H} NMR (81 .0 MHz, CD2C I2) : δ
62.0 (d, J = 35.6 Hz), 45.3 (d, J = 35.6 Hz).
Example 16
Synthesis of RuCI(CNN )(dppp) (16).
R = Me; PP = dppp
In a 100 mL Schlenk were introduced, under argon atmosphere, RuCI2(PPh3)3 (445 mg , 0.46 mmol),
dppp ( 199 mg , 0.48 mmol) and 2-propanol ( 10 mL). The reaction mixture was refluxed for 1 h ,
compound 12 ( 13 1 mg , 0.506 mmol) and triethylamine (0.64 mL, 4.6 mmol) were added and the
reaction mixture was refluxed overnight. The reaction mixture was cooled to RT and the solid was
filtered off. The precipitate was washed with MeOH (2 mL) and dried in vacuum (16 , 278 mg , 78 %
yield). HRMS found: [M-CI] + 735. 1638, calcd for C42H39N2P2RU: 735.1 627. H NMR (400 MHz, CDCI 3) :
δ 8.47 (pseudo t , J = 8.0 Hz, 2H), 8.37 (d, J = 6.5 Hz, 1H), 8.1 1 (pseudo t , J = 8.0 Hz, 2H), 8.0-6.9 (m,
15H), 6.48 (t, J = 7.2 Hz, 1H), 6.42 (s, 1H , aromatic proton) , 6.22 (t, J = 6.9 Hz, 2H) , 5.85 (t, J = 8.1
Hz, 2H), 4.56 (m, 1H), 3.79 (m, 2H) , 3.25 (m, 1H), 3.08 (m, 2H) , 2.83 (m, 1H), 2.62 (m, 1H) , 2.30 (m,
5H). C{ H} NMR ( 100 MHz, C D ) : 142.9, 139.9, 139.4, 139.0, 136.2, 133.3, 132.1 , 128.4, 127. 1,
126.7, 125.2, 64.5, 28.5, 25.2, 18.7, 17.8. P{ H} NMR ( 162 MHz, C D ) : δ 54.2 (d, J = 47.7 Hz),
35.5 (d, J = 47.7 Hz).
Example 17
Synthesis of RuCI(CNN )(dppb) (17).
R = Me; PP = dppb
The preparation of 17 was carried out substantially as described for complex 16 , but using dppb (237
mg, 0.56 mmol) in place of dppp (17 , 300 mg , 83 % yield). HRMS found: [M-CI]+ 749. 1788, calcd for
C43H41 N2P2RU: 749. 1783. H NMR (400 MHz, CDCI 3) : δ 8.71 (pseudo t , J = 8.0 Hz, 2H), 8.45 (d, J =
7.0 Hz), 8.23 (pseudo t , J = 8.0 Hz, 2H), 7.85-7.36 (m, 8H), 7.25-7. 16 (m, 7H), 6.39 (pseudo t , J = 7.4
Hz, 1H), 6.28 (s, 1H , aromatic proton), 6 .15 (pseudo t , J = 7.5 Hz, 2H), 5.67 (t, J = 7.8 Hz, 2H), 4.09
(m, 1H), 3.55-3.4 (m, 2H), 3.25-3. 15 (m, 2H), 2.4-2.3 (m, 1H), 2 .15 (s, 3H, Me), 2 .10-1 .70 (m, 6H).
C{ H} NMR ( 100 MHz, C D ) : 155.1 , 153.7, 146.4, 154.3, 144.6, 14 1 .7, 136.4, 136.3, 133.8, 133.6,
13 1 .4, 13 1 .3, 13 1 .2, 130.6, 130.5, 129.6, 129. 1, 125.8, 125.1 , 125.0, 123.8, 118.6, 116.7, 5 1 .6, 33.0,
29.7, 26.3, 2 1 .4, 17.8. P{ H} NMR ( 162 MHz, CDCI 3) : δ 57.5 (d, J = 38.5 Hz), 43.2 (d, J = 38.5 Hz).
Example 18
Synthesis of RuCI(CNN )(dppf) (18).
R = Me; PP = dppf
The preparation of 18 was carried out substantially as described for complex 16 , but using dppf (31 1
mg, 0.56 mmol) in place of dppp (18 , 184 mg , 44 % yield). HRMS found: [M-CI]+ 877. 1148, calcd for
C49H4 FeN2P2Ru : 877.1 132. H NMR (400 MHz, CDCI3) : δ 9 .11 (d, = 6.0 Hz, 1H) , 9.0 (pseudo t , J =
8.0 Hz, 2H), 8.79 (m, 1H), 8.0-7.71 (m, 5H), 7.4-7.07 (m, 10H), 6.45 (t, J = 6.4 Hz, 1H), 6.27-6. 17 (m,
4H), 5.8 (s, 1H , aromatic proton), 5.01 (m, 1H), 4.38-4.35 (m, 2H), 4.2 (m, 1H), 3.98 (m, 2H), 3.65 (m,
2H), 3.32 (m, 1H), 3.08 (m, 1H), 2.22 (s, 3H , Me), 1.92 (m, 1H). C{ H} NMR ( 100 MHz, C D ) : 176.8,
155.4, 152.1 , 147.2, 146.8, 144. 1, 143.8, 14 1 .6, 139.7, 139.4, 138.7, 138.6, 135.8, 135.4, 135.2,
133.9, 132.6, 126.6, 126. 1, 125.3, 123.8, 119.0, 118.6, 117.5, 88.7, 88.3, 86.8, 86.3, 77.9, 77.2, 75.5,
73.9, 73.3, 69.2, 68.9, 68.6, 63.6, 50.9, 25.2, 17.9. P{ H} NMR ( 162 MHz, C D ) : δ 6 1 .4 (d, J = 35.7
Hz), 45.1 (d, J = 35.7 Hz).
Example 19
Synthesis of RuCI(CNN h)(rac-BINAP) (19).
[RuCI2(p-cymene)] 2 (71 mg, 0 .116 mmol) and rac-BINAP ( 152 mg, 0.244 mmol) were suspended in 2-
propanol (2 mL) and the mixture was refluxed in a 25 mL round bottom flask for 2 h. Compound 6 (82
mg, 0.256 mmol) and NEt3 (0.32 mL, 2.3 mmol) were added and the mixture was refluxed for 6 h . The
mixture was cooled to room temperature and heptane (4 mL) was added. The precipitate was filtered,
washed with MeOH ( 1 mL), diethyl ether (5 x 2 mL) and dried under reduced pressure, obtaining the
complex as mixture of two stereoisomers in about 4/3 molar ratio (19 , 150 g , 62 % yield). HRMS
found: [M-CI]+ 1007.2254, calcd for 1007.2258. H NMR (200. 1 MHz, CD2CI2) : δ 8.59
(d, J = 6.4 Hz), 8.40-8. 13 (m) , 8.02-6.22 (m, aromatic protons), 6 .13-5.78 (m, aromatic protons), 5.36
(d, J = 7.6 Hz), 4.74-3.35 (m, CH2 and NH2) , 2.43-2.24 (m, CH2) , 1.73-1 .40 (m, NH2) . C{ H} NMR
(50.3 MHz, CD2C I2) : δ 178.0 (dd, J = 12.3, 9.1 Hz, CRu), 176.5 (dd, J = 14.3, 9.2 Hz, CRu), 156.3,
154.6, 153.6, 153.2, 147.5-1 23.4 (m, aromatic carbon atoms) , 120.5, 120.0, 119.3, 118.2, 117.4 (d , J
= 2.6 Hz), 115.9 (d, J = 2.7 Hz), 52.8 (br s , NCH2) , 52.4 (br s , NCH2) . P{ H} NMR (81 .0 MHz,
CD2C I2) : δ 60.6 (minor diastereoisomer, d , J = 39.7 Hz), 52.4 (minor diastereoisomer, d , J = 39.7 Hz),
52. 1 (major diastereoisomer, d , J = 34.8 Hz), 5 1 .2 (major diastereoisomer, d , J = 34.8 Hz).
Example 20
Synthesis of RuCI(CNN h)[(S, )-JO
R = Ph; PP = (S,R)-JOSIPHOS
[RuCI2(p-cymene)] 2 (71 .0 mg, 0 .116 mmol) and (S,f?)-JOSIPHOS ( 165.5 mg, 0.278 mmol) were
suspended in 2-propanol (4 mL) and the mixture was refluxed in a 25 mL round bottom flask for 1 h .
Compound 6 (82 mg , 0.256 mmol) and NEt3 (0.32 mL, 2.3 mmol) were added and the mixture was
refluxed for 5 h . The solvent was removed and the solid was dried under reduced pressure The solid
was dissolved in CH2C I2 ( 1 mL), kept at -20 °C for 18 h , affording the precipitation of
triethylammonium chloride which was eliminated by filtration. Addition of heptane (2 mL) to the filtrate
gave an orange precipitate which was filtered, washed with heptane and dried under reduced
pressure (20, 125 mg , 53 % yield). HRMS found: [M-CI]+ 979.2543, calcd for C56H59FeN2P2Ru:
979.2546. H NMR (200. 1 MHz, CD2C I2) : δ 8.38 (d, J = 7 Hz, 1H), 8.21 (m, 2H), 7.82-7. 13 (m, 20H),
4.76-4.35 (m, 5H), 4.22 (m, 1H), 3.79 (s, 5H), 1.98-1 .7 (m, 3H), 1.45-0.95 (m, 22H). C{ H} NMR
(50.3 MHz, CD2CI2) : δ 157.3, 154.8, 147.7, 146.6, 146.0, 145.2, 144.7, 144.6, 140.1 , 139.2, 138.7,
137.3, 133.4, 132.2, 130. 1, 129.8, 129.2, 128.9, 128.6, 127.5, 127. 1, 126.6, 120.3, 118.2, 117.2, 97.6
(dd, J = 2 1 .2 Hz, J = 3 .1 Hz; ipso-C 5H3) , 74.0 (s; C5H3) , 72.5 (dd , J = 37.2 Hz, J = 5.0 Hz ipso-C 5H3) ,
70.4 (s; C5H5) , 69.8 (d, J = 13.3 Hz; C5H3) , 68.5 (m, C5H3) , 52.2 (d, J = 2.3 Hz; NCH2) , 40.0 (d, J =
15.8 Hz; CH of Cy), 37.6 (d, J = 17.6 Hz; CH of Cy), 3 1 .5-26.2 (m; CH2 of Cy), 29. 1 (d, J = 3.8 Hz;
PCHCH 3) , 15.5 ppm (d, J = 6.9 Hz; PCHCH 3) . P{ H} NMR (81 .0 MHz CD2C I2) : δ 66.5 (d, J = 42.1
Hz), 4 1 .3 (d, J = 42. 1 Hz).
Example 2 1
Synthesis of 1-napthyl-propionamide (21 )
The 1-naphthylamine reagent used might have contained a few ppm quantity of the highly
carcinogenic 2-naphtylamine. While the 1-naphthylamine reagent had a quality allowing its use, 2-
naphtylamine is banned from use in Europe and many other countries. An occupational health
assessment required that in order to minimise exposure the N-(naphthalen-l -yl)- propionamide 2 1
should be assayed and characterised as a crude product and then converted on as described in
Example 22.
In a 500 mL round bottomed flask were introduced 1-naphthylamine (28.0 g ; 156 mmol) and 200 mL
of dry dichloromethane. The solution was cooled to 0°C and triethylamine (24.0 mL, 172 mmol) was
added . Propionyl chloride ( 15.88 g ; 17 1 .6 mmol; 14.8 mL) was slowly ((due to a very exothermic
reaction) added . The reaction mixture was stirred at 0°C and allowed to warm up slowly to room
temperature. A formed precipitate was removed by filtration and the filtrate was extracted with 10%
aqueous hydrochloric acid. The aqueous extract was further extracted twice with 100 mL of
dichloromethane. The dichloromethane layers were combined and dried over magnesium sulfate.
Dichloromethane was removed under reduced pressure, affording 2 1 . Yield: 2 1 .90 g ; 109.9 mmol,
7 1% . H NMR (400 MHz, CDCI3) : δ 7.70 (4H, t , J = 7.4 Hz), 7.56 ( 1 H , d , J = 7.9 Hz), 7.37 (2 H , m ,
broad), 7.30 ( 1 H , t , J = 7.6 Hz), 2.36 (2 H , d , J = 7.0 Hz), 1.17 (3 H , t , J = 7.0 Hz). C{ H} NMR
( 100.61 MHz, CDC3) : δ 172.95, 134.09, 128.62, 127.20, 126.1 4 , 125.91 , 125.82, 125.63, 12 1 .39,
120.96, 30.43, 9.94 (possible overlap of two carbon resonances).
Example 22
Synthesis of 2-chloro-3-methylbenzo[/7] quinoline (22)
In a 100 mL two neck round bottom flask were introduced, under argon atmosphere, 1-naphthyl-
propionamide ( 10.0 g , 50.2 mmol) and anhydrous dimethylformamide (3.89 mL, 1 eq). POCI3 (20
mL; 4.2 eq) was added dropwise and the reaction mixture was heated to reflux releasing the formed
HCI gas through a silicone oil filled bubbler. After heating overnight the reaction mixture was cooled to
room temperature and then carefully hydrolysed in a mixture of crushed ice and water. After stirring
for 2 hours, a precipitate had formed that was filtered off, washed with water and dried in vacuum. A
yield of 8.01 g (35. 18 mmol, 70%) of 22 was obtained. H NMR (400 MHz, CDCI3) : δ 9 .19 (d, 1H , J =
7.9 Hz), 7.93 (s, 1H), 7.88 (d, 1H , J = 7.9 Hz) 7.78 (d , 1H , J = 8.8 Hz), 7.71 (q, 2H , J = 7.3 Hz), 7.58
(d, 1H , J = 8.8 Hz) 2.55 (s, 3H). C{ H} NMR ( 100.61 MHz, CDC3) : δ 150.67, 144.66, 138.02,
133.40, 130.64, 130.42, 128.24, 128.00, 127.74, 127. 15 , 125.59, 124.43, 124.20, 19.96.
Example 23
Transfer hydrogenation of ketones.
-propano
23 24 25 26 27
28 29 30 3 1 32
The catalyst (2.5 µηιοΙ) used was dissolved in 2.5 mL of 2-propanol. The ketone (2.0 mmol) was
dissolved in 2-propanol and the solution (final volume 19.4 mL) was heated under argon at reflux. By
addition of 400 µ of NaO/'Pr (0. 1 M , 40 µηιοΙ) in 2-propanol and 200 of the solution containing the
catalyst the reduction of the ketone started immediately and the yield was determined by GC after
reaction times given in the Table 1
Table 1. Catalytic transfer hydrogenation of ketones (0.1 M) with complexes 13-20 (S/C = 5000-
20000) and NaO/'Pr (2 mol %) in 2-propanol at 82 °C.
Conv.
Entry Complex Ketone S (M) S/C t (min)
(%)a
1 13 23 0 .1 10000 2 98
2 14 23 0 .1 5000 10 99
3 14 23 0 .1 10000 15 99
4 14 23 0 .1 20000 15 98
5 14 23 0.2 10000 15 96
6 14 23 0.5 10000 15 93
7 15 23 0 .1 10000 2 97
8 15 23 0 .1 20000 10 97
9 16 23 0 .1 10000 10 96
10 17 23 0 .1 10000 10 95
11 18 23 0 .1 10000 20 93
12 19 23 0 .1 10000 10 97
13 20 23 0 .1 10000 2 97
14 17 24 0 .1 10000 10 94
15 15 25 0 .1 10000 20 99
16 15 26 0 .1 10000 40 95
17 18 26 0 .1 10000 20 93
18 13 27 0 .1 5000 40 99
19 18 27 0 .1 5000 14 h 97
20 13 28 0 .1 5000 40 99
2 1 18 28 0 .1 5000 14 h 98
22 15 29 0 .1 10000 10 99
23 15 30 0 .1 10000 10 98
24 17 3 1 0 .1 10000 5 99
25 17 32 0 .1 10000 5 99
a The conversion was determined by GC analysis. ee = 85% (S)
The catalysts of this investigation reduce a wide structural variety of ketones. In 2-propanol at reflux
and in the presence of NaO/Pr (2 mol %) the ketones in Table 1 are efficiently reduced via transfer
hydrogenation with a S/C ratio up to 20000/1 . The ketones are selected to cover a broad range of
structures: alkyl-arylketones 23-27, benzophenone 29 and dialkylketones 28, 30-32. Ketones 27 and
28 having bulky tertBu substituents are reduced with near complete conversion of the substrate.
Reduction of C=0 bond of 5-hexen-2-one 30 is entirely chemoselective, without saturation or
isomerization of the terminal C=C bond.
The use of methyl-benzo[/?]quinoline or phenyl-benzo[/?] quinoline ligands allows a fine tuning of
catalyst activity and selectivity. The chiral complex 20 containing the (S,R)-JOSIPHOS ligand reduced
23 quantitatively to (S)-1 -phenylethanol in 2 min and with 85 % ee.
Example 24
Diastereomeric transfer-hydrogenation of L-Menthone
(-)-menthol (+)-neomenthol (+)-neo-isomenthol (+)-isomenthol
34 35 36 37
A single batch of L-menthone 33 (Alfa Aesar, Product A 13679, batch 10 17 1537) was used for this
comparative example. In the presence of even traces of either acid or base the menthone
diastereomer equilibrates with the isomenthone diastereomer.
Catalytic runs were carried out (Table 2).
The complex ( 1 µηιοΙ) and 0 .17 mL ( 1 mmol) of L-menthone were dissolved in 9.83 mL of 2-propanol
and the solution was purged with argon with three vacuum/argon cycles. The mixture was then
heated in an oil bath at reflux. After 2 minutes at temperature, 0.2 mL (0.02 mmol) of a 0 .1M solution
of NaO/-Pr in 2-propanol was added and the samples were analysed by GC after reaction times given
in the Table 2 . Pure samples of (-)-menthol 34, (+)-neomenthol 35, and (+)-isomenthol 37 were used
as analytical standards to confirm the identity of GC peaks.
Table 2. Catalytic transfer hydrogenation of menthone (0.1 M) with complexes 13-1 8 (S/C =
1000) and NaO/'Pr (2 mol %) in 2-propanol.
Entry Complex T Time Conv. 34 35 36 37
(°C) (h) (%)a (%) (%) (%) (%)
1 13 82 3 98 2 79 4 13
2 14 82 1 97 2 58 25 12
3 15 82 2 90 14 48 18 10
4 16 50 1 94 6 57 20 11
5 17 82 1 92 4 53 23 12
6 18 82 4 99 72 18 6 3
a The conversion was determined by GC analysis.
Catalysts 13 - 17 convert the substrate mainly to (+)-neomenthol 35 (derived from the menthone
diastereomer) and to 36, 37 (both derived from the iso-menthone diastereomer). Surprisingly, the
complex 18 is both selective in the formation of the (-)-menthol 34 and more selective than others in
the substrate consumption, preferring reaction with the menthone diastereomer over the iso-
menthone diastereomer.
Example 25
Transfer hydrogenation of ,β-unsaturated ketones
The ,β-unsaturated ketones benzylideneacetone 38 and ( 1£,3£,6£,8£)-1 ,9-diphenylnona-1 ,3,6,8-
tetraen-5-one 4 1 were studied in the TH catalyzed by complexes 13 , 14 and 16 in 2-propanol. The
commercially available compound 38 can also be prepared by reaction of benzaldehyde and acetone,
whereas the ketone 4 1 was prepared by double aldol type condensation between trans-
cinnamaldehyde and acetone. Compounds 38 and 4 1 are also formed as side products during the TH
of benzaldehyde and frans-cinnamaldehyde, respectively in basic 2-propanol, catalyzed by
complexes 13-1 8 .
Allylic alcohols 39 and 42 were obtained by NaBH4 reduction of 38 and 4 1 and were available as
analytical standards.
Catalytic runs were carried out at a molar substrate to complex ratio as indicated in Table 3 . Substrate
concentration 0.1 M and a base to complex ratio as indicated in the table. 1 mmol of
benzylideneacetone 38 or 1 mmol of ( 1£,3£,6£,8£)-1 ,9-diphenylnona-1 ,3,6,8-tetraen-5-one 4 1 was
dissolved in 10 mL of 2-propanol and the solution was purged with argon followed by three
vacuum/argon cycles. The required complex quantity and 6.9 mg (0.05 mmol) of K2C0 3 was charged
and the reaction mixture was heated in a preheated oil bath to reflux (82°C). After the reaction time,
the solvent was evaporated under vacuum, the crude mixture dissolved in CDCI3 and analyzed by H-
NMR spectroscopy.
Table 3. Catalytic transfer hydrogenation of 38 and 4 1 (0.1 M) with complexes 13, 14, 16 (S/C =
1000-5000) and K2C0 3 in 2-propanol.
Entry Substrate Complex S/C S/Base Base/C Time Conv. (%) (%)
molar molar molar (min)
(%)a
1 38 14 5000 50/1 100/1 45 93 0 93
( 146 mg) (0. 16 mg) 39 40
2 4 1 13 1000 50/1 20/1 15 100 0 95
(286 mg) (0.8 mg) 42 43
3 4 1 14 1000 50/1 20/1 15 100 0 95
(286 mg) (0.8 mg) 42 43
4 4 1 16 5000 50/1 100/1 45 99 0 82
(286 mg) (0. 16 mg) 42 43
5 4 1 16 5000 50/1 100/1 45 100 0 95
(286 mg) (0. 16 mg) 42 43
a The conversion was determined by NMR analysis.
None of the reaction allowed identifying any allylic alcohol 39 or 42 in the reaction product. Only the
alcohols 40 and 43 were isolated. Mechanistically either a 1,4-addition pathway (no formation of allylic
alcohols at any time) or a very fast catalytic allylic alcohol isomerisation step is observed.
Example 26
Reduction of ketones with hydroge
23 24 27 3 1
In an autoclave glass insert at 40°C, 5 mmol of substrate and the required amount of base (Tables 4
and 5) were dissolved in the alcohol solvent (total reaction volume 10 ml_) and with agitation switched
on , purged with nitrogen (pressurise to 3 bar and vent to ambient pressure). The required amount of
a complex stock solution in the reaction solvent was added . Directly after the addition, the mixture
was purged three times with nitrogen (pressurise to 3 bar and vent to ambient pressure). Then it was
purged twice with hydrogen (pressurise to 5 bar and vent to ambient pressure) and then kept
pressurised at reaction pressure for the time defined as reaction duration. After this, the autoclave
was vented and the product analysed by GC.
Table 4. Catalytic hydrogenation of ketones (0.5 M) with complexes 13-1 5 and 18 (S/C = 10000)
under 5 bar of H2 and a base (2 mol%) in methanol at 40 °C.
Conv. to
Entry Complex Ketone Base t (min)
alcohol (%)a
1 13 23 NaOMe 20 95
2 14 23 NaOMe 60 96
3 15 23 NaOMe 20 95
4 15 23 NaOH 30 96
5 15 23 KOH 15 95
6 18 23 KOH 60 94
7 15 24 KOH 15 93
8 13 27 KOH 120 8
9 13 27 KOH 20 h 25
10 15 3 1 KOH 120 9 1
a As determined by GC analysis the conversion of the substrate and the conversion to alcohol was the
same in all cases. There is no decomposition of the substrate under reaction conditions, allowing e.g.
the use of higher hydrogen pressure and the use of longer reaction times. Higher temperatures (i.e.
70 °C) can be applied without inducing decomposition of the substrate
Table 5. Catalytic hydrogenation of acetophenone (23) (0.5 M) with complex 15 at 40 °C with
different solvent base combinations.
Conv. to alcohol
Entry Solvent Base S/C t (min)
(%)a
1 EtOH KOfBu 5000 30 2
2 EtOH KOfBu 5000 180 2
3 MeOH KOfBu 25000 300 34
4 MeOH KOfBu 25000 420 38
5 MeOH KOH 10000 15 95
10 MeOH KOH 10000 30 98
As determined by GC analysis the conversion of the substrate and the conversion to alcohol was the
same in all cases. There is no decomposition of the substrate under reaction conditions, allowing e.g.
the use of higher hydrogen pressure and the use of longer reaction times. Higher temperatures (i.e.
70 °C) can be applied without inducing decomposition of the substrate
The complexes display high catalytic activity in the hydrogenation of ketones in basic alcohol media.
Strong solvent effects (MeOH vs EtOH), choice of base effects are evident from the data. No
decomposition of the substrate is observed under reaction condition. Compared to transfer
hydrogenation the reactions can be run more volume efficiently i.e. at higher concentration of
substrate.
Example 27
Reduction of Me-benzoate (44) with hydrogen.
A 10 mL glass tube was charged with complex (0.01 mmol, S/C 500/1 ) , loaded in a Biotage
Endevaour, purged with nitrogen five times by pressurizing to 2 bar and releasing pressure. Methyl
benzoate (5 mmol, 0.63 mL), 1M KOfBu solution in t-BuOH (0.5 mL) and solvent (4.37 mL) were
injected . The vessel was purged again with nitrogen three times, five times under stirring and a further
five time with hydrogen (by pressurizing to 28 bar and releasing pressure). The pressure was set at
28 bar of hydrogen and the reaction was stirred (600 rpm) at 50 C for 16 hours. After cooling to room
temperature the pressure was released and the reaction was sampled (2mL MeOH and 0.5 mL water
were added). An aliquot of 100 µ was diluted in 1 mL acetonitrile and analyzed by GC (Table 6).
Table 6. Catalytic hydrogenation of Me-benzoate (44) with complex 14(0.2 mol%) in the
presence of KOfBu at 50 °C with H2 (28 bar) in different solvents.
Complex Solvent / Conversion Benzyl Benzyl Others
10% tBuOH (%) Alcohol (%) benzoate (%)
[A](%)
1 14 MeTHF 75 63 10 2
2 14 Toluene 55 33 14 8
Benzylbenzoate is the benzyl alcohol ester of benzoic acid and it formation requires the conversion
of methyl benzoate by hydrogenation.
The pincer complex 14 catalyses the ester hydrogenation.
Example 28
Transfer hydrogenation with 2-propanol as hydride donor on aromatic aldehydes
ase,
An aldehyde selected from 45 - 49 ( 1 mmol), K2C0 3 (6.9 mg ; 0.05 mmol) and 2-propanol were
introduced in a Schlenk, subjected to three vacuum-argon cycles and the tube was put in an oil bath
at 90 °C. From a 250 µΜ solution of the ruthenium complex in 2-propanol, the required quantity of
complex were added to the refluxing mixture to reach a final volume of 10 mL. The reaction was
sampled by removing an aliquot of the reaction mixture, adding diethyl ether ( 1 / 1 in volume) and after
filtration over a silica pad , the conversion was determined by GC analysis. For solid and high boiling
compounds, the solvent was evaporated by gently heating under vacuum, the crude mixture was
dissolved in CDCI3 and analyzed by H-NMR spectroscopy;
Table 7. TH of aromatic aldehydes (0.1 M) catalyzed by complexes 13-1 8 and K2C0 3 (5 mol%) in
2-propanol at 82 °C.
13 2000 2 100 99 1
14 2000 1.5 100 >99 < 1
15 2000 1.25 99 98 1
16 2000 5 99 98 1
17 2000 5 99 98 1
18 2000 1.25 99 98 1
13 2000 0.5 98 78 20
14 2000 2 100 82 18
46 15 2000 0.5 98 98 < 1
16 2000 3 67 54 23
17 2000 1 100 8 1 19
18 2000 0.5 >99 >99 < 1
13 5000 1.5 95 95 < 1
13 10000 3 98 98 < 1
14 2000 <0.5 98 98 < 1
14 5000 0.5 98 98 < 1
14 10000 1.5 97 97 < 1
14 20000 3 98 98 < 1
15 5000 1.5 92 92 < 1
15 10000 3 98 98 < 1
16 2000 2 98 98 < 1
17 2000 2 99 99 < 1
18 2000 2 98 98 < 1
14 2000 2 4 1 3648
14 500 2 80 70
13 2000 5 52 52 < 1
14 2000 5 75 75 < 1
15 2000 0.75 95 95 < 1
49
16 2000 6 33 33 < 1
17 2000 5 53 53 < 1
18 2000 1 96 96 < 1
[al The conversion was determined by GC analysis or by H-NMR spectroscopy.
With complexes 13 - 18 the transfer hydrogenation with 2-propanol as hydride donor on aromatic
aldehydes benefits from using K2C0 3 as base. This allows a reaction temperature of 82 °C (reflux of
solvent) with byproduct formation < 1 % for benzaldehyde 45. Typically, in the reduction of
benzaldehyde 45 with 4 mol % of /-PrONa as base and at a temperature of 50°C to limit by-product
formation 45 is completely consumed within 2 hours. 8-1 5 % of byproducts are observed under these
conditions.
Table 8. Transfer hydrogenation of aldehydes. Comparative examples catalyzed by complexes
RuCI2(dppb)(AMPY) (50) a and RuCI2(dppf)(AMPY) (51 ) with K C0 3 (5 mol %), aldehyde 0.1 M in
2-propanol at 82 °C.
Aldehyde Complex s/c Time Conv. Alcohol By-products
(h) (%) [cl (%) (%)
50 2000 1.75 98 92 6
5 1 2000 4 85 74 11
45
50 5000 5 43 39 4
5 1 5000 5 59 49 10
50 2000 0.5 98 97 1
46
5 1 2000 2.5 92 62 30
50 5000 1 99 >98 < 1
50 10000 4.5 96 89 6
47
5 1 2000 0.5 98 >97 < 1
5 1 5000 4 52 49 3
Λ 50 2000 12 0 0 048
5 1 2000 12 0 0 0
W . Baratta, E . Herdtweck, K . Siega, M . Toniutti, P. Rigo, Organometallics 2005, 24, 1660.
E . Putignano, G . Bossi, P. Rigo, W. Baratta, Organometallics 201 2 , 3 1 , 1133.
The conversion was determined by GC analysis or by H-NMR spectroscopy.
These complexes are active on commercial grade aldehydes that have not been distilled prior to the
reaction. Aldehydes are known to form several side products that can be detrimental to catalytic
reactivity. The examples in Table 7 and 8 , therefore, demonstrate robust catalytic activity under non-
optimal conditions on unpurified substrates.
The reduction of aromatic aldehydes is more selective with pincer complexes 13 - 18 of the present
invention in comparison to the non-pincer complexes DPPB RuCI2 AMPY 50 and DPPF RuCI2 AMPY
5 1 .. RuCI2(dppb)(AMPY) (50) and RuCI2(dppf)(AMPY) (51) are not able to reduce the aldehyde 49,
containing a benzoic ester group. This substrate inhibition is not found for the more robust complexes
13 - 18 using the same batch of 49.
Example 29
Transfer hydrogenation with 2-propanol as hydride donor on frans-cinnamaldehyde (52) as
example of an ,β-unsaturated aldehyde
Trans-cinnamaldehyde 52 ( 1 mmol), K2C0 3 (6.9 mg ; 0.05 mmol) and 2-propanol were introduced in a
Schlenk tube, subjected to three vacuum-argon cycles and the tube was put in an oil bath at 90 °C.
From a 250 µΜ solution of the ruthenium complex in 2-propanol, the required quantity of complex was
added to the refluxing mixture to reach a final volume of 10 ml_. At the end of reaction the solvent was
evaporated by gently heating under vacuum, the crude mixture was dissolved in CDCI3 and analyzed
by H-NMR spectroscopy.
Table 9. TH of frans-cinnamaldehyde (52) (0.1 M) catalyzed by complexes 13-1 8 and 50,51 with
K2C0 3 (5 mol%) in 2-propanol at 82 °C.
Complex s/c Time Conv (%) iai 53 (%) By-products 54 (%)
(h) (%)
13 5000 1 99 89 10 10
13 10000 6.5 68 59 9 1
14 5000 1 99 90 9 7
14 10000 6.5 98 84 14 4
15 5000 0.5 96 77 19 19
15 10000 4 98 80 18 3
16 5000 4 93 73 20 3
16 10000 4 96 77 19 4
17 5000 4 93 73 20 3
17 10000 4 96 77 19 4
18 5000 1 98 84 14 5
18 10000 4 57 44 13 2
50 2000 3 78 77 1 1
5 1 5000 3 11 10 1 1
la The conversion was determined by GC analysis or by Ή -NMR spectroscopy.
Trans-cinnamaldehyde (52) is efficiently reduced by complexes 13 - 19 . The non-pincer complexes
50 and 5 1 are less efficient. For mostcomplexes, the amount of formation of the saturated alcohol 54
can be reduced by using lower complex loadings. It is likely that the intermediate substrate that forms
54 is the saturated ketone. The saturated ketone can be produced either by the catalyzed
isomerization of an allylic alcohol intermediate (known to be efficiently catalyzed by non-pincer
complex 51) or following a 1,4 addition pathway by converting the enol intermediate to the saturated
ketone.
Exam le 30
Transfer hydrogenation in a biphasic system with formate salts as hydride donor on ketone
substrates
Catalyst
formic acid reagent in water
In a Schlenk flask a 0.5M solution of the substrate in toluene (5 mL) was prepared and degassed by 3
vacuum/argon cycles. 5 mL of an argon saturated aqueous stock solution containing the formic acid
reagent was added. A paraffin filled bubbler was attached to the Schlenk flask to vent any C0 2
produced. The Schlenk flask was placed in an preheated oil bath at 90°C and the mixture was
vigorously stirred for the required time. H NMR and GC was used to assay the reaction mixtures.
Table 10. TH of ketones (0.5 M) catalyzed by complexes 14 and 50,51 with HC0 2NH4'
Ketone Complex S/C Reagent Time Alcohol By-
(h) (%) products
(%)
50 2000 NH4-formate l 24 1 0
5 1 2000 NH4-formate 24 2 0
23
50 1000 NH4-formate 24 5 0
5 1 1000 NH4-formate' 24 4 0
14 2000 NH4-formate' 4.5 9423
29 14 2000 NH4-formate' 11 50
14 Na-formate l 89 0
14 2000 (5 NEt3 + 1 HCOOH)' 24 69 0
29
14 2000 (5 NEt3 + 1 HCOOH)' 36 90 0
23 is acetophenone, 29 is benzophenone, 50 is RuCI2(dppb)(AMPY) and 5 1 is
RuCI2(AMPY)(dppf). [Bl 2 molar equivalents of NH4-formate. [Cl 2 molar equivalents of Na-formate. 2
molar equivalents of formic acid . 5 molar equivalents of formic acid.
The pincer complex 14 reduces the ketone substrates most efficiently and with the lowest amount of
reagent when NH4-formate is used as hydride transfer reagent. The non-pincer complexes
RuCI2(dppb)(AMPY) (50) and RuCI2(dppf)(AMPY) (51) are poor catalysts with formate reagents.
Example 3 1
Transfer hydrogenation in a biphasic system with formate salts as hydride donor on aldehyde
substrates
The selected aldehyde (2.5 mmol), HCOONH4 ( 1 0 mmol, 0.63 g) and complex (e.g. 1.25 µηιοΙ , 1 mg;
S/C = 2000) are transferred into a 50 ml Schlenk tube. Then toluene ( 1 .2 ml) and water (5 ml) are
sequentially added . The biphasic mixture is subjected to four vacuum-argon cycles under vigorous
stirring and then put into an oil bath at 90°C for the desired time. The reaction is sampled by removing
~ 1 ml of the mixture, diethyl ether (4 ml) is added , the organic phase separated, dried over MgS0 4,
filtered and the solvent gently removed under reduced pressure. The crude residue was dissolved
with CDCI3 and analyzed by H-NMR. Alternatively, the dried organic fraction is filtered over a short
silica pad and the conversion determined by GC analysis.
Table 11. TH of aldehydes catalyzed by complexes 13-1 5 with HC0 2NH4 in toluene/H20 at 90°C
Aldehyde Complex S/C Substrate NH4-formate Time Alcohol By-
molar molar;equivalents (h) (%) products
(%L_
13 5000 0.5 1; 2 16 60 0
13 5000 0.5 1; 2 22 76 0
14 5000 0.5 1; 2 15 96 0
14 5000 0.5 1; 2 24 97 0
14 5000 1.0 1; 2 15 86 0
14 5000 1.0 1; 2 24 95 0
14 5000 0.5 1; 4 15 96 0
14 5000 0.5 1; 4 24 96 0
14 5000 1.0 1; 4 15 96 0
14 5000 1.0 1; 4 24 96 0
14 20000 2.0 2 ; 4 24 94 0
14 20000 2.0 2 ; 4 48 96 0
15 5000 0.5 1; 2 16 96 0
15 10000 2.0 1; 2 20 86 0
15 20000 2.0 1; 2 40 96 0
14 2000 0.5 1; 2 10 97 0
14 20000 2.0 2 ; 4 24 62 0
14 20000 2.0 2 ; 4 48 72 0
14 2000 0.5 2 ; 4 10 >99 0
14 2000 0.5 1; 2 3.5 >99 0
14 2000 0.5 1; 1.5 9 57: 83 0
58: 17
14 2000 0.5 1; 2 10 57: 7 1 0
58: 2 1
014 2000 0.5 1;4 10 57: 0
58: 99
14 2000 0.5 1; 2 10 97 54 :10
14 5000 2.0 2 ; 4 16 78 0
14 5000 2.0 2 ; 4 24 86 0
14 5000 2.0 2 ; 4 48 97 0
14 5000 2.0 4 ; 4 16 84 0
14 5000 2.0 4 ; 4 24 9 1 0
14 5000 2.0 4 ; 4 48 94 0
14 10000 0.5 1; 2 24 38 0
14 10000 0.5 1; 2 38 49 0
With complexes 13 - 15 the transfer hydrogenation of aldehydes with NH4-formate is an improvement
compared to using 2-propanol as hydride donor and K2C0 3 as base (examples 28 and 29). The use
of less complex (higher S/C ratio) is possible and less by-products are formed. It is important to note
that no primary amines are produced by reductive amination of the aldehyde. Interestingly, the
presence of the toluene solvent as co-solvent is not entirely required, as shown in the table below.
Toluene was not added to the reactions carried out on a 2.5 mmol substrate scale.
Table 12. TH of aldehydes catalyzed by complex 14 with HC0 2NH4 in H20 at 90°C
Aldehyde Complex S/C Substrate NH4-formate Time Alcohol By-
molar molar;equivalents (h) (%) products
(%)
13 5000 0.5 1; 2 16 60
13 5000 0.5 1; 2 22 76
14 2000 2.5 mmol 1; 2 2 50
14 2000 2.5 mmol 1; 2 4 76
14 2000 2.5 mmol 1; 2 7 97
14 5000 2.5 mmol 1; 2 14 53
14 5000 2.5 mmol 1; 4 24 97
14 5000 2.5 mmol 2 ; 4 24 90
45 14 5000 0.5 1; 2 15 96
14 5000 0.5 1; 2 24 97
14 5000 1.0 1; 2 15 86
14 5000 1.0 1; 2 24 95
14 5000 0.5 1; 4 15 96
14 5000 0.5 1; 4 24 96
14 5000 1.0 1; 4 15 96
14 5000 1.0 1; 4 24 96
14 20000 2.0 2 ; 4 24 94
14 20000 2.0 2 ; 4 48 96 0
15 5000 0.5 1; 2 16 96 0
15 10000 2.0 1; 2 20 86 0
15 20000 2.0 1; 2 40 96 0
14 2000 2.5 mmol 1; 2 14 33 6
14 2000 2.5 mmol 1; 2 16 6 1 0
14 2000 0.5 1; 2 10 97 0
4 6
14 2000 2.0 2;4 11 97 0
14 10000 2.0 2;4 24 24 0
14 20000 2.0 2 ; 4 24 62 0
14 20000 2.0 2 ; 4 48 72 0
14 5000 2.0 2 ; 4 15 96 04 7
>99,
14 2000 0.5 2 ; 4 10 04 8 65
14 2000 0.5 1; 2 3.5 >99 055
14 2000 2.0 2;4 3.5 99, 65 0
14 2000 0.5 1; 1.5 9 57: 83 056 58: 17
14 2000 0.5 1; 2 10 57: 7 1 0
58: 2 1
14 2000 0.5 1;4 10 57: 0 0
58: 99
14 2000 0.5 1; 2 10 97 54 :10
14 5000 2.0 2 ; 4 16 78 54 :6
14 5000 2.0 2 ; 4 24 86 0
52
14 5000 2.0 2 ; 4 48 97 54 :12
14 5000 2.0 4 ; 4 16 84 0
14 5000 2.0 4 ; 4 24 92 54 :5
14 5000 2.0 4 ; 4 48 94 54 :7
14 10000 0.5 1; 2 24 38
14 10000 0.5 1; 2 38 49
59 14 10000 2.0 4 ; 4 20 98 0
60 14 10000 2.0 2 ; 4 24 65 0
60 14 10000 2.0 4 ; 4 24 97 0
6 1 14 5000 2.0 4;4 20 98, 88
62 14 5000 2.0 2;4 8 95
63 14 2000 2.0 4;4 9 96, 79
Conversion and product content were determined by GC analysis or by Ή -NMR spectroscopy.
Isolated yield.
On 2.5 mmol scale, reduction of benzaldehyde 45 (0.5 molar in toluene) at S/C =2000, 90°C and 4
equivalents of 2M aqueous Na-formate gave only traces of benzylalcohol after 14 hours. Use of 4
equivalents of (NEt3H)-formate improves the yield to 50 % in 22 hours. Use of 5 equivalents of
(NEt3H)-formate on frans-cinnamaldehyde 52 gives after 18 hours 80 % of allylic alcohol 53 and 15 %
of saturated alcohol 54. NH4-formate is preferred over the other formate reagents.
Example 32
Reduction of aldehydes with hydrogen.
In an autoclave glass insert 10 mmol of substrate and the required KOfBu (2 mol%) were dissolved in
the alcohol solvent (4 ml_) and with stir agitation switched on, purged with nitrogen (pressurise to 3
bar and vent to ambient pressure). The required amount of a complex stock solution in the reaction
solvent was added. Directly after the addition, the mixture was purged three times with nitrogen
(pressurise to 3 bar and vent to ambient pressure). Then it was purged twice with hydrogen
(pressurise to 13 bar and vent to ambient pressure) and then kept pressurised at reaction pressure for
the time defined as reaction duration. After this, the autoclave was vented and the product analysed
by GC and HNMR.
Table 13. Hydrogenation of 2 molar in methanol solutions of benzaldehyde 45 and trans-
cinnamaldehyde 52 catalyzed by complexes RuCI2(dppb)(AMPY) (50) and RuCI2(dppf)(AMPY)
(51 ) and pincer complexes 13-1 5. Base KOfBu (2 mol%). Hydrogenation in a Biotage
Endeavour apparatus at 50 °C.
Complex Loading . . Alcohol By-products.
Substrate 1 P (H2) [atm] Time [h] Conv. [%] [al[S/C] [%] a [%] a
45 50 1000 10 3 35 33 2
45 50 2000 10 8 22 7 15
45 5 1 2000 10 16 100 98 2
45 13 10000 10 8 100 96 4
45 13 20000 10 8 100 99 1
45 14 10000 10 16 98 98 2
45 14 40000 13 32 27 26 1
45 15 10000 13 16 63 60 3
52 50 1000 10 3 95 87 54: 8
52 5 1 2000 10 8 98 89 54: 9
52 13 10000 10 8 99 89 54: 10
52 13 20000 10 8 96 75 54: 2 1
52 14 10000 10 8 99 90 54: 11
la Conversion and product content were determined by GC analysis or by Ή-NMR spectroscopy.
Table 14. Hydrogenation of 2 molar solutions of benzaldehyde 45 catalyzed pincer complexes
13-1 5. Base KOfBu (2 mol%). Hydrogenation at S/C = 10000 in a Biotage Endeavour apparatus
at 50 °C and 13 bar H2for 16 hours.
Complex By-products.
Solvent Conv. [%] [al Alcohol [%] [al [%] [al
13 MeOH 100 96 4
13 MeOH/EtOH = 3/1 100 93 7
13 MeOH/EtOH = 1/ 1 100 88 12
13 MeOH/EtOH = 1/3 100 86 11
14 MeOH 100 98 2
14 MeOH/EtOH = 3/1 100 97 3
14 MeOH/EtOH = 1/ 1 100 97 3
14 MeOH/EtOH = 1/3 90 80 10
14 EtOH 100 82 18
15 MeOH 63 60 3
15 MeOH/EtOH = 3/1 23 19 4
15 MeOH/EtOH = 1/ 1 23 18 5
15 MeOH/EtOH = 1/3 19 16 3
[al Conversion and product content were determined by GC analysis or by Ή-NMR spectroscopy.
Table 15. Hydrogenation of methanol solutions of aldehydes catalyzed by complex 14. Base
KOfBu (2 mol%). Hydrogenation in Parr autoclave at 50 °C and 5 bar H2.
Loading Alcohol By-products.
Substrate' 1 [S] Time [h] Conv. [%] [al[S/C] [%] [al [%] [al
47 1M 10000 1 100 >99 0
47 1M 20000 7 98 >97 0
47 1M 40000 22 98 >97 0
60 1M 10000 1 100 99 1
60 2M 5000 0.66 100 95 5
6 1 2M 15000 24 100 >99 < 1
62 1M 5000 1.5 99 >90 <9
Conversion and product content were determined by GC analysis or by Ή -NMR spectroscopy.
The advantage of using the pincer complexes 13-1 5 compared to using RuCI2(dppb)(AMPY) (50) and
RuCI2(dppf)(AMPY) (51) is again shown by the hydrogenation data. In the hydrogenation of trans -
cinnamaldehyde 52 the formation of fully saturated product cannot be suppressed to a similar degree
as with the NH4-formate hydrogenation . Methanol as reaction solvent is clearly preferable over
ethanol and methanol/ethanol mixtures.
Claims
1. A benzo [ 7]quinoline compound of formula ( 1a) or ( 1 b), or salts thereof:
wherein:
and R2 are independently selected from the group consisting of -H, -OH, unsubstituted
C1-2o-alkyl, substituted C1-2o-alkyl, unsubstituted C3_2o-cycloalkyl, substituted C3_2o-cycloalkyl,
unsubstituted C5.20-aryl, substituted C5.20-aryl, unsubstituted C o-heteroalkyl, substituted
20-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted C2.20-heterocycloalkyl,
unsubstituted C4.20-heteroaryl and substituted C4.20-heteroaryl;
R3 is selected from the group consisting of -H, unsubstituted C1-2o-alkyl, substituted C1-20-
alkyl, unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C5-20-aryl,
substituted C5-20-aryl, unsubstituted C1-20-heteroalkyl, substituted C1-20-heteroalkyl,
unsubstituted C2.20-heterocycloalkyl, substituted C2.20-heterocycloalkyl, unsubstituted C4_20-
heteroaryl and substituted C4.20-heteroaryl;
R4 is selected from the group consisting of unsubstituted C1-20-alkyl, substituted C1-20-alkyl,
unsubstituted C o-alkoxy, substituted C o-alkoxy, unsubstituted C5-20-aryl, substituted C5_
R5 is selected from the group consisting of unsubstituted C1-20-alkyl, substituted C1-20-alkyl,
unsubstituted C o-alkoxy, substituted C o-alkoxy, unsubstituted C5-20-aryl, substituted C5_
R is selected from the group consisting of -CF3, unsubstituted C1-20-alkyl, substituted C1-20-
alkyl, unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C o-alkoxy,
substituted C o-alkoxy, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C1-20-
heteroalkyl, substituted C1-20-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted
C2.20-heterocycloalkyl, unsubstituted C4.20-heteroaryl, substituted C4.20-heteroaryl, -NR'R" -
COOR', -S(0) 2OH, -S(0) 2-R', -S(0) 2NR'R" and -CONR'R", wherein R' and R" are
independently selected from the group consisting of H , unsubstituted C1-20-alkyl, substituted
C1-20-alkyl, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C7.20-arylalkyl,
substituted C7_2o-arylalkyl, or R' and R" together with the atom to which they are attached
form a substituted or unsubstituted C2-2o-heterocycloalkyl group;
R7 is selected from the group consisting of -CF3, unsubstituted C1-2o-alkyl, substituted C1-20-
alkyl, unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C^o-alkoxy,
substituted C^o-alkoxy, unsubstituted C5.20-aryl, substituted C5.20-aryl, unsubstituted C1-20-
heteroalkyl, substituted C^o-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted
C2.20-heterocycloalkyl, unsubstituted C4.20-heteroaryl, substituted C4.20-heteroaryl, -NR'R" -
COOR', -S(0) 2OH, -S(0) 2-R', -S(0) 2NR'R" and -CONR'R", wherein R' and R" are
independently selected from the group consisting of H , unsubstituted C1-20-alkyl, substituted
C1-20-alkyl, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C7.20-arylalkyl,
substituted C7.20-arylalkyl, or R' and R" together with the atom to which they are attached
form a substituted or unsubstituted C2.20-heterocycloalkyl group;
b is an integer selected from 0 , 1 or 2 ; and
c is an integer selected from 0 , 1, 2 , 3 or 4 .
The compound according to claim 1, wherein the compound of formula ( 1a) is selected from
the group consisting of:
The compound according to claim 1, wherein the compound of formula ( 1 b) is selected from
the group consisting of:
A process for preparing a compound of formula ( 1a) or ( 1 b), the process comprising the step
of reacting a compound (4a) or (4b) with a base and a compound of formula (5):
(4a) (4b)
wherein:
and R2 are independently selected from the group consisting of -H, -OH, unsubstituted
C1-2o-alkyl, substituted C1-2o-alkyl, unsubstituted C3_2o-cycloalkyl, substituted C3_2o-cycloalkyl,
unsubstituted C5.20-aryl, substituted C5.20-aryl, unsubstituted C^o-heteroalkyl, substituted
20-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted C2.20-heterocycloalkyl,
unsubstituted C4.20-heteroaryl and substituted C4.20-heteroaryl;
R3 is selected from the group consisting of -H, unsubstituted C1-2o-alkyl, substituted C1-20-
alkyl, unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C5-20-aryl,
substituted C5-20-aryl, unsubstituted C1-20-heteroalkyl, substituted C1-20-heteroalkyl,
unsubstituted C2.20-heterocycloalkyl, substituted C2.20-heterocycloalkyl, unsubstituted C4_20-
heteroaryl and substituted C4.20-heteroaryl;
R4 is selected from the group consisting of unsubstituted C1-20-alkyl, substituted C1-20-alkyl,
unsubstituted C^o-alkoxy, substituted C^o-alkoxy, unsubstituted C5-20-aryl, substituted C5_
2o-aryl;
R5 is selected from the group consisting of unsubstituted C1-2o-alkyl, substituted C1-2o-alkyl,
unsubstituted C^o-alkoxy, substituted C^o-alkoxy, unsubstituted C5_2o-aryl, substituted C5.
R is selected from the group consisting of -CF3, unsubstituted C1-2o-alkyl, substituted C1-20-
alkyl, unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C^o-alkoxy,
substituted C^o-alkoxy, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C1-20-
heteroalkyl, substituted C1-20-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted
C2.20-heterocycloalkyl, unsubstituted C4.20-heteroaryl, substituted C4.20-heteroaryl, -NR'R" -
COOR', -S(0) 2OH, -S(0) 2-R', -S(0) 2NR'R" and -CONR'R", wherein R' and R" are
independently selected from the group consisting of H , unsubstituted C1-20-alkyl, substituted
C1-20-alkyl, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C7.20-arylalkyl,
substituted C7.20-arylalkyl, or R' and R" together with the atom to which they are attached
form a substituted or unsubstituted C2.20-heterocycloalkyl group;
R7 is selected from the group consisting of -CF3, unsubstituted C1-20-alkyl, substituted C1-20-
alkyl, unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C^o-alkoxy,
substituted C^o-alkoxy, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C1-20-
heteroalkyl, substituted C1-20-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted
C2.20-heterocycloalkyl, unsubstituted C4.20-heteroaryl, substituted C4.20-heteroaryl, -NR'R" -
COOR', -S(0) 2OH, -S(0) 2-R', -S(0) 2NR'R" and -CONR'R", wherein R' and R" are
independently selected from the group consisting of H , unsubstituted C1-20-alkyl, substituted
C1-20-alkyl, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C7.20-arylalkyl,
substituted C7.20-arylalkyl, or R' and R" together with the atom to which they are attached
form a substituted or unsubstituted C2.20-heterocycloalkyl group;
b is an integer selected from 0 , 1 or 2 ;
c is an integer selected from 0 , 1, 2 , 3 or 4 ; and
Y is a leaving group.
5 . A process according to claim 4 , wherein the compound of formula (4a) or (4b) is prepared
by reducing a compound (6a) or (6b), or salts thereof.
(6a) (6b)
A process according to claim 5 , wherein the compound (6a) or (6b), or salts thereof, is
prepared by the reaction of a compound of formula (7a) or (7b) with a compound of formula
(8), or salt thereof, in an alcohol solvent to form compound (6a) or (6b).
wherein,
R30 is selected from the group consisting of - H and -OH.
A process according to claim 6 , wherein the compounds of formula (7a) or (7b) are prepared
in a process comprising the steps of:
(a) reacting a compound of formula (9a) or (9b) with a lithiating agent in an ethereal
solvent to form the lithiated compound ( 10a) or ( 1Ob); and
reacting the lithiated compound ( 10a) or ( 10b) with a compound of formula ( 1 1) to
form the compound of formula (7a) or (7b).
( 1 1)
wherein:
Z is -N(alkyl)2 or -Hal.
A process according to claim 7 , wherein the compound of formula (9a) or (9b) is prepared in
a process comprising the reaction of a compound of formula ( 12a) or ( 12b) with a
halogenating agent in a solvent.
A process according to claim 8 , wherein the compound of formula ( 12a) or ( 12b) is prepared
in a process comprising the step of reacting a compound of formula ( 13a) or ( 13b) with an
acid.
( 13a) ( 13b)
0 . A process according to claim 9 , wherein the compound of formula ( 13a) is prepared in a
process comprising the step of reacting a naphthylamine of formula ( 14), or salt thereof, with
a compound of formula ( 15):
( 14) ( 15)
wherein:
LG is a leaving group.
1. A process according to claim 9 , wherein the compound of formula ( 13b) is prepared by
reacting a compound of formula ( 14) with a compound of formula ( 16) or a compound of
formula ( 17).
( 14) ( 16) ( 17)
wherein:
R40 and R4 are independently selected from the group consisting of unsubstituted alkyl and
substituted alkyl, or R40 and R4 are interconnected to form a ring with the carbon to which
they are attached ; and
LG is a leaving group.
2 . A process according to claim 4 , wherein the compounds of formulae ( 1a) and ( 1 b), or salts
thereof, are prepared by reducing a compound of formula (20a) or (20b), or salts thereof.
wherein:
R R2 and R3 in the compounds of formulae ( 1a) and ( 1 b) are all -H.
3 . A process according to claim 12 , wherein the compounds of formulae (20a) and (20b) are
prepared by cyanating the compounds of formulae (9a) and (9b).
4 . A compound which is selected from the compounds of formulae (4a), (4b), (6a), (6b), (7a),
(7b), (9a), (9b), ( 12a), ( 12b), ( 13a), ( 13b), (20a) or (20b).
101
wherein:
is selected from the group consisting of -H, -OH , unsubstituted C1-2o-alkyl, substituted
2o-alkyl, unsubstituted C3.2o-cycloalkyl, substituted C3_2o-cycloalkyl, unsubstituted C5.2o-aryl,
substituted C5.2o-aryl, unsubstituted C^o-heteroalkyl, substituted C^o-heteroalkyl,
unsubstituted C2.20-heterocycloalkyl, substituted C2.20-heterocycloalkyl, unsubstituted C4_20-
heteroaryl and substituted C4.20-heteroaryl;
R3 is selected from the group consisting of -H, unsubstituted C1-2o-alkyl, substituted C1-20-
alkyl, unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C5.20-aryl,
substituted C5.20-aryl, unsubstituted C^o-heteroalkyl, substituted C^o-heteroalkyl,
unsubstituted C2.20-heterocycloalkyl, substituted C2.20-heterocycloalkyl, unsubstituted C4_20-
heteroaryl and substituted C4.20-heteroaryl;
R4 is selected from the group consisting of unsubstituted C1-20-alkyl, substituted C1-20-alkyl,
unsubstituted C^o-alkoxy, substituted C^o-alkoxy, unsubstituted C5-20-aryl, substituted C5_
R5 is selected from the group consisting of unsubstituted C1-20-alkyl, substituted C1-20-alkyl,
unsubstituted C^o-alkoxy, substituted C^o-alkoxy, unsubstituted C5-20-aryl, substituted C5_
R is selected from the group consisting of -CF3, unsubstituted C1-20-alkyl, substituted C1-20-
alkyl, unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C^o-alkoxy,
substituted C^o-alkoxy, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C1-20-
heteroalkyl, substituted C1-20-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted
C2.20-heterocycloalkyl, unsubstituted C4.20-heteroaryl, substituted C4.20-heteroaryl, -NR'R" -
COOR', -S(0) 2OH, -S(0) 2-R', -S(0) 2NR'R" and -CONR'R", wherein R' and R" are
independently selected from the group consisting of H , unsubstituted C1-20-alkyl, substituted
C1-20-alkyl, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C7.20-arylalkyl,
substituted C7.20-arylalkyl, or R' and R" together with the atom to which they are attached
form a substituted or unsubstituted C2.20-heterocycloalkyl group;
R7 is selected from the group consisting of -CF3, unsubstituted C1-2o-alkyl, substituted C1-20-
alkyl, unsubstituted C3.2o-cycloalkyl, substituted C3_2o-cycloalkyl, unsubstituted C^o-alkoxy,
substituted C^o-alkoxy, unsubstituted C5_2o-aryl, substituted C5.20-aryl, unsubstituted C1-20-
heteroalkyl, substituted C^o-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted
C2.20-heterocycloalkyl, unsubstituted C4.20-heteroaryl, substituted C4.20-heteroaryl, -NR'R" -
COOR', -S(0) 2OH, -S(0) 2-R', -S(0) 2NR'R" and -CONR'R", wherein R' and R" are
independently selected from the group consisting of H , unsubstituted C1-20-alkyl, substituted
C1-20-alkyl, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C7.20-arylalkyl,
substituted C7.20-arylalkyl, or R' and R" together with the atom to which they are attached
form a substituted or unsubstituted C2.20-heterocycloalkyl group;
b is an integer selected from 0 , 1 or 2 ;
c is an integer selected from 0 , 1, 2 , 3 or 4 .
15 . A transition metal complex of formula (3):
[M X (L1)m (L2)]
(3)
wherein:
M is ruthenium, osmium or iron;
X is an anionic ligand;
L is a monodentate phosphorus ligand, or a bidentate phosphorus ligand;
m is 1 or 2 , wherein,
when m is 1, L is a bidentate phosphorus ligand;
when m is 2 , each L is a monodentate phosphorus ligand ; and
L2 is a tridentate ligand of formula (2a) or (2b):
wherein:
R and R 2 are independently selected from the group consisting of -H, -OH, unsubstituted
C1-20-alkyl, substituted C1-20-alkyl, unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl,
unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C1-20-heteroalkyl, substituted
2o-heteroalkyl, unsubstituted C2-2o-heterocycloalkyl, substituted C2-2o-heterocycloalkyl,
unsubstituted C4.20-heteroaryl and substituted C4.20-heteroaryl;
R3 is selected from the group consisting of -H, unsubstituted C1-2o-alkyl, substituted C1-20-
alkyl, unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C5.20-aryl,
substituted C5.20-aryl, unsubstituted C^o-heteroalkyl, substituted C^o-heteroalkyl,
unsubstituted C2.20-heterocycloalkyl, substituted C2.20-heterocycloalkyl, unsubstituted C4_20-
heteroaryl and substituted C4.20-heteroaryl;
R4 is selected from the group consisting of unsubstituted C1-2o-alkyl, substituted C1-20-alkyl,
unsubstituted C^o-alkoxy, substituted C^o-alkoxy, unsubstituted C5-20-aryl, substituted C5_
R5 is selected from the group consisting of unsubstituted C1-20-alkyl, substituted C1-20-alkyl,
unsubstituted C^o-alkoxy, substituted C^o-alkoxy, unsubstituted C5-20-aryl, substituted C5_
R is selected from the group consisting of unsubstituted C1-20-alkyl, substituted C1-20-alkyl,
unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C^o-alkoxy,
substituted C^o-alkoxy, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C1-20-
heteroalkyl, substituted C1-20-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted
C2.20-heterocycloalkyl, unsubstituted C4.20-heteroaryl, substituted C4.20-heteroaryl, -NR'R" -
COOR', -S(0) 2OH, -S(0) 2-R', -S(0) 2NR'R" and -CONR'R", wherein R' and R" are
independently selected from the group consisting of H , unsubstituted C1-20-alkyl, substituted
C1-20-alkyl, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C7.20-arylalkyl,
substituted C7.20-arylalkyl, or R' and R" together with the atom to which they are attached
form a substituted or unsubstituted C2.20-heterocycloalkyl group;
R7 is selected from the group consisting of -H, unsubstituted C1-20-alkyl, substituted C1-20-
alkyl, unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C^o-alkoxy,
substituted C^o-alkoxy, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C1-20-
heteroalkyl, substituted C1-20-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted
C2.20-heterocycloalkyl, unsubstituted C4.20-heteroaryl, substituted C4.20-heteroaryl, -NR'R" -
COOR', -S(0) 2OH, -S(0) 2-R', -S(0) 2NR'R" and -CONR'R", wherein R' and R" are
independently selected from the group consisting of H , unsubstituted C1-20-alkyl, substituted
C1-20-alkyl, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C7.20-arylalkyl,
substituted C7.20-arylalkyl, or R' and R" together with the atom to which they are attached
form a substituted or unsubstituted C2.20-heterocycloalkyl group;
b is an integer selected from 0 , 1 or 2 ; and
c is an integer selected from 0 , 1, 2 or 3 .
6 . A transition metal complex according to claim 15 , wherein M is a ruthenium.
7 . A transition metal complex according to claim 15 or claim 16 , wherein L is a tertiary
phosphine ligand PR R 2R 3, wherein R , R12 and R13 are independently selected from the
group consisting of unsubstituted C1-2o-alkyl, substituted C1-2o-alkyl, unsubstituted C3_20-
cycloalkyl, substituted C3.2o-cycloalkyl, unsubstituted C o-alkoxy, substituted C o-alkoxy,
unsubstituted C5_2o-aryl, substituted C5.20-aryl, unsubstituted C o-heteroalkyl, substituted
20-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted C2.20-heterocycloalkyl,
unsubstituted C4.20-heteroaryl and substituted C4.20-heteroaryl.
18 . A transition metal complex according to claim 15 or claim 16 , wherein L is a chiral or
achiral, monodentate or bidentate phosphorus ligand in which the phosphorus atom is
covalently bonded to either 3 carbon atoms or to n heteroatoms and 3-n carbon atoms,
where n = 1, 2 or 3 .
19 . A transition metal complex according to claim 18 , wherein the heteroatom is selected from
the group consisting of N and O.
20. A transition metal complex according to claim 18 or claim 19 , wherein the phosphorus ligand
L is selected from the group consisting of unsubstituted or substituted Binap ligands, PPhos
ligands, PhanePhos ligands, QPhos ligands, Josiphos ligands, Bophoz ligands and
Skewphos ligands.
2 1 . A transition metal complex according to claim 18 or claim 19 , wherein the phosphorus ligand
L is selected from the group consisting of PPh3, dppf ( 1 ,1 -
bis(diphenylphosphino)ferrocene), dppp ( 1 ,3-bis(diphenylphosphino)propane), dppb ( 1 ,4-
bis(diphenylphosphino)butane), Dipfc ( 1 ,1'-bis(di-isopropylphosphino)ferrocene) and
dCyPfc.
22. A process for preparing a transition metal complex of formula (3) as defined in any one of
claims 15 to 2 1, the process comprising the step of reacting a transition metal complex, a
ligand L , a compound of formula ( 1a) or ( 1 b) or salts thereof, and a base in an alcohol
solvent,
wherein:
the transition metal complex is selected from the group consisting of [ruthenium (arene)
(halogen)2]2, [ruthenium (halogen) (P(unsubstituted or substituted aryl)3)], [osmium (arene)
(halogen)2] , [osmium (halogen)2 (P(unsubstituted or substituted aryl)3)] and [osmium
(N(unsubstituted or substituted alkyl)3)4 (halogen)2] ;
wherein:
and R2 are independently selected from the group consisting of -H, -OH, unsubstituted
C1-2o-alkyl, substituted C1-2o-alkyl, unsubstituted C3_2o-cycloalkyl, substituted C3.2o-cycloalkyl,
unsubstituted C5.20-aryl, substituted C5.20-aryl, unsubstituted C^o-heteroalkyl, substituted
20-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted C2.20-heterocycloalkyl,
unsubstituted C4.20-heteroaryl and substituted C4.20-heteroaryl;
R3 is selected from the group consisting of -H, unsubstituted C1-2o-alkyl, substituted C1-20-
alkyl, unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C5-20-aryl,
substituted C5-20-aryl, unsubstituted C1-20-heteroalkyl, substituted C1-20-heteroalkyl,
unsubstituted C2.20-heterocycloalkyl, substituted C2.20-heterocycloalkyl, unsubstituted C4_20-
heteroaryl and substituted C4.20-heteroaryl;
R4 is selected from the group consisting of unsubstituted C1-20-alkyl, substituted C1-20-alkyl,
unsubstituted C^o-alkoxy, substituted C^o-alkoxy, unsubstituted C5-20-aryl, substituted C5_
R5 is selected from the group consisting of unsubstituted C1-20-alkyl, substituted C1-20-alkyl,
unsubstituted C^o-alkoxy, substituted C^o-alkoxy, unsubstituted C5-20-aryl, substituted C5_
R is selected from the group consisting of -CF3, unsubstituted C1-20-alkyl, substituted C1-20-
alkyl, unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C^o-alkoxy,
substituted C^o-alkoxy, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C1-20-
heteroalkyl, substituted C1-20-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted
C2.20-heterocycloalkyl, unsubstituted C4.20-heteroaryl, substituted C4.20-heteroaryl, -NR'R" -
COOR', -S(0) 2OH, -S(0) 2-R', -S(0) 2NR'R" and -CONR'R", wherein R' and R" are
independently selected from the group consisting of H , unsubstituted C1-20-alkyl, substituted
C1-20-alkyl, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C7.20-arylalkyl,
substituted C7.20-arylalkyl, or R' and R" together with the atom to which they are attached
form a substituted or unsubstituted C2.20-heterocycloalkyl group;
R7 is selected from the group consisting of -CF3, unsubstituted C1-20-alkyl, substituted C1-20-
alkyl, unsubstituted C3.20-cycloalkyl, substituted C3.20-cycloalkyl, unsubstituted C^o-alkoxy,
substituted C^o-alkoxy, unsubstituted C5-20-aryl, substituted C5-20-aryl, unsubstituted C1-20-
heteroalkyl, substituted C1-20-heteroalkyl, unsubstituted C2.20-heterocycloalkyl, substituted
C2-2o-heterocycloalkyl, unsubstituted C4.2o-heteroaryl, substituted C4.2o-heteroaryl, -NR'R" -
COOR', -S(0) 2OH, -S(0) 2-R', -S(0) 2NR'R" and -CONR'R", wherein R' and R" are
independently selected from the group consisting of H , unsubstituted C^o-alkyl, substituted
C^o-alkyl, unsubstituted C5.20-aryl, substituted C5.20-aryl, unsubstituted C7.20-arylalkyl,
substituted C7.20-arylalkyl, or R' and R" together with the atom to which they are attached
form a substituted or unsubstituted C2.20-heterocycloalkyl group;
b is an integer selected from 0 , 1 or 2 ; and
c is an integer selected from 0 , 1, 2 , or 3 ; and
C-8 of the compound of formula ( 1a) or ( 1 b) is -H.
23. A method of catalysing a reaction, the method comprising the step of reacting a substrate
comprising a carbon-oxygen double bond in the presence of a complex of formula (3) as
defined in any one of claims 15 to 2 1 .
24. The method of claim 23, which is a reduction reaction.
25. The method of claim 24, where the reduction reaction comprises reacting the substrate with
hydrogen, deuterium or tritium in the presence of the complex.
26. The method of claim 24, where the reduction reaction is a transfer hydrogenation reaction.
27. The method of claim 26, wherein the transfer hydrogenation reaction comprises the reduction
of an aldehyde to form a primary alcohol and the hydrogen donor is ammonium formate.
28. A method of catalysing a reaction, the method comprising the step of performing the reaction
in the presence of a complex of formula (3) as defined in any one of claims 15 to 2 1 , wherein
the reaction is selected from the group consisting the isomerization of allylic alcohols,
dehydrogenation reactions, the reduction of the alkenyl bond in α,β-unsaturated carbonyls
and in "hydrogen borrowing" reactions.
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